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CHAPTER  1  
    Introduction 
1.1 Introduction to Nucleic Acids 
Nucleic acids play a vital role in biological systems. Nucleic acids, more 
specifically DNA and RNA, are present in all organisms. Though DNA and RNA 
have very few differences chemically, their three-dimensional structures and 
biological functions are very different. The presence of a 2'-OH group and uracil, 
instead of thymine, are the main chemical differences in RNA compared to DNA. 
In secondary structures, DNA is generally helical and double stranded, whereas 
RNA contains numerous tertiary structures and is quite diverse (5-7). With an 
increasing number and types of RNAs still being discovered, our understanding 
of RNA structure and function also has to increase greatly. Traditionally, there 
are three major classes of RNAs: messenger RNA (mRNA), transfer RNA 
(tRNA), and ribosomal RNA (rRNA), which are responsible for the conversion of 
genetic information in DNA to proteins (8). In the past, other cellular RNAs were 
considered as junk or degraded pieces of mRNA. Later, catalytic activities of 
these RNA molecules were identified (9-13). In 1989, Thomas Cech and Sidney 
Altman were awarded the Nobel Prize in chemistry for the discovery of catalytic 
properties of RNA. They discovered the catalytic activity of the group I intron (9) 
and ribonuclease P, respectively (11). These catalytic RNA, called ribozymes, 
are found to be involved in a number of cellular processes. In the last decade, 
the number of newly discovered small RNAs (sRNAs) in bacteria and non-coding 
RNAs (ncRNAs) in eukaryotes has increased dramatically (14). They have been 
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shown to carry out important regulatory functions such as transcriptional 
regulation, RNA processing and modification, as well as mRNA stability and 
translation (15-16). Although the overall function of known non-coding RNAs is 
similar, the mechanism of action and processing of these RNAs is very different 
(17-18). Riboswitches, upon binding to small molecules, refold and control 
expression (19-20), while double-stranded short interfering RNAs (siRNAs) 
suppress gene expression by cleaving target mRNA at specific sites (21). The 
discovery of RNA interference (RNAi) and its role in defending cells against 
parasitic genes has significantly increased its application in therapeutics (22-23). 
In addition, RNAi has been used as a genetic tool in molecular biology to 
suppress gene expression selectively. In 2006, Andrew Z. Fire and Craig C. 
Mello received the Nobel Prize in physiology or medicine for the discovery of 
RNA interference. With cutting-edge techniques and genome sequencing, more 
non-coding RNAs, along with their functions and applications, are expected to be 
uncovered in the future. 
1.2  Introduction to the Ribosome 
The ribosome is a large and complex organelle of living organisms, 
identified as a ribonucleoprotein particle by Palade (24). The E. coli ribosome is 
composed of 65% ribosomal RNA and 35% proteins, although the ratio varies a 
little from organism to organism. In bacteria, the size of the ribosome is about 20 
nm and it has a mass of more than 2 x 106 Daltons (25-26). The ribosome is an 
essential component of all living organisms because of its important role in 
protein synthesis. The cell uses a large amount of energy for its biogenesis.  
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1.2.1 Composition 
The ribosome of all organisms consists of two unequal subunits, each 
contains one third proteins and two thirds RNA. The unequal subunits of the 
ribosome are measured in terms of their sedimentation coefficient unit (Svedberg 
constant) rather than their size. In bacteria, the ribosome (70S) consists of a 
larger 50S subunit and smaller 30S subunit. The larger 50S subunit is composed 
of 23S ribosomal RNA with 2900 nucleotides and 5S ribosomal RNA with 120 
nucleotides. Along with RNA, the larger subunit also contains 34 different 
proteins. The smaller 30S subunit consists of 16S ribosomal RNA (1546 
nucleotides) and 21 different proteins (Figure 1.1). In eukaryotes, the 80S 
ribosome consists of a larger 60S subunit and a smaller 40S subunit. The large 
subunit is composed of 28S ribosomal RNA (4700 nucleotides), 5.8S rRNA (160 
nucleotides) and 49 proteins. The small subunit contains 18S ribosomal RNA 
(1800 nucleotides) and 33 proteins. Despite the differences in size and 
composition, the ribosome has common important functional regions such as the 
decoding region, peptidyl transferase center, and peptide exit tunnel. 
High-resolution X-ray crystal structures of the bacterial ribosome in 
bacteria reveal that the smaller 30S subunit consists of four distinct structural 
domains, previously referred to as the head, neck, body and platform based on 
EM images (Figure 1.2 A) (27). The 30S subunit of the ribosome is mainly 
involved in the formation of a pre-initiation complex and the selection of correct 
aminoacyl tRNAs during protein synthesis.  
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Figure 1.1. The composition of bacterial ribosomes is shown. The bacterial 70S ribosome 
is composed of 50S and 30S subunits, which are also composed of ribosomal RNA and 
proteins. This figure was created with Pymol using PDB: 3I1M and 3I1N (28). 
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Figure 1.2. Crystal structures of the E. coli 30S and 50S subunits as seen from the 
interface side are shown: (A) 30S crystal structure (PDB: 3I1M) and (B) 50S crystal 
structure (PDB: 3I1N) (28). 
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The larger 50S subunit consists of a body and three protuberances (Figure 1.2 
B). The central protuberance consists of 5S rRNA and associated proteins, while 
the other two arms that extend to the right and left are formed by L1 and L7/L12 
proteins. The catalytic center of the ribosome, or peptidyl transferase center 
(PTC), is located in the 50S subunit and catalyzes peptide-bond formation. 
Because of this property, the ribosome is also called a ribozyme (29). Another 
important component of the 50S subunit is the peptide exit tunnel, which provides 
a stable path for the growing polypeptide. The assembly and maturation 
processes of the ribosomal subunits consist of a complex series of events, 
including the processing of the ribosomal RNA, modification of nucleotides, 
binding of ribosomal proteins and metal ions, as well as conformational changes 
in sequential order (30-31). 
1.2.2 Structure 
The ribosome is organized into distinct three-dimensional structures (32). 
The folded RNA makes the ribosome very diverse in secondary and tertiary 
structures. The standard Watson-Crick base pairs found in RNA are G-C and A-
U; however, G-U and G-A non-canonical base pairs are also observed. Along 
with these, there are several modified nucleotides and mismatches, which further 
increase the diversity of the rRNA structure.  Some of the common secondary 
structures found in the ribosomal RNA, such as a hairpin loop, double-stranded 
region, bulge, internal loop, and junction are shown in Figure 1.3. The secondary 
structure of RNA is mainly composed of single- and double-stranded regions, but 
when they fold on themselves, they form various complex tertiary structural 
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Figure 1.3. Common secondary structures of RNA are shown: (A) single- and double-
stranded regions, (B) hairpin, (C) bulge, (D) internal loop, and (E) four-way junction. 
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motifs, such as the pseudoknot and A-minor motif. These tertiary structural motifs 
stabilize loop-loop interactions, contact between helices, and conformations of 
junctions (32). 
Phylogenetic sequence analysis was initially used to predict the rRNA 
secondary structure (33). Sequence comparison is a robust method to predict the 
secondary and tertiary structure of RNA. It is based on the principle that 
homologous RNA molecules, consisting of unique primary sequences, adopt the 
same secondary and tertiary structures (34). It identifies base pairing by finding 
sites of covariation between sequences in an alignment. Secondary structure 
predicted by this approach was initially validated by chemical and enzymatic 
probing. It was further confirmed when the crystal structure of tRNA was solved, 
and all of the predicted secondary interactions were shown to be accurate. After 
this, other RNA structures including 5S, 16S and 23S were also predicted based 
on covariation approach (35-36). With continuous improvements in the 
covariation algorithms and increase in the diversity of ribosomal RNA sequences, 
the secondary structure of 16S rRNA and 23S rRNA was further refined. This 
secondary map was validated initially with chemical probing, and afterwards with 
the subunit and later complete ribosome crystal structures. Approximately ~98% 
of the base pairs predicted by sequence comparison in 16S rRNA and 23S rRNA 
were found to be correct when the crystal structure was solved (34). The 
secondary structure of 16S rRNA is divided into four domains: the 5' domain 
(nucleotides 1-556), central domain (nucleotides 557-918), 3' major (nucleotides 
919-1396), and 3' minor domain (nucleotides1397-1542) (Figure 1.4) (37-38). 
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Similarly, the secondary structure of 23S has six domains (domains I-VI) 
(Figure1.5) (39). 
Secondary and tertiary structures found in the ribosome have very 
important roles in RNA stability and function. In ribosomal RNA, about 60% of the 
nucleotides are involved in Watson-Crick base pairing and 62% of adenosines 
are unpaired, while only about 30% of G, C and U are unpaired (34). However, 
the majority of nucleotides are involved in some kind of interaction within the 
folded RNA structure, and nucleotides that are not involved in any kind of 
interaction are very rare (40). The secondary structure of rRNA contains short 
helices that are connected by bulge or internal loops of unequal lengths. They 
have important roles in initiating RNA folding, stabilizing helical stems, making 
contacts with proteins, and participating in long-range tertiary interactions (40-
41). In all domains of life, the functional center of rRNA is highly conserved. 
Several studies have shown that the key functional part of the ribosome is in fact 
ribosomal RNA. Noller and coworkers treated 50S subunits of T. thermophilus 
with sodium dodecyl sulfate and proteinase K followed by phenol extraction, and 
found that 80% activity of the peptidyl transferase reaction was retained (42-43). 
In addition, these structural motifs are important target sites for a number of 
antibiotics. 
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Figure 1.4. The secondary structure of 16S rRNA of E. coli is shown (34). Domains are 
indicated and shown in different colors. (Figure taken from: http://rna.ucsc.edu/rnacenter). 
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1.2.3 Function 
The main function of the ribosome is protein synthesis. For this process to 
occur, the DNA sequence is first transcribed into mRNA by an RNA polymerase 
(44). In bacteria, the transcribed mRNA is directly used for translation and does 
not undergo post-transcriptional modifications. In eukaryotes, the transcribed 
mRNA from DNA is called the primary transcript and undergoes different 
maturation steps such as capping and splicing to produce mature mRNA (45). 
The process of capping adds a 7-methyl guanosine to the 5' end, and splicing 
removes non-coding sequences. 
Both ribosomal subunits have three tRNA binding sites: the A site 
(aminoacyl), which accepts the aminoacylated tRNA; the P site (peptidyl), which 
catalyzes peptide-bond formation; and the E site (exit), from which deacylated 
tRNAs leave during elongation. Protein synthesis begins with the binding of 
mature mRNA to the 30S subunit, guided by the Shine-Dalgarno sequence (46). 
Initiation factor 3 (IF3) prevents binding of the 50S, and initiation factor 1 (IF1) 
blocks initiator fMet-tRNA binding to the A site of the 30S subunit (47-48). After 
the f-Met-tRNA is correctly positioned, IF3 and IF1 are released and 50S binds to 
30S to form the 70S initiation complex. During this process GTP bound to IF2 is 
hydrolyzed. At this stage, all three initiation factors dissociate from the ribosome. 
This process leads to the formation of a functional 70S ribosome called the 
initiation complex (Figure 1.6) (49). 
The next step of protein synthesis is elongation, in which a new aminoacyl 
tRNA complex with GTP and EF-Tu (elongation factor thermo unstable) binds to  
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the A site (50). The decoding region present in the 16S rRNA of the small subunit 
selects the cognate tRNA according to the mRNA codon (51-52). Upon 
aminoacyl tRNA binding to the A site, GTP is hydrolyzed and EF-TU-GDP is 
released from the ribosome. After the correct aminoacyl tRNA is placed in the A 
site, peptide-bond formation occurs at the peptidyltransferase center (PTC) of the 
50S (50, 53). The amino acid f-Met from the initiator tRNA is then transferred to 
the aminoacid of the A-site tRNA. In the process of translocation, the deacylated 
tRNA and A-site tRNA, along with mRNA, move to the E site and P site, 
respectively. GTP hydrolysis and EF-G (elongation factor G) are the driving 
forces for this translocation step (54-55). This translocation process makes the 
ribosome ready for the next round of elongation, which continues until the 
ribosome reaches the stop codon on the mRNA (Figure 1.7). 
The final step of protein synthesis is termination and recycling of the 
ribosome. Termination occurs when the mRNA stop codon reaches the A site. 
The stop codon is recognized by release factors, RF1 and RF2 (56). Binding of 
release factor in the ribosome activates hydrolysis of the peptide chain from 
tRNA, and RF3 then promotes dissociation of RF1 and RF2. The ribosome is left 
with mRNA and deacylated tRNA in the P site after the peptide chain is released. 
This complex is dissociated by RRF (ribosome recycling factor) and EF-G with 
subsequent hydrolysis of GTP (57-59).  
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It is necessary to accurately match the correct aminoacyled-tRNA with the 
mRNA codon for protein translation. Before the sequence of 16S rRNA was 
known, it was observed that the modification of 16S rRNA by kethoxal abolished  
binding of tRNA to the ribosome (60). Afterward, footprinting techniques revealed 
that binding of the A-site tRNA strongly protected G529, G530, A1492, and 
A1493 against chemical modification (3). In further experiments, it was found that 
A1492 and A1493 of helix 44, as well as G530 of helix 18, are involved in the 
decoding process (48). This process selects the cognate tRNA and rejects the 
non-cognate or near-cognate tRNA. The accuracy of translation is 10-3 to 10-4  
per amino acid residue (61).  Similarly, two residues, A2451 and G2447, of the 
50S subunit in the PTC are crucial for peptide-bond formation. It has been shown 
that peptidyl transferase remains mildly active once many of the ribosomal 
proteins are removed, indicating this activity is largely catalyzed by rRNA (42). In 
addition, several structural and mutational studies have been carried out to 
establish the role of nucleotides in peptide-bond formation (62-64). To investigate 
the role of individual nucleotides in various regions of the ribosome, a number of 
mutational and structural studies have been carried out. From the random mutant 
library of 30S and 50S subunits, changes at 53 positions in 16S rRNA and 77 
positions in 23S rRNA displayed deleterious phenotypes (2, 65). In the decoding 
region, all 15 possible mutations were constructed at conserved nucleotides 
C1402 and A1500 of helix 44 of 16S rRNA. The results showed that most of the 
mutations lead to deleterious phenotypes showing the importance of these 
nucleotides for proper ribosome functioning (66).  
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1.3  Ribosome as a Drug Target and Antibiotic Resistance 
The ribosome is a well-validated drug target site because of its 
accessibility, structural diversity, and lack of known repair enzymes. Various 
classes of antibiotics bind within the functional centers of the ribosome and inhibit 
protein synthesis by different mechanisms. About 40% of the known drugs bind 
to the ribosome (67-68). The binding sites are found to be within a limited 
functional region of the ribosome, such as the decoding region, 
peptidyltransferase center, peptide exit tunnel, and intersubunit regions. The 
smaller subunit, 30S, is targeted by many antibiotics, including tetracycline, 
pactamycin and aminoglycosides (Figure 1.8 A, Table 1.1) (69-71). 
Aminoglycosides, such as neomycin, paromomycin, and geneticin, bind to the 
decoding region and cause bases 1492 and 1493 to flip out (70, 72). In addition, 
binding of these antibiotics to helix 44 of 16S rRNA causes a conformational 
change, which interferes with translational fidelity by increasing the 
misincorporation of aminoacylated tRNAs (73). Recent crystal structures of 30S 
complexed with aminoglycosides have greatly increased our understanding of 
antibiotic sites in the ribosome (69, 74). Before the success of crystallography, 
model systems of RNA were used to map the binding sites and interaction of 
antibiotics by chemical probing and NMR spectroscopy (70, 75-77). This early 
work in solution allowed researchers to compare and validate the results 
obtained from crystallography.  
Several important regions of the large subunit, 50S, are also targeted by 
antibiotics (Figure 1.8 B, Table 1.1). Several clinically important antibiotics such 
as macrolides, streptogramins, chloramphenicol, and oxazolidinones, bind to the  
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Figure 1.8. Various antibiotics bound to the ribosome are shown. A) Common antibiotics 
binding to the 30S subunit (PDB: 1FJG, 1HNX, 1HNJ, and 1HNW) are overlaid. B) Common 
antibiotics binding to the 50S subunit (PDB: 3CC4, 3CPW, 1K9M, 2ZJP 1NJI, and 1YJN) are 
shown.  
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Table 1.1. Common antibiotics targeting to the ribosome. Helix number and subunits are 
indicated. 
Antibiotics  Binding sites  Mechanism of action  
Aminoglycosides  
(neomycin, paromomycin, 
geneticin) (69, 78-79) 
A site  
(30S subunits)  
Decrease translational  
accuracy and inhibit 
ribosomal translocation  
   
Tetracycline (78, 80)  
 
helix 34/31 
 (30S) 
Inhibits A-site tRNA 
binding  
   
Peptides (viomycin, 
capreomycin, edeine) (80) 
30S subunits Inhibit translocation  
   
Spectinomycin (69)  helix 34 (30S) EF-G binding inhibitor  
   
Pactamycin (78) helix 24/P site (30S) Inhibits initiation factor  
   
Macrolides (erythromycin, 
azithromycin) (81-82) 
Peptide exit tunnel  
near PTC  
Block outlet of 
polypeptide 
   
Lincosamides (lincomycin, 
clindamycin) (82) 
Peptide exit tunnel  Interfere with peptide-
bond formation  
   
Chloramphenicol (82-83) A site, PTC  Inhibits peptide-bond 
formation 
Oxazolidinones (linezolid) 
(84-85) 
P site (50S) Compete with incoming  
aminoacyl-tRNA  
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large subunit near the PTC and inhibit protein synthesis (86). The macrolides are 
one of the important classes of ribosome-targeting antibiotics. Crystal structures 
of macrolides complexed with the 50S ribosomal subunit revealed that they block 
the ribosomal exit tunnel for the progress of nascent polypeptide (81). Similarly, 
streptogramins and chloramphenicol bind to the PTC and lock the conformation 
of the ribosome (83). Still, there are several antibiotics for which binding sites and 
mechanism of action have yet to be determined in detail. 
The enormous use of antibiotics and increasing antibiotic resistance of 
pathogens are the current challenges for scientists.  Bacteria may become 
resistance to antibiotics by various mechanisms, including target site 
modification, drug modification, and efflux (Figure 1.9) (87). To keep antibiotic 
concentrations low, drugs such as tetracyclines or erythromycins are pumped out 
through efflux mechanisms by bacteria (88). Penicillins were found to be 
destroyed by β-lactamases, while aminoglycosides such as kanamycin are 
chemically modified, which blocks binding to the recognition site (89). Mutations 
or nucleotide modifications such as methylation of the target residue have also 
been observed with several antibiotics targeting the ribosome. Modifications or 
mutations are found in both ribosomal proteins and ribosomal RNA. In 
spectinomycin resistance, mutation of a serine to proline at position 21 of the S5 
protein has been observed (90). Similarly, a lysine to arginine change at position 
42 of the S12 protein leads to streptomycin resistance (90). In RNA, modification 
of target residues has been found in several antibiotic resistance strains. 
Methylation of A1408 or G1405 leads to resistance to many aminoglycosides  
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Figure 1.9. Various mechanisms of antibiotic resistance in bacteria are shown.  
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(91-92). Similarly, N7 methylation of G1405 produces resistance to the geneticin 
class of aminoglycosides (93). Mutation of key residues in the decoding region, 
such as A1408G and C1409G, also causes resistance to most of the 
aminoglycosides (94-96). In the large subunit, methylation of A2058 at N6 leads 
to resistance of macrolide, clindamycin, lincosamide and spreptogramin, whereas 
methylation of C1920 makes bacteria resistant to capreomycin (97-100). In 
anisomycin resistance, mutations of U2500A and C2453U have been observed 
(101). Target-site mutation for ribosome-binding drugs is difficult because 
eubacteria carry multiple copies of ribosomal operons. E. coli has seven 
ribosomal operons, and at least half of them must be in the mutant form to confer 
antibiotic resistance (102-103). In addition, mutations often alter the ribosomal 
structure, which prevents binding without impairing the biological function. 
Mutations of certain nucleotides in the ribosome have been found to be lethal 
and several of them are essential for fidelity of protein synthesis (103). 
The antibiotic binding sites and resistance mechanisms determined from 
biochemical and genetic approaches are clarified by the high-resolution crystal 
structures (85, 104). High-resolution crystal structures can now be used to 
predict novel drug-binding sites as well as modified versions of existing drugs in 
order to overcome resistance. The binding sites of about half of the known 
antibiotics are found to be clustered in the central functional regions of the 
ribosome (71). A greater challenge is to identify and target unexploited sites in 
the ribosome. We do not know whether the known sites are the only ones for 
effective inhibition, or whether there are more possible target sites on the 
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ribosome. The ribosome is a complex and dynamic molecule that directs 
translation in several steps. For the purpose of identifying novel target sites or 
designing drugs on the basis of structure, a better understanding of the ribosome 
structure in solution, as well as functional importance of individual nucleotides, is 
needed.  
1.4  RNA Structural Studies 
There are a variety of methods for studying RNA structure. Cryo-electron 
microscopy (cryo-EM) X-ray crystallography and nuclear magnetic resonance 
(NMR) spectroscopy are the most popular methods for obtaining structural 
information of biomolecules. X-ray crystallography and cryo-EM are particularly 
well suited for large macromolecular complexes such as the ribosome. Solution 
studies such as NMR spectroscopy are typically limited to smaller systems.  
Other biophysical methods such as circular dichroism (CD) spectroscopy, UV 
melting, and fluorescence energy transfer (FRET) experiments are also very 
useful for understanding RNA structure and function (105-106). Another method 
to understand the RNA structure is chemical and enzymatic probing. The 
available probes are widely used to understand the environment of individual 
nucleotides at physiological conditions (e.g., solvent exposure, base pairing 
interactions, etc.) (107-108).  
1.4.1 Biophysical methods 
 Cryo-EM in combination with single-particle reconstruction has been 
utilized by Joachim Frank and coworkers to obtain pictures of the ribosome 
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during different stages of translation (109). In cryo-EM, molecules are rapidly 
frozen to maintain them in a nearly native state. Unlike crystallography, cryo-EM 
does not require highly ordered crystals (110). A 6.7 Å map of the E. coli 
ribosome was published in association with aminoacyl-tRNA (111). By this 
method, it is possible to analyze the motions and dynamic changes of the 
ribosome during translation. The resolution, however, is not as high as that 
obtained by X-ray crystallography.  
X-ray crystallography is the most powerful technique for studying larger 
RNA structures such as the ribosome. The first RNA structure determined by X-
ray crystallography was tRNAPhe (112). After that, the crystal structures of several 
small RNA were determined; however, the requirement of highly ordered crystals 
and solving the phase problem took a much longer time to solve in order to 
obtain crystal structures of the ribosome. In 1998, Tom Steitz and coworkers 
published the first crystal structure of the 50S ribosomes from Haloarcula 
marismortui at 9 Å (113). In 2000, Yonath’s, Steitz’s, and Ramakrishnan’s groups 
succeeded in determining the 30S or 50S subunit crystal structures at ~ 3 Å 
resolutions (69, 114-116). A considerable amount of effort has been made to 
obtain high-resolution structures of the ribosome, and for this groundbreaking 
work, the 2009 Nobel prize in chemistry was awarded to the three pioneers of 
ribosome crystallography, Thomas Steitz, Ada Yonath, and Venketash 
Ramakrishanan. Recent success in obtaining 70S ribosome structures in the 
presence of various antibiotics and initiation factors at highresolution has greatly 
increased our understanding of protein translation and the mechanism of 
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antibiotic action (104, 117). It has not only helped to understand ribosome 
function, but also increased information about antibiotic binding sites in various 
regions (118). For instance, neomycin binding was previously believed to occur 
only in the A site of the small subunit; however, a recent crystal structure showed 
that it also binds to helix 69 of 23S ribosomal RNA in the large subunit (119). 
Despite these successes from X-ray crystallography, detailed structural 
information in solution has not been obtained. 
NMR spectroscopy is a powerful tool for studying RNA structure in 
solution. This method gives high-resolution structural information of RNA in 
solution. The RNA folding and interactions with various ligands such as peptides, 
antibiotics, and proteins can also be determined by this method (120). However, 
the structure of a larger RNA structure such as rRNAs cannot be determined by 
this method. The current size limit is ~100 nucleotides (121). Another limitation of 
this method is the requirement for a large amount of highly pure sample and 
technical expertise. 
Several other biophysical methods are used extensively to obtain RNA 
structural information. Single-molecule spectroscopy and FRET measurements 
have been widely used to understand RNA folding, metal ion effects, and ligand 
binding. Notably, it was used to understand the movement of ribosomes at 
various stages of translation (106, 122). CD spectroscopy and UV melting are 
also helpful in determining the conformations and stabilities of small RNA 
constructs (105, 123). 
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1.4.2 Probing RNA Structure 
Structure probing carried out in solution is a popular method for RNA 
structure determination. It is based on the reactivity of RNA molecules with 
various chemicals or enzymes that target specific regions or nucleotides of the 
RNA (124). These probes can react with RNA in free form or in complex with 
ligands. Various chemical and enzymatic probes have been used to obtain RNA 
structural information (Figure 1.10). Though there are many advantages of using 
chemical and enzymatic probes, they also have their limitations. One advantage 
of this method is being able to test the reactivity of individual nucleotides in near 
physiological conditions. In addition, the effects of changing pH or salt 
concentrations can also be monitored (125). The RNA does not need to be highly 
pure, and any size of RNA molecule can be used. Due to their larger size, 
enzymes are not accessible to all small-molecule binding sites in the RNA. 
Similarly, chemical probes are limited to in vitro studies due to their inability to 
penetrate the cell due to size and/or charge. Only limited chemical probes such 
as dimethyl sulfate (DMS), Pb2+, and hydroxyl radicals have been utilized to gain 
structural information in vivo (108, 124). More recently, in-line probing (126) and 
selective 2’-hydroxyl acylation analyzed by primer extension (SHAPE) chemistry 
have been developed to determine RNA structure and to locate the binding sites 
of small molecules (127). For in-line probing, labeled RNA is incubated for 
extended periods of time (e.g., 40 hours) at higher pH (9.0), and spontaneous 
cleavage is detected. Small-molecule-binding sites can be observed as protected 
sites, whereas the other regions undergo strand scission. In SHAPE chemistry, 
reactivity of the 2'-OH groups with a bulky reagent is determined (128). Due to  
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Figure 1.10. Sites of RNA modification by base specific chemical probes and sequence 
independent probing methods are shown (129).  
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steric hindrance of the bulky group on the reagent, reverse transcriptase stop 
sites can be detected. The geometrical constraints of the 2'-OH group only allow 
the reaction to occur in the flexible regions, such as loop or bulges. Hence, this 
method is independent of the nucleotide type and measures the local dynamics 
of the nucleotide. This method is also useful for determining small-molecule-
binding sites and for acquiring information about secondary structure of RNA 
(129). 
1.4.2.1 Enzymatic probing  
RNases are structure or nucleotide specific and widely used for probing 
RNA structure (130). The commonly used nucleases with their specificity are 
listed in Table1.2. RNase V1 is specific to the double-stranded region (131). This 
ribonuclease cleaves in a sequence-independent manner, but requires at least 
two residues on either side of the cleavage site to be double stranded or stacked. 
Nucleotide-specific enzymes cleave after certain nucleotides. RNases A, T1, and 
T2 are the most common enzymes used to determine single-stranded regions 
(132). RNase T1 cleaves on the 3’ side of guanosine, whereas RNase A cuts 
single-stranded UpN and CpN containing sequences. RNase T2 cleaves all 
phosphodiester bonds in a single-stranded region, irrespective of the sequences 
(124, 132). RNases are useful for obtaining structural information and ligand 
binding sites in vitro. Unfortunately, RNases are bulky molecules and susceptible 
to steric hindrance, so in the folded RNA structure, the accessibility information 
obtained from enzymatic probing is less informative.  
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Table 1.2. Structure-specific enzymes for RNA structure probing. 
Nuclease  Specificity  Detection method  
RNase V1  Paired or stacked nucleotides  A and B            (131) 
Nuclease S1 Unpaired nucleotides  A and B            (108) 
RNase T1  Unpaired G  A and B            (133) 
RNase U2  Unpaired A>G>>C>U A and B            (134) 
RNase T2  Unpaired A>C, U, G A and B            (135) 
Mung bean 
nuclease  Single-strand specific  A and B            (136) 
RNase H  RNA only from DNA-RNA hybrids  A and B            (137) 
 
A: detection of cleavage on end-labeled RNA and B: detection by primer extension 
method.  
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1.4.2.2 Chemical probing 
Chemical reagents are smaller in comparision to enzymes and able to 
react with nucleotides of the RNA molecule (125). Chemical probes can react 
with nucleotide bases or the backbone of RNA. Their reactivity with nucleotide 
bases or the backbone is directly influenced by interactions present in the 
molecule. Base pairing or interactions with ligands strongly reduce reactivity 
towards the chemical probe. Chemical probes were developed based on specific 
criteria such as single-hit reactions per molecule of RNA, small size, and easy 
detection. Depending on the size of the RNA, identification of strand scission or 
modification sites is achieved by two different methods. For small RNA 
constructs, the RNA is directly radiolabeled on either the 3' or 5' end, and strand 
scission can be monitored by gel electrophoresis. This direct detection method 
works best for short RNAs containing less than 200 nucleotides (108). For larger 
RNAs, the strand scission or modification is detected by using primer extension. 
Reverse transcriptase shows pauses or stops before the 3' side of modified or 
cleaved nucleotides. The most commonly used chemical probes with their 
respective modification or cleavage sites and the methods for their detection are 
listed in Table 1.3.  
Chemical probes are basically of two types on the basis of their target 
sites; base-specific and backbone (ribose-phosphate) specific. The base-specific 
probes are the most widely used to gain information about the secondary 
structure of RNA. Dimethyl sulfate (DMS) methylates the N1 position of adenine, 
and N3 of cytosine, which are not involved in Watson-Crick base pairing. 
Similarly, kethoxal reacts with N1 and N2 of guanine, while CMCT (1-cyclohexyl 
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Table 1.3.  Structure-specific chemical probes for RNA. 
Probing agents  Specificity 
Detection method 
 
Nucleotide 
modifying 
agents 
(107, 124, 138) 
DMS 
A (N1), C (N3),  
G (N7) 
       A, B, C 
C 
DEPC A(N7) A, B, C 
Kethoxal G (N1-N2) B, D 
CMCT G (N1), U(N3) B 
Hydrazine U>>C A, B. C 
Radical 
generators/ 
metal 
complexes 
(139-141) 
 
Fe(EDTA)2- Solvent-exposed 
backbone (C1', C4') A, B 
Cu(phen)2+ Accessible SS 
regions A, B 
Rh(DIP)33+  
SS solvent exposed 
G & Ψ, 3' side of GU 
wobble pairs 
A, B 
CoCl2 SS solvent-
accessible G A, B 
Synchrotron X-rays (142) Solvent-exposed 
backbone (C1', C4') A, B, C 
Backbone 
modifying 
agent (124) 
Ethylnitrosourea Phosphate A, B 
 
A: detection of cleavage on end-labeled RNA; B: detection by primer extension; C: 
chemical treatment is necessary for strand scission prior to the detection; D: RNaseT1 
hydrolysis can be used after modification; SS: single stranded (108, 124-125). 
32 
 
 
-(2-morpholinoethyl)carbodiimide metho-p-toluene sulfonate) modifies N3 of 
uridine (138, 143). Based on the reactivity of these chemical probes, the folded 
structure of RNA can be determined. Since the modification occurs in the 
Watson-Crick base pair regions, these sites of modification can be detected by 
primer extension directly. However, DMS and diethyl pyrocarbonate (DEPC) can 
also methylate the N7 position of guanine and adenine, respectively. To detect 
these modifications, aniline treatment and strand scission are required (124). 
These chemical probes are not only used for smaller RNA structures, but also 
larger RNA structures such as 16S and 23S rRNA. Danesh Moazad and Harry 
Noller have mapped nucleotide reactivity in free rRNA, in intact subunits, and 
70S ribosomes (144-145). They have not only determined the higher-order 
structure of rRNA, but also explored protected and exposed nucleotides after 
ribosome assembly (145-147).  
Another class of probes attacks the ribose-phosphate backbone, resulting 
in strand scission. This type of chemical probe generates free radicals from a 
reaction between the reagents, such as the Fe•EDTA complex and H2O2 (148). 
The hydroxyl radical generated by the Fe•EDTA attacks the C1' and C4' 
hydrogens of the ribose sugar, which leads to strand scission. More recently, 
synchrotron X-ray beams were used to generate hydroxyl radicals in the 
millisecond range. This time-resolved probing method is very useful in 
determining the larger RNA folding pathway (149-150). Another reagent, 
ethylnitrosourea, ethylates phosphates, which become unstable and easily 
cleaved with mild alkaline treatment (151). 
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1.4.2.3 Probing RNA structure in vivo 
Structural features of RNA are significant for biological function. The use 
of X-ray crystallography, NMR spectroscopy, and other biochemical and 
biophysical approaches have enhanced the ability for determining RNA structure. 
Since the folding of RNA might be different in a more complex environment such 
as living cells, it is highly important to study RNA structures in vivo. Methods and 
probes that are useful for studying RNA structure in vivo are limited. The most 
commonly used are DMS, kethoxal, and lead (II) (152-153). DMS can cross the 
cell wall and membrane efficiently by diffusion, but other reagents need 
permeabilization of the cells. 
Chemical and enzymatic probes are very useful to test the reactivity of 
individual nucleotides and predict their accessibility, as well as function in RNA 
structures. Several chemical and enzymatic probes have been used to probe the 
RNA structure, but most of them are limited for in vitro study. Another limitation is 
that enzymes can induce conformational rearrangements, which generates 
possible new target sites and makes the results harder to interpret. In addition, 
these chemical and enzymatic probes cannot be utilized to monitor the kinetics of 
the reaction. Hence, a chemical probe that can be used for probing and 
monitoring kinetics would be very useful. The aquated platinum complex to be 
discussed is positively charged and can be utilized as a model to understand the 
kinetics of charged small molecules. Further, it has already been shown to have 
potential for probing the ribosome structure in vitro and in vivo. Another 
advantage of cisplatin is that its size and charge can be altered easily, and hence 
would be useful to gain more information of RNA structure.  
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1.5 Cisplatin  
Cisplatin, cis-diamminedichloridoplatinum (II), is an anticancer drug used 
to treat various cancers such as testicular, head and neck, and cervical (154-
156). The cure rate is over 90% in testicular cancer when tumors are diagnosed 
early (157). Despite its success, cisplatin is only active against limited cancers 
and causes several side effects such as nephrotoxicity, neurotoxicity, and 
hearing loss (158-159). The biological activity of cisplatin was first discovered in 
the 1960 by Rosenberg and co-workers at Michigan State University (160). While 
testing the effects of electric current in E. coli, they observed inhibition of cell 
growth. They observed that cells were unable to divide and the morphology 
changed. Cells were elongated 300 times longer than the normal cells (160). It 
was later found that this effect was not caused by the electric current, but rather 
the production of the cisplatin from platinum electrodes. This result led 
Rosenberg to test cisplatin in several mice with tumors, and subsequently 
anticancer activity was observed (161). After the successful treatment of several 
tumors in clinical trials, cisplatin was finally approved by the FDA in 1978.  
1.5.1  Biological targets of cisplatin  
 Cisplatin can enter the cell by passive diffusion or using by copper 
transporters (162-163). The low chloride concentration in the cell facilitates the 
exchange of a chlorido ligand with water to form the aquated species. The 
resulting species [PtCl(NH3)2(H2O)]+ is more reactive and subsequently attacks 
the N7 of purine bases. The primary target of cisplatin is found to be DNA, but it 
can also attack RNA, proteins, and sulfur-containing biomolecules (156, 163). 
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Cisplatin preferentially binds to G-rich sequences in DNA. The number of 
platinum molecules bound to these macromolecules has been determined in 
HeLa cells with a colony forming assay (164). This result showed that one DNA 
contained 22 platinum atoms, while only one platinum atom was found per 
mRNA. Similarly, one platinum atom was observed per 30 ribosomes and one 
per 1500 tRNA. Proteins contained a fewer number of platinum atoms; out of 
1500 protein molecules, only one equivalent cisplatin was observed. Another 
study was carried out with 195mPt-radiolabeled cisplatin to determine the 
number of platinum atoms that would bind to macromolecules in Hela cells (165). 
This study showed similar results, which indicated DNA as the main cellular 
target. These early studies showed that the most important cellular target of 
cisplatin was DNA, while its effects on RNA and other macromolecules was 
mostly overlooked. The binding of cisplatin to DNA has been discussed 
extensively in the literature (156, 163, 165-166), but only a handful of 
publications focus on RNA as a target. 
Recent studies showed that RNA is a competitive target for cisplatin under 
similar conditions as DNA reactions (167-169). When DNA and RNA molecules 
with similar structures and sizes were compared, RNA was found to be the 
kinetically preferred target over DNA (167). In addition, RNA showed a more 
pronounced salt dependence, indicating that electrostatic interactions are 
important (167). A similar result was published by DeRose and coworkers, in 
which the kinetic preference for cisplatin in the U2/U6 RNA compared well to its 
DNA counterpart (170). They have compared cisplatin binding to RNA with an 
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internal loop, double-stranded RNA, and a corresponding looped DNA. Among 
these constructs, the RNA with an internal loop had the highest reactivity, while 
DNA had the lowest. Another study was done with tRNA by Elmorth and 
coworkers (168). Mapping of the binding sites in tRNA and its corresponding 
microhelix revealed that cisplatin forms cross-links in a common site on the 
RNAs, despite the difference in their sizes (168). 
1.5.2 Types of platinum-DNA adducts and their effects 
The identification of major cisplatin cross-links formed with DNA was 
carried out by digestion of cisplatin-treated salmon sperm DNA (171). After 
enzymatic digestion, the products were separated by a chromatographic 
technique and analyzed by NMR spectroscopy (172). The most common cross-
links were the 1,2-intrastrand adducts with purine bases, mostly the 1,2-
intrastrand d(GpG) and d(ApG) adducts which constitute ~65% and ~25% of all 
adducts respectively. Less common was the 1,3-intrastrand d(GpXpG) adduct 
(Figure 1.11). Cisplatin also formed a small amount of interstrand and 
monofunctional adducts with guanine (171-172). 
The formation of cisplatin DNA cross-links leads to distortion of the DNA 
structure. Previous studies showed that cisplatin lesions cause bending, 
unwinding, and destabilization of the DNA double helix (173-174). The formation 
of cisplatin cross-links also inhibits DNA and RNA polymerases for replication 
and transcription processes (163). Bifunctional adducts inhibit polymerases more 
effectively than monofunctional adducts (175-177). In addition, the bending of 
DNA serves as a recognition site for a number of cellular proteins, such as high 
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mobility group proteins (HMG), histones, and transcriptional proteins (178-179). 
The binding of these proteins is believed to shield the platinum adducts from 
repair so that when the DNA repair machinery works to fix the cross-links, failed 
attempts activate apoptosis and cell death (166).  
 
 
Figure 1.11. The types of cisplatin DNA cross-links and their corresponding ratios are 
shown.  
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1.5.3 Cisplatin analogues    
Compared to cisplatin, its trans isomer, trans-DDP, is clinically ineffective. 
This might be due to its inability to form adducts similar to that of cisplatin. 
Although both of these isomers form bifunctional adducts through the N7 position 
of purine bases, trans-DDP is unable to form 1,2-intrastrand cross-links due to its 
stereochemistry. More than 3000 analogues of cisplatin have been synthesized 
to overcome cisplatin resistance (180); however, only less than 30 compounds 
have entered clinical trials and only one has been approved by the FDA (166).  
Hitherto, only four platinum compounds are listed as marketed drugs, namely, 
cisplatin, carboplatin, oxaliplatin, and nedaplatin (Figure 1.12) (166, 181). Among 
these, carboplatin is less toxic than cisplatin, but has the same spectrum of 
antitumor activity (182). Oxaliplatin is the only platinum compound that shows 
acitivity against cisplatin-resistant colorectal cancers (181). Most of the useful 
antitumor analogues are mostly associated with the property of labile group. 
Complexes with highly labile groups are very toxic and cannot be used as drugs. 
Those types of complexes react with almost all types of nucleophiles available in 
the cell. In contrast, strongly bound ligands produce kinetically inactive 
complexes (183). The second generation platinum drug, carboplatin, has lower 
reactivity due to the weaker labile carboxylate group. This effect causes a slower 
rate of conversion of carboplatin to aquated reactive species. Due to slower 
reactivity, higher doses can be tolerated and give fewer side effects. Carboplatin 
has been used for ovarian cancer, but shows cross resistance with cisplatin (166, 
184). Another analogue, oxaliplatin, is most effective against colon cancer (163). 
In this compound, both the ammine ligands and chlorido groups are altered from 
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those of cisplatin (166). Most recently, water-soluble platinum complexes and 
complexes that can be used orally, such as JM216, have been synthesized (166, 
185). 
 
 
Figure 1.12. Cisplatin and its analogues are shown.  
 
Several amino-acid and peptide-conjugated cisplatin analogues have 
been synthesized and tested against various tumor cell lines (Figure 1.13) (186-
187). Modifications include platinum complexes with charged, neutral, or 
hydrophobic amino acids coordinated to the platinum (188-189). Those 
modifications increase the charge or hydrophobicity of the complex, and could 
potentially alter the binding interactions with the target. Similarly, peptide-
tethered platinum conjugates were also synthesized and their interactions with  
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Figure 1.13. Structures of platinum(II) amino acid complexes are shown. 
 
DNA were studied; however, additional functionalities did not increase their 
reactivity (186, 190). The uncharged compounds have lower reactivity compared 
to cisplatin and positively charged compounds have higher reactivity than the 
negatively charged compounds, possibly due to electrostatic interactions (186). 
Although the overall reactivity of the amino-acid platinum complexes was lower 
than cisplatin in DNA, their interactions with RNA have not been discussed in the 
literature, to the best of my knowledge. 
1.6 Objective of Research  
With the continually expanding antibiotic resistance of pathogens it has 
been a challenge for researchers to design and develop new antibiotics. Out of 
the various drug target sites, the ribosome is an important target to which 
different classes of antibiotics bind at its key functional regions, such as the 
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decoding center, peptidyltransferase center, and peptide exit tunnel. Recent 
crystal structures have revealed a number of antibiotic-binding sites in the 
ribosome, and it is interesting to note that many of these sites are overlapping. 
Now, it is important to develop novel target sites and to design new drugs that 
can help to solve the ever-growing problem of resistance. To achieve this goal, 
the ideal target sites should not only be functionally important, but also 
accessible to various small molecules. A number of chemical and enzymatic 
probes have been used to gain structural information and to understand solvent 
accessibility of the ribosome, but most of them are limited to in vitro studies or 
they are difficult to detect in solution. Cisplatin has advantages due to its stable 
coordination chemistry, which makes its detection easier; thus, more information 
about structural accessibility can be gained. Further, the platinum complexes can 
be modified with various ligands to alter the charge and size. A number of 
antibiotics bind to the ribosome by electrostatic interactions and it is difficult to 
monitor the kinetics. Cisplatin and its charged analogues can be utilized as a 
model to understand how charged small molecules such as neomycin find their 
target sites out of the numerous possible sites on the ribosome. 
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CHAPTER  2  
Binding Studies and Adduct Characterization of Cisplatin in 16S 
Ribosomal RNA  
2.1 Abstract  
DNA is a well-validated target of cisplatin and various mechanisms leading 
to the anticancer activity have been extensively studied. In comparison to DNA, 
much less is known regarding the extent to which cisplatin interacts with cellular 
RNAs and whether that influences the activity and toxicity of the drug. Recently, 
cisplatin binding to small RNA constructs and tRNA has been studied. In this 
chapter, the binding sites of cisplatin on 16S rRNA, which were mapped by the 
primer extension method, are discussed. Most of the consecutive guanosines in 
free 16S rRNA were found to be reactive with cisplatin. In addition, the number, 
as well as types, of adducts formed with cisplatin on 16S rRNA were also 
characterized.  
2.2 Introduction  
Cis-diamminodichloridoplatinum(II), or cisplatin, is an antitumor drug that 
has been utilized effectively in the treatment of several types of cancers, such as 
testicular, breast, ovarian, lung, and head and neck (156, 163, 166). After the 
discovery of its antitumor activity, much research has focused on understanding 
the mode of action of this compound (160-161). The formation of several types of 
stable adducts with nucleic acids, such as 1,2-intrastrand and 1,3-intrastrand 
along with a lower number of interstrand, through coordination to the N7 position 
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of purines, is believed to contribute to its antitumor activity (172, 191). The 
formation of these adducts with DNA causes structural changes, which block 
replication and transcription processes (163). An X-ray crystal structure revealed 
that the 1,2-intrastrand adduct induces a bend in a DNA duplex by 35-40º and 
unwinds the DNA by ~25º; however, solution structures by NMR showed 60-70º 
bend angles (Figure 2.1) (192-194). Cellular proteins recognize these DNA 
lesions and undergo a series of events, eventually leading to cell death (163, 
166, 195). The reaction of cisplatin with DNA has been studied and discussed 
extensively in the literature (163, 166, 172, 191, 196-197); however, the effects of 
cisplatin on RNA function are poorly understood. Despite RNA’s chemical 
similarity to DNA and its greatly increased role in various cellular processes (198-
199), very little is known about cisplatin’s effects on cellular processes involving 
RNA.  
Previous reports suggested that the amount of cisplatin reacting with RNA 
is much less than with DNA (165, 200), which might be the reason why RNA has 
been overlooked as a target of cisplatin. However, there are several pieces of 
evidence that show RNA is a competitive target for cisplatin. Previously, cisplatin 
was found to cause disruption of translation and splicing in cell extracts (201-
203). This fact is further supported by recent in vitro studies showing disruptions 
in the activity of various enzymes (170, 204), so it can be expected that the 
binding of cisplatin to RNA may also contribute to the drug’s anticancer effect. In 
another study, when similar structures and sizes of DNA and RNA hairpins were 
compared for cisplatin reaction, RNA was found to be the kinetically preferred 
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target (167, 205). A similar result was reported by DeRose and coworkers in 
U2/U6 RNA; they have shown that platination of the U2/U6 RNA a has higher 
kinetic preference for RNA than the corresponding DNA construct (169).  
 
 
 
Figure 2.1. X-Ray crystal structures of double-stranded DNA containing the cisplatin 
adduct are shown: A) cisplatin 1,2-d(GpG) intrastrand cross-link (3LPV) (193) and B) 
cisplatin 1,3-d(GpTpG) intrastrand cross-link (1DA4) (206). 
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Cisplatin binds DNA in a structure specific manner and forms cross-links 
at specific sites despite the sizes of the nucleic acids (168, 207). Elmroth and co-
workers studied the rate of platination of 17-nucelotide DNA sequences with 
guanosines at different locations (﴾TnGT16-n﴿ DNA constructs) (207). The rate of 
adduct formation was found to be the highest when guanosine was in the middle 
of the sequence. In addition, they compared cisplatin reactions with tRNAAla and 
a corresponding micro-helix, which revealed similar platination sites at the G○U 
wobble pair in an acceptor stem of tRNA, despite the different RNA sizes (168). 
Furthermore, cisplatin binding to tRNAPhe observed in a crystal structure showed 
cross-links at certain GG and AG sites that caused a distortion in the tRNA 
structure (208-209). Hence, targeting RNAs such as tRNA, mRNA, and rRNA 
may provide another potential pathway for cisplatin and related drugs’ 
mechanism of action (210). Cisplatin effects in model RNA systems have been 
studied to some extent; however, the mechanistic details and binding sites in 
larger RNA have yet to be discovered.   
Although the primary structure of DNA and RNA are very similar, larger 
RNAs such as ribosomal RNAs have a tendency to fold into complex three-
dimensional structures (40). The folding of RNA creates local microenvironments 
with various properties in terms of solvent accessibility and metal coordination. 
Various metal complexes have been used to identify structural motifs or 
mismatches in DNA and RNA structure (139-140, 211-212). Metal complexes are 
capable of specific interactions with target sites in nucleic acids. Rhodium 
complexes such as Rh(byp)2(chrysi)3+ bind with high specificity and affinity to 
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single base mismatches (213). Similarly, Rh(DIP)33+ induces a strand scission in 
RNA near the G○U mismatches, as well as exposed Gs (211). Cisplatin has 
been found to react with G-rich sequences in DNA and small RNA constructs. 
Hence, metal complexes were found to have some specific interaction with 
nucleic acids. The study of cisplatin binding to the ribosome may increase our 
understanding of its interactions with much larger RNA structures. 
The number and types of cross-links formed with DNA by cisplatin and 
various analogues have been well characterized (171-172). Two research 
groups, Eastman and Fichtinger-Schepman et al., have determined various 
adducts formed with DNA (171-172, 191). Both of these research groups 
observed intrastrand bifunctional cross-links as the major adducts along with a 
small amount of monofunctional adducts with guanosine (171). In the context of 
RNA, the number of cisplatin binding sites and possible types of adducts have 
not been well documented.  
The overall goal of this chapter is to find the cisplatin binding sites in 16S 
rRNA and determine the types of adducts formed by using various methods 
(Figure 2.2). The results from these experiments will be significant to understand 
the mechanism of cisplatin action on large folded RNA structures. Due to 
structural differences, it was expected that the binding sites and types of adducts 
formed with RNA might be different than DNA. In this study, mapping of the 
cisplatin binding sites in 16S rRNA, as well as characterization of the cisplatin 
adducts was performed. 
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Figure 2.2. An overview of the cisplatin binding study in 16S rRNA is shown. Cisplatin, the 
corresponding monoaquated species, tertiary structure of 16S rRNA, and various methods 
used in this study are indicated. 
2.3 Materials and Methods 
2.3.1  Chemicals, solutions, and DNA  
  [5'-32P-γ]ATP was purchased from Perkin-Elmer Life Sciences, Inc. 
(Waltham, MA), and T4 polynucleotide kinase was obtained from New England 
Biolabs (Ipswich, MA). RNaseT1 and P1 nuclease were purchased from Sigma 
Chemicals. A reverse transcriptase kit (Improm_IITM Reverse Transcriptase) was 
purchased from Promega (Madison, WI). The remaining chemicals for buffers, 
and reagents such as DTT (dithiothreitol), EDTA (ethylenediaminetetraacetic 
acid), DMF (N, N-dimethyl formamide) were obtained from Sigma Chemicals or 
Fisher. RNase-free, distilled, deionized water (ddH2O) was used for all 
experiments. 
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 Cisplatin, cis-diamminedichloridoplatinum(II), was purchased from Alfa 
Aesar (MA, USA). The complexes cis-[PtCl(NH3)2X]+/0 or cis-[Pt(NH3)2X2]2
+/0, in 
which X was H2O, DMF, or NO3-, were prepared by addition of 0.98 or 1.96 
equivalents of AgNO3 to a DMF solution of cis-[PtCl2(NH3)2], respectively. The 
reaction mixture was vortexed in the dark for 12 hours, the AgCl precipitate was 
removed by centrifugation, and the supernatant containing platinum complex was 
recovered. Platinum-DMF complex stock solutions were stored at -20 °C up to 1 
week and diluted as required just prior to use. 
 Single-stranded DNA primers were purchased from Sigma Genosys and 
purified by using polyacrylamide gel electrophoresis (20%, 19:1 
acrylamide:bisacrylamide, 7 M urea ) in 1X TBE (90 mM Tris·HCl, 90 mM boric 
acid, 2.5 mM  EDTA, pH 8.3) followed by electroelution in 0.5X TBE in an Amicon 
CentrilutorTM and desalted. Aqueous solutions of DNA were kept frozen at -20 °C 
and concentrations were determined spectrophotometrically at 260 nm. 
Sequences of the DNA primers were named according to the position of the 
transcribed nucleotides, and are as follows: 
1) 5'-CAC TCG TCA GCA AAG AAG-3 (p_86), 2) 5'-GCG ACG TTA TGC GGT 
AT-3' (p_171), 3) 5'-GTT ACC CCA CCT ACT AGC T-3 (p_245), 4) 5'-AGT CTG 
GAC CGT GTC TC-3'  (p_323), 5) 5'-CCC GCT GAA AGT ACT TT-3 6) (p_431), 
5'-GTG CTT CTT CTG CGG GTA-3' (p_485), 7) 5′-CGC TTT AGG CCC AGT 
AAT-3 (p_561), 8) 5′-GCC AGT ATC AGA TGC AGT-3 (p_631), 9) 5′-CTA CGC 
ATT TCA CCG CT-3′ (p_686), 10) 5'-CGC ACC TGA GCG TCA GTC T-3' 
(p_746), 11) 5′-ACC AAG TCG ACA TCG TTT-3′ (p_813), 12) 5′-CCG TCA ATT 
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CAT TTG AGT TT-3′ (p_906), 13) 5′-GTC AAG ACC AGG TAA GGT-3′ (p_982), 
14) 5′ GAG CTG ACG ACA GCC AT-3′ (p_1054)) 15) 5′-GCA ACA AAG GAT 
AAG GGT-3 (p_1110), 16) 5′-TCG TAA GGG CCA TGA TG -3′(p_1199), 17) 5′-
GCG AGG TCG CTT GTC TTT-3′ (p_1251), 18) 5′-CTC CAA TCC GGA CTA 
CG-3 (p_1296), 19) 5′-GAA CGT ATT CAC CGT GGC-3 (p_1365), 20) 5'-GTT 
AAGCTA CCT ACT TCT-3′ (P_1430), 21) 5'-TAC CTT GTT ACG ACT TC-3'  
(p_1490). 
 The primer hybridization sites on the secondary structure of 16S rRNA are 
shown in Figure 2.3, with primer numbers 1 to 21.  
2.3.2  Isolation of 16S rRNA 
The 70S ribosomes and 30S subunits were isolated from E. coli DH5 
strain by the sucrose gradient method (145, 214). E. coli was grown to 0.6 OD 
and cooled on ice for 20 min followed by centrifugation at 7,000 rpm for 15 min to 
pellet the cells. The pellet was resuspended in buffer A (50 mM Tris·HCl, 100 
mM ammonium chloride, 10 mM MgCl2 and 1 mM EDTA). The cells were lysed 
by using a French Press at 1800 psi. In the lysate, 5 U of DNase I was added 
and incubated on ice for 15min. The lysate was centrifuged at 15,000 rpm for 20 
min to remove the cellular debris and about 2/3 of the supernatant was 
transferred to a new tube. After a second centrifugation, the supernatant was 
transferred to a new tube and the ammonium chloride concentration was raised 
to 200 mM. To pellet the ribosome, centrifugation was carried out in an 
ultracentrifuge at 42,000 rpm for 4 hrs. The supernatant was discarded and the 
pellet was washed with buffer B (50 mM Tris·HCl, 100 mM ammonium chloride,  
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Figure 2.3. Secondary structure map of 16S rRNA with primer hybridization sites with 
primer numbers (1 to 21) is shown. 
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10 mM MgCl2). The 70S ribosome pellet was resuspended in buffer B by shaking 
overnight at 4 ºC. The dissolved ribosome was taken carefully and its 
concentration was measured spectrophotometrically. To get pure 70S ribosomes, 
50S subunits and 30S subunits, the crude ribosomes were layered in a 10% to 
30% sucrose gradient in buffer B with 5 mM MgCl2 and centrifuged in a swinging 
bucket rotor at 18,000 rpm for 16 hrs. Fractions corresponding to the 70S 
ribosomes, 50S subunits, and 30S subunits were pooled and the Mg2+ 
concentration was again raised to 10 mM. Sucrose was removed by 
centrifugation in an ultracentrifuge at 42,000 rpm for 18 hrs and the pellet was 
dissolved in buffer E (10 mM Tris·HCl, 60 mM ammonium chloride, 10 mM 
MgCl2). Naked 16S rRNA was isolated from 30S subunits by three extractions 
with phenol and two with chloroform in the presence of 6 mM EDTA. The 16S 
rRNA was precipitated by addition of 0.1 volumes of 3 M sodium acetate, pH 5.3, 
and 2.5 volumes of ethanol. The isolated 16S rRNA was renatured in 20 mM 
Tris·HCl (pH 7.5), 25 mM NaCl, and 10 mM MgCl2 by heating to 90 °C for 2 min 
and slowly cooling to room temperature.  
2.3.3  Platination reactions 
The platination reactions with naked 16S rRNA were performed with 
monoaquated cisplatin. Prior to platination, the 16S rRNA was renatured as 
stated above. Platination was carried out in 20 mM sodium phosphate buffer, pH 
6.5, 10 mM MgCl2 and 10 mM NaCl (buffer P) (215). Alternatively, 20 mM 
HEPES, pH 6.5, 10 mM MgSO4 and 10 mM Na2SO4 (buffer H) was used, which 
had a lower chloride concentration. The 16S rRNA was incubated at 37 °C with 
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aquated complex in 1:150, 1:75, and 1:30 ratios of metal complex to nucleotides 
(16S rRNA to metal complex is 1:10, 1:20, and 1:50). The reactions were 
quenched with 2 M NaCl followed by immediately freezing. A salt dependence 
study was carried out with the 1:75 ratio of complex to nucleotides in the same 
buffer (buffer H) with increasing concentration of Na+ using NaClO4.  
2.3.4 Primer labeling and primer extension 
Primers were labeled at the 5' end in T4 PNK buffer (50 mM Tris·HCl, pH 
7.6, 10 mM MgCl2, 5 mM DTT, 0.1 mM spermidine, 0.1 mM EDTA) with 10 µCi [γ 
-
32P] –ATP  and 10 units T4 polynucleotide kinase in a volume of 50 µl at 37 °C. 
RNA was ethanol precipitated after the reaction. The labeled primer was used for 
primer extension on the free 16S rRNA (216). Primer extension was carried out 
with 2 pmol of 16S rRNA after reaction with cisplatin. Next, 2 μl of the appropriate 
5'-end-labeled primer (200,000 cpm) and 2 μl of 1 pmol/μl 16S rRNA were mixed 
with 6 μl ddH2O and heated to 90 °C and then slowly cooled to room temperature 
for hybridization. The extension mix was prepared by mixing 4 μl of reverse 
transcriptase buffer (Promega), 2.4 μl of 25 mM MgCl2 and 1 μl of 10 mM dNTPs 
(10 mM each dATP, dCTP, dGTP, and dTTP), 5.6 μl H2O and 1 μl reverse 
transcriptase (Promega). For sequencing, 1 μl of the 10 mM dNTP mix and 1 μl 
of the appropriate 1 mM ddNTP were used. Unmodified RNA (no cisplatin 
treatment) was used as a template for sequencing and for control lanes to 
monitor artifacts of reverse transcriptase. Extension of the primer was carried out 
at 42 °C for one hour and terminated by heating at 80 °C for 15 minutes. To each 
sample, 2 μl of loading buffer (80% formamide, 1X TBE, 0.02% bromophenol 
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blue, and 0.02% xylene cyanol) was added and the products were denatured by 
heating to 95 °C for 2 min followed by rapid cooling on ice. To the sequencing gel 
(0.4 mm thick, 8% polyacrylamide, acrylamide:bisacrylamide 19:1, 1X TBE, 7 M 
urea), 60,000 cpm per sample was loaded. The gel was run at 1500 volts for 
approximately 2 hours until the bromophenol blue migrated off the gel. The 
products were identified by imaging on a Molecular Dynamics Phosphorimager 
and Image QuantTM Software. 
The gels were quantified using Image Quant software. The intensity was 
normalized by calculating the percentage intensity at the corresponding stop with 
respect to intensity of the whole lane. More than 1% intensity at the 
corresponding stops were considered as strong hits, 0.5 to 1.0% were moderate 
hits, and less than 0.5% were considered as weak stops. The reaction ratio 
cisplatin:nucleotide (1:75) and control were used for quantification.  
2.3.5 High performance liquid charomatography 
HPLC was carried out with a Waters system equipped with a C18 
Discovery column (250 x 4.6 mm, 0.5 µm). Separation was carried out by using 
buffer A (40 mM ammonium acetate) and B (40% acetonitrile) with a linear 
gradient in which the ratio of A to B changed from 95:5 to 70:30 over 30 minutes 
at a constant flow of 1 ml/min. The retention times of the standard nucleosides 
were confirmed by injection of known standard nucleosides. Control and 
platinated 16S rRNAs were digested with nuclease P1 to convert to nucleotides, 
and calf intestinal phosphatase (CIP) was used to remove phosphates and give 
free nucleosides. Nuclease P1 digestion was carried out in 50 µl of digestion 
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buffer (1 mM ZnCl2, 20 mM sodium acetate, pH 5.3), for both the control and the 
platinated 16S rRNAs with 10 µl (10 U) of nuclease P1 at 37 ºC overnight. The 
enzyme was then deactivated by heating at 75 ºC for 15 min. Five µl of 1.5 M 
Tris·HCl, pH 8.8, and 1 µl (10 U) of CIP was added to each sample, which were 
incubated for 4 hrs at 37 ºC. After 4 hrs of incubation, samples were again 
heated at 75 ºC for 15 min, vortexed, and centrifuged at 12,000 rpm for 5 min. 
Finally, samples were filtered through YM-3 microcon filters before injection into 
the HPLC or LC-MS.  
Samples were analyzed by HPLC and peaks areas were normalized to 
account for the differences in extinction coefficients at 260 nm (C = 9,100 M-1 cm-
1, U= 10,100 M-1 cm-1, G= 13,600 M-1 cm-1, A= 14,900 M-1 cm-1) (217) and then 
peak ratios were calculated relative to the cytidine peak. 
2.3.6 Liquid chromatography mass sectrometry 
LC-MS (Liquid Chromatography Mass Spectrometry) is a powerful 
technique to separate and analyze complex mixtures with high sensitivity. LC-MS 
was carried out on an AQUITY Ultra Performance LC chromatography (UPLC) 
system (Waters Corporation, MA USA) equipped with an HSST3 C18 column 
(2.1 X 100 mm 1.8 µm). The column was maintained at 50 ºC and elution was 
carried out with a linear gradient of acetonitrile and 100 mM ammonium acetate, 
pH 6.0. The gradient was run for 3 min with a flow rate 700 µl/min, starting at 
100% ammonium acetate and decreasing to 60% over the course of the gradient. 
The column eluent was analyzed by directing it to the mass spectrometer. Mass 
spectra were collected in the positive ion mode. The percentage of adducts were 
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calculated by normalizing the area with extinction coefficients followed by relative 
ratios of adduct present in sum of adducts.   
2.4 Results 
2.4.1 Mapping platination sites in 16S rRNA 
Cisplatin, after aquation, was used to probe 16S rRNA. The monoaquated 
complex was employed because it is cationic and has ideal reaction kinetics 
compared to the slowly reacting cisplatin. The binding sites of monoaquated 
cisplatin were mapped on free 16S rRNA by primer extension. In order to map 
the binding sites, 16S rRNA was first isolated from E. coli, renatured, and then 
incubated with monoaquated cisplatin (1:10, 1:20 and 1:50 molar ratios of 16S 
rRNA:cisplatin; or 1:150, 1:75, and 1:30 molar ratios of cisplatin:nucleotides) in 
20 mM HEPES buffer, pH 6.5, at 37 °C in the dark for 5 hrs. The binding sites of 
cisplatin were observed by reverse transcriptase pauses or stop one nucleotide 
prior to the coordination site. A set of 20 DNA primers were used, covering from 
nucleotides 1 to 1513 of the 16S rRNA. The 5'-32P-end-labeled primers were 
hybridized with the RNA and extended with reverse transcriptase in the presence 
of dNTPs. The transcripts were separated by 8% denaturing polyacrylamide gels. 
Coordination sites of cisplatin were then determined by comparing with dideoxy 
sequencing lanes on the same gel. Bands on the gel arising due to nicks in the 
RNA or strong secondary structures were distinguished from the cisplatin binding 
sites by comparing with a control treated in a similar manner, but lacking 
cisplatin.  
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The magnitudes of the reactivity were classified by the intensities of the 
bands on the autoradiograms. The intensities of bands could be measured up to 
approximately 100 nucleotides from the transcription start site. The reactive 
nucleotides were mostly found to be consecutive Gs, mismatched or present in 
loop regions. Since cisplatin was known to prefer Gs in DNA targets, it was not 
surprising that major hits on the 16S rRNA were consecutive Gs. There are 488 
guanosines in 16S rRNA and 103 sites with consecutive Gs, some of which 
include two or more guanosines (consecutive Gs are considered as one reactive 
site). Out of these 103 sites, strong reactivity was observed in 56 sites, 29 were 
moderate hits, and 3 showed very weak hits. In addition, several nonconsecutive 
Gs also showed strong or moderate reactivity. There were 11 consecutive Gs 
that were not reactive with cisplatin (excluding 4 sites with consecutive Gs in 
helix 45, which were not probed). Figures 2.4 to 2.6 show representative 
autoradiograms of the cisplatin probing experiments with free 16S rRNA. 
Additional gels are shown in the Appendix. The overall summary of results of 
cisplatin binding to naked 16S rRNA in Figure 2.7 show a secondary structure 
model of 16S rRNA with reactive sites in red (strong hits) and green (moderate 
hits). 
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Figure 2.4. Probing results of 16S rRNA at the 5' domain with primers 245 and 561 are 
shown. (A) The autoradiogram shows the reverse transcriptase pauses or stops by using 
primer 245. (B) The autoradiogram shows the reverse transcriptase pauses or stops by 
using primer 561. In both gels, C, U, A, G represent the sequencing lanes, 0 represents the 
control, and remaining 3 lanes are 16S rRNA treated with increasing concentrations of 
monoaquated cisplatin (cisplatin:nucleotide is 1:150, 1:75, and 1:30). The strong and 
moderate hits are indicated with arrows and corresponding nucleotides numbers (▲ 
﴾strong hits﴿ and Δ ﴾moderate hits﴿). 
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Figure 2.5. Probing results of 16S rRNA at the central domain with primers 825 and 910 are 
shown. (A) The autoradiogram shows the reverse transcriptase pauses or stops by using 
primer 825. (B) The autoradiogram shows the reverse transcriptase pauses or stops by 
using primer 910. In both gels, C, U, A, G represent the sequencing lanes, 0 represents the 
control, and remaining 3 lanes are 16S rRNA treated with increasing concentrations of 
monoaquated cisplatin (cisplatin:nucleotide is 1:150, 1:75, and 1:30). The strong and 
moderate hits are indicated with arrows and corresponding nucleotides numbers (▲ 
﴾strong hits﴿ and Δ ﴾moderate hits﴿). 
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Figure 2.6. Probing results of 16S rRNA at the 3' domain with primers 1110 and 1435 are 
shown. (A) The autoradiogram shows the reverse transcriptase pauses or stops by using 
primer 1110. (B) The autoradiogram shows the reverse transcriptase pauses or stops by 
using primer 1435. In both gels, C, U, A, G represent the sequencing lanes, 0 represents 
the control, and remaining 3 lanes are 16S rRNA treated with increasing concentrations of 
monoaquated cisplatin (cisplatin:nucleotide is 1:150, 1:75, and 1:30). The strong and 
moderate hits are indicated with arrows and corresponding nucleotides numbers (▲ 
﴾strong hits﴿ and Δ ﴾moderate hits﴿). 
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Figure 2.7. Secondary structure map of 16S rRNA (34) with probing results is shown. 
Strong hits (reactive nucleotides) are colored red (shown with ▲), moderate hits are 
colored green (shown with Δ), and very weak stops are colored blue (shown with ●). The 
helix numbers are also indicated (1-45).  
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The cisplatin binding sites are distributed throughout the bacterial 16S 
rRNA. Inspection of Figure 2.7 shows that in 16S rRNA, more than 50% Gs are 
reactive towards cisplatin (286/476), excluding helix 45. In the 5' domain 
(nucleotides 1-566), a number of prominent strong stops were observed, such as 
at G147, A160, U166, G203, G242, G260, and C352 (Figures 2.4 A, 2.8 and 
Appendix). All of these stops are on the 3' side of consecutive guanosines that 
contained at least one G○U pair or a mismatch, or resided next to a loop region. 
One of the very strong stops observed at G203 contain a G-C-rich sequence and 
G○U mismatch, similar to the binding sites observed previously in the tRNA 
acceptor stem (168). In addition to these sites, a number of minor and weak 
stops were also observed in this region, such as A129, C214, and A319, which 
were also before consecutive guanosines (Figures 2.4 and Appendix). Most of 
these weaker sites contain repeating G-C pairs without a mismatch. None of the 
single guanosines in this region showed strong stops, and not all of the 
consecutive Gs were targeted. Only moderate or weak stops were observed on 
the 3' side of non-consecutive guanosines or with guanosines adjacent to 
adenosines.  
In the upper part of the 5' domain, the stops at C379, C418, U426, A456, 
U463, and U543 (Figures 2.4 B, 2.8 and Appendix) were the strongest hits 
observed with cisplatin. Most of the strongest hits in this region were before 
consecutive guanosines, except for U463 which is on the 3' side of a single 
guanosine. In this region, several of the strong reactive sites contain either a 
mismatch, unpaired  
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Figure 2.8. The 5' domain secondary structure map of 16S rRNA with probing results is 
shown. Strong hits (reactive nucleotides) are colored red (shown with ▲), moderate hits 
are colored green (shown with Δ), and very weak stops are colored blue(shown with ●). 
The helix numbers are also indicated. 
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 bases in loop regions, or G○U wobble base pairs, indicating that cisplatin 
binding preferences are not simply limited to GG sites as was observed with 
DNA. 
In the central domain (nucleotides 567-915), which includes helices 19 to 
27, also showed a number of strong as well as moderate hits by cisplatin. The 
majority of the strong hits were observed in helices 22 and 24, such as at A743, 
A777, A792, U801, and U804 (Figure 2.5 A). These strong stops also appeared 
on the 3' side of the consecutive guanosines, except for U804, which occurred 
before the closing base-pair of the internal loop of helix 24. Most (22/28) 
consecutive guanosines in other helices with 16S rRNA also showed reactivity 
towards cisplatin. Strong stops occurred at C618 and A629 in helix 21 at two sets 
of GGG sites. Similarly, strong stops at U683 and A715 were observed on helix 
23. The functionally important helix 27 also contains a strong stop at A889 
(Figure 2.5 B) before a cluster of four consecutive Gs containing a G○U pair. In 
addition to these, several moderate and weak stops were observed, as shown in 
Figures 2.5 and 2.9.  
The 3' side of 16S rRNA contains two domains: 3' major (nucleotide 916-
1396) and 3' minor (nucleotide 1397-1542). Nucleotides in helix 45 of the 3' 
minor domain could not be mapped due to lack of appropriate nucleotides 
needed for primer hybridization. In the 3' major domain, C1059, G1187, C1208, 
and A1339 (Figures 2.6, 2.10 and Appendix) were a few of the very strong 
stops observed. The 3' minor domain contains two important helices: helix 44 
and 45. Helix 44 contains the decoding region, which has a key role in protein 
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synthesis. Several consecutive Gs in this helix are targeted by cisplatin and 
strong stops were observed at G1416, U1424, U1440, C1460, and G1488 
(Figures 2.6 B and Appendix), which are all located adjacent to consecutive 
guanosines. 
 
Figure 2.9. The central domain secondary structure map of 16S rRNA with probing results 
is shown. Strong hits (reactive nucleotides) are colored red (shown with ▲), moderate hits 
are colored green (shown with Δ), and very weak stops are colored blue(shown with ●). 
The helix numbers are also indicated. 
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Figure 2.10. The 3' domain secondary structure map of 16S rRNA with probing results is 
shown. Strong hits (reactive nucleotides) are colored red (shown with ▲), moderate hits 
are colored green (shown with Δ), and very weak stops are colored blue (shown with o). A) 
3' Major and B) 3' minor domains with helix numbers are represented. 
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2.4.2 Salt dependence binding study 
The interaction of charged metal complexes with oligomers is known to be 
strongly influenced by salt concentration (218). The salt dependence of the 
cisplatin reaction with 16S rRNA under various Na+ concentrations (10 to 300 
mM) was carried out. First, reactivity increased in the presence of 20 mM Na+, 
and then further increases of the salt concentration resulted in decreased 
platination (Figure 2.11), which suggests that electrostatic interactions play an 
important role in cisplatin binding to RNA. 
2.4.3 Quantification of the platinum adducts on 16S rRNA 
 The number of platinum atoms bound per molecule of 16S rRNA was 
determined by using atomic absorption spectrometry (AAS). Free 16S rRNA and 
monoaquated cisplatin were reacted at various ratios to determine the total 
number of possible adducts. After the reaction, excess platinum was removed by 
ethanol precipitation followed by dialysis for 12 hrs at 4 ºC. The 16S rRNA was 
then hydrolyzed with NaOH to obtain individual nucleotides. The absorbance of 
16S rRNA was measured spectrophotometrically in triplicate by using a 
NanoDrop UV visible spectrometer and the concentration was calculated by 
using the extinction coefficient of hydrolyzed 16S rRNA (ε = 17,588,970 M-1 cm-
1). The concentration of platinum was measured by AAS with a graphite furnace 
and hollow cathode platinum lamp. At lower reaction ratios, all of the platinum 
atoms were bound to the 16S rRNA. More specifically, at reaction ratios of 1:50 
and 1:100 (16S rRNA:Pt) the number of platinum atoms per rRNA molecule was 
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52±3 and 101±8, respectively (Figure 2.12), suggesting that all Pt complexes 
reacted with 16S rRNA. 
 
 
Figure 2.11. An autoradiogram illustrating salt dependence of the cisplatin reaction with 
16S rRNA and quantification of the gel is given. A) The autoradiogram shows a strong 
cisplatin stop site at U801 at various Na+ concentrations. B) Quantification of the reverse 
transctiptase stop site at U801 after cisplatin reaction is given. Quantification was 
performed using ImageQuant software. The gel data were normalized over the entire lane 
to account for loading differences and then compared at the level of intensity at U801. The 
relative intensity at U801 was calculated by percentage intensity at U801 with respect to 
the total intensity of that lane. The data represents an average of two independent 
experiments. 
 
 
Figure 2.12. The number of platinum atoms bound on each molecule of 16S rRNA at 
different reaction ratios determined by AAS is shown. The data represents an average of 
three independent experiments. 
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2.4.4 Identification of the platinum adducts on 16S rRNA 
 In DNA, cisplatin forms various types of adducts, such as 1,2-intrastrand 
and interstrand crosslinks; however, the types of adducts formed with RNA have 
not been well characterized previously. For this purpose, control 16S rRNA and 
RNA treated with cisplatin were digested with P1 nuclease and calf intestinal 
phosphatase (CIP) to generate free nucleosides or possibly dinucleotides. The 
products were separated and identified by HPLC and high-resolution LC-MS.  
In HPLC, four unknown peaks along with four standard nucleoside peaks 
were observed (Figure 2.13 A). The retention times of standard nucleosides 
were confirmed by injection of standard nucleosides separately. Quantification 
was carried out by Empower HPLC software and the peak areas were divided by 
the corresponding extinction coefficients to account for the differences in 
absorbance at 260 nm. Then, peak ratios were calculated relative to the cytidine 
peak. Quantification of the nucleosides revealed that free guanosine and 
adenosine levels decreased with increasing cisplatin concentrations (Figure 2.13 
B and C). To identify other unknown peaks, LC-MS was carried out with an 
Acquity UPLC system equipped with an HSST3 (2.1 × 100 mm, 1.8 µm) C18 
column. The chromatogram and mass of the corresponding peaks are shown in 
Figure 2.14. The observed and calculated masses with retention times are 
shown in Table 2.1. The major peak at retention time 0.96 min is assigned as the 
bifunctional adduct, GpGPt(NH3)2, with a molecular mass of 856.14 Da. Similarly, 
the peak at 1.61 min with mass 840.14 Da corresponds to ApGPt(NH3)2, and the 
peak at 1.69 min with mass 795.19 Da is assigned as GGPt(NH3)2. The peak at  
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Figure 2.13. HPLC chromatogram and the quantification of digested 16S after reaction with 
aquated cisplatin are shown. A) An overlay of HPLC chromatograms of control (digested 
16S rRNA) and platinated 16S rRNA after digestion is given. New peaks following 
platination of 16S rRNA are indicated by symbols (♦Δ●o).  B) The relative molar 
concentration of unreacted nucleosides vs. reaction ratios of 16S:cisplatin is plotted. C) 
The relative number of unreacted guanosines after the reaction in various ratios is shown 
graphically. The data represents an average of two independent experiments. 
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Figure 2.14. LC-MS data of digested 16S rRNA after reaction with cisplatin are shown. The 
chromatogram with retention times (upper) and mass spectra of the corresponding peaks 
(lower) are shown. 
 
Table 2.1. Masses, rentention time and % of various adducts of cisplatin with 16S rRNA.  
Types of 
adducts 
+1 charged state (Da) +2 charged state (Da) 
Retention 
time 
Relative 
% 
Calculated  Observed Calculated Observed
GpG[Pt(NH3)2] 857.13 856.14 428.56 428.57 0.96 min  63 ± 5 
ApG or 
GpA[Pt(NH3)2] 
841.15 840.14 420.57 420.57 1.61 min 20 ± 3 
GG[Pt(NH3)2] 796.20 795.19 398.1 397.60 1.70 min  6 ± 2 
AG or 
GA[Pt(NH3)2] 
780.21 778.19 390.1 389.60 2.10 min  11 ± 2 
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2.12 min with mass 778.19 Da is assigned as AGPt(NH3)2. The above assigned 
adducts are shown in Figure 2.15. These results show that cisplatin 
preferentially reacts with guanosine, forming bifunctional adducts as the major 
products. The coordination site is presumed to be N7 of the purine, but this has 
not been confirmed. 
 
 
Figure 2.15. Proposed structures of adducts obtained after digestion of 16S rRNA are 
shown.  
2.5 Discussion 
Probing data reveal strong and weak stops of reverse transcriptase due to 
cisplatin cross-links with RNA. Similar to DNA, a majority of the adducts formed 
72 
 
 
with RNA are observed at consecutive guanosines. On DNA, cisplatin prefers G-
rich regions and forms the major bifunctional adducts with purines (191). 
Therefore, it is not surprising that the preference for RNA reactivity is at GG sites. 
Most of the consecutive Gs that showed strong reactivity with cisplatin contained 
G-C-rich sequences with a G○U wobble pair. The structural distortion at this base 
pairing type in RNA might enhance the accessibility for reaction with platinum 
complex. There are several G-C-rich regions that do not contain G○U pairs or 
mismatches, and these showed relatively weaker reactivity towards cisplatin. The 
G○U pair has very important functional roles. For example, in E. coli tRNAAla, it 
serves as a recognition element for cognate synthetase (219-220). In addition, 
the G○U pair is also important for ribosomal protein recognition (221). Thus, the 
cisplatin complex may reveal preferred sites for protein binding on RNA that have 
ideal accessibility, electrostatics, and/or structural compatibility. Furthermore, it is 
possible that such RNA reactivity might be an alternate pathway leading to 
cisplatin toxicity.  
Upon examination of the crystal structure of the bacterial ribosome, the 
strong and weak cisplatin coordination sites do not display major structural 
differences. The distances between the N7 position of two consecutive Gs N7 
are 3-4 Å when they are stacked (Figure 2.16); however, several single 
guanosines that showed strong reactivity were observed to have their 
neighboring nucleotide flipped out. This conformational change may provide 
more space for cisplatin to form monofunctional adducts.  
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Figure 2.16. Structural features of cisplatin binding sites in 16S rRNA with nucleotide 
numbering are shown: A) strong binding sites observed in helix 24 with consecutive 
guanosines; B) strong binding sites observed in helix 17 with single guanosines; C) 
strong and no hits with consecutive guanosines in helix 44. Secondary structures of the 
corresponding helices are shown in the lower panel. Nucleotides with strong hits (red) and 
no hits (black) are represented. This figure is created with Pymol (2AVY) (222).  
 
The reactivity of monoaquated platinum species showed differences in 
reactivity with each of the guanosines in 16S rRNA. This result might be primarily 
due to the folding and tertiary interactions which change accessibility of the 
nucleotides within the RNA structure. In addition, RNA may contain preferred 
ligand-binding pockets that serve as unique recognition sites for small molecules 
(223). The negatively charged phosphodiester groups on the RNA could attract 
the positively charged platinum complexes, which increases the local 
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concentration of complex in the RNA environment. Hence, due to preassociation 
of the complexes, adduct formation at certain sites might be kinetically favored. 
Similarly, the binding of ligands in the reactive sites might alter the RNA 
structures, which makes other sites more or less accessible for the reaction. 
Cisplatin reactions with RNA can be greatly influenced by cation 
concentrations and reaction times (167-168). Reactivity of cisplatin can be based 
on oligonucleotide length, electronegativity, target site geometry, as well as 
secondary and tertiary structures (197, 224-225). An increase in cation 
concentration decreases cisplatin binding due to altered electrostatic interactions 
(167). Hence, it can be expected that larger RNA structures might have charged 
pockets that are preferable for metal coordination (226). The positively charged 
aquated cisplatin complex is known to associate with nucleic acid surfaces by an 
electrostatic-driven process prior to formation of the final adduct (218). It has 
been observed that the reactivity of platinum at G-N7 is influenced by the 
presence of Na+ concentration. The maximum reactivity was obtained at the 
middle of an oligonucleotide (17 mer DNA) at 34.5 mM Na+ concentration (218). 
With the increase in reactivity at the middle of the sequence, the reactivity 
towards 5' and 3' ends was decreased. Similar results were observed in this work 
with 16S rRNA, in which reactivity increased at U801 with increasing Na+, then 
decreased with higher salt concentrations. In this study, only helix 24 was 
monitored and changes in reactivity at other sites are not known.  
On DNA, adduct formation is more specific (at lower platinum 
concentrations); however, at higher concentrations adduct formation with 
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adenosines also increases (227). The monoaquated cisplatin derivative readily 
coordinated with the N7 position of purines to form a monofunctional adduct (t1/2 
= 0.1 hr) (Figure 2.17) (156, 228-229). The second chlorido ligand was aquated 
with a half-life of ~2 hr and finally a bifunctional adduct was formed (166, 229). 
Hence, the monoaquated species used for the reaction can ultimately result in 
formation of a stable bifunctional adducts. 
 
Figure 2.17. Schematic representation of proposed mechanism (229) for the binding of 
cisplatin to double-stranded DNA is shown. 
 
The types of adducts formed with RNA are similar to those found with 
DNA. The major peak observed in HPLC following cisplatin reaction and rRNA 
digestion was assigned as a 1,2-intrastrand bifunctional adduct with two 
neighboring guanosines. The molecular mass corresponding to GpG-Pt(NH3)2 
indicates a product that is not susceptible towards hydrolysis by P1 nuclease at 
the phosphodiester linkage between adjacent Gs, suggesting protection by the 
cisplatin coordination. In contrast, the product with a molecular mass 
corresponding to GG-Pt(NH3)2 could be either a 1,2-intrastrand, 1,3-intrastrand, 
or interstrand bifunctional adduct, since these nucleosides were linked by 
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cisplatin, but not by a phosphodiester bond. Along with these bifunctional 
adducts, adducts with adenosine and guanosine were also observed (i.e., 
AG(PtNH3)2 or GA(Pt(NH3)2). The higher reactivity with non-consecutive 
guanosines and formation of ApG adducts in RNA are unique compared to DNA. 
This result is likely because of structural difference between RNA and DNA. In 
RNA, the structure is more diverse and with a large number of unique secondary 
and tertiary structural motifs, which leads to different reactivity than DNA.  
If indeed cisplatin has a kinetic preference for RNA over DNA, then once it 
enters the cell, it could react with various cellular RNAs, including the ribosome. 
Previous studies have shown that modification of 16S rRNA by kethoxal greatly 
affected ribosome assembly (60); similar results might be expected with cisplatin. 
The binding of cisplatin to the spliceosome greatly inhibits its assembly and 
function (202). Several of the functionally important helices such as 18, 24, 28 
and 44 showed reactivity with cisplatin. In helix 18, G530 is a universally 
conserved residue and plays an important role in decoding (3). Similarly, helix 24 
is present in the subunit interface and has contact with tRNA and initiation factors 
(230-231). Helix 28 and 44 also contain several conserved nucleotides that are 
involved in decoding (232). A number of nucleotides that are universally 
conserved, such as G530 and G926, showed reactivity with cisplatin. The binding 
of cisplatin at these functionally important regions could impair its function of 
protein synthesis.  
The repair machinery for the ribosome is largely unknown; hence, the cell 
may be unable to remove cisplatin adducts from the ribosome. From the 
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abundance and lifetimes of RNAs, it is suggested that platinum binding may 
affect RNA function. The transport of cisplatin in the cell and possible 
intermediate binding with RNA and proteins is still largely unknown. With the 
increasing number of roles of cellular RNAs that are being identified, detailed 
binding studies of cisplatin and its effects in vivo will determine possible 
complementary modes of cisplatin action. 
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CHAPTER  3  
Exploring Novel Drug Target Sites in the Ribosome by Using 
Cisplatin as a Chemical Probe 
3.1 Abstract 
Knowledge of RNA structure and its relationship to function is fundamental 
to understanding the biological mechanisms of RNA. Large RNA molecules, such 
as those in the ribosome, have complex three-dimensional structures. Due to its 
diverse structure, the ribosome is an ideal target for antibiotics. A number of 
biophysical and biochemical methods have been utilized to understand its 
structure-function relationship. In this study, to gain knowledge about small-
molecule accessibility on the ribosome, cisplatin has been utilized as a chemical 
probe. Cisplatin forms stable adducts through coordination to the N7 position of 
purines and can be detected by primer extension. A number of guanosines in the 
structurally and functionally important helices are found to be accessible to 
cisplatin. 
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3.2 Introduction  
The ribosome, the molecular machine for protein synthesis, is a large, 
folded RNA assembled with proteins (27, 48, 222). The folded rRNA can form a 
number of different secondary and tertiary structural motifs and 
microenvironments that are solvent accessible (233). Due to its structural 
diversity, solvent accessibility, and general lack of repair enzymes, the bacterial 
ribosome has been a well-known target of antibiotics (71, 104). Various classes 
of antibiotics such as aminoglycosides and macrolides bind within the ribosome 
and inhibit protein synthesis (234-235). Unfortunately, many strains of bacteria 
have become resistant to antibiotics, and it is therefore important to design new 
drugs, as well as explore potential new target sites. Much of the current research 
is focused on the development of new antibiotics; however, fewer attempts have 
been made to explore new target sites (2, 103, 236).  
The first step towards the development of novel therapeutics or target 
sites is to carry out structure studies. In addition to high-resolution techniques, 
such as X-ray crystallography and NMR spectroscopy, there are several methods 
to elucidate the solution structure of nucleic acids, such as chemical or enzymatic 
probing (124, 130). Among these methods, RNA modification or cleavage, 
induced by a variety of structure-specific enzymes or chemicals, followed by 
various detection systems, such as reverse transcription or mass spectrometry 
have been widely used to gain structural information (108, 129-130). High-
resolution structural analyses of the 70S ribosomes and the 30S subunits have 
greatly expanded our understanding of the overall folding of the ribosomal RNA 
when assembled with proteins (237-238); however, cooperative interactions 
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between nucleotides and the formation of charged pockets might occur during 
the process of ribosome assembly, which have yet to be determined in detail. In 
addition, RNA structures might differ under various buffer concentrations, 
temperature, or levels of protein binding. 
Several probes have been used to obtain structural information of nucleic 
acids, but most of them are limited to in vitro studies because of their inability to 
penetrate the cell wall due to their size, structure, and/or charge (124). Only a 
few compounds have been used to probe RNA structure in vivo, such as DMS 
(152), kethoxal (239), and lead(II) (240); however, some of these compounds are 
toxic to the cell and the detection of their cleavage or reactive sites is also 
challenging. The various structural features of RNA will be important for 
biological function in vivo. The RNA structures obtained by various in vitro 
methods might be different than the corresponding RNAs present in the complex 
environment found in living cells; thus, methods to compare the in vitro and in 
vivo structures would be useful. 
Recent crystal structures have revealed a number of antibiotic binding 
sites in the ribosome, and it is interesting to know that many of these sites are 
overlapping (117). Now, it is important to develop novel target sites to design 
new drugs that can help to overcome the ever-growing problem of resistance. In 
this context, a chemical probe able to work both in vitro and in vivo can be 
utilized to explore structure accessibility in RNA. The accessible sites of the RNA 
can be compared with their functional importance, which might be useful to 
develop as a new drug target sites. Previously, we have shown that cisplatin can 
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be used to probe larger RNA structure, the ribosome, in vitro and in vivo (204). 
Cisplatin has several advantages, such as the formation of stable adducts and an 
easy detection system. Further extended studies to map the accessible regions 
in the 30S subunits and the 70S ribosomes with cisplatin in vitro and in vivo were 
carried out. 
3.3 Materials and Methods 
3.3.1 Chemicals, solutions, and DNA  
  [5'-32P-γ]ATP was purchased from Perkin-Elmer Life Sciences, Inc. and 
T4 polynucleotide kinase was obtained from New England Biolabs. A reverse 
transcriptase kit (Improm_IITM Reverse Transcriptase) was purchased from 
Promega. The remaining chemicals for buffers and reagents were obtained from 
Sigma Chemicals or Fisher. RNase-free, distilled, deionized water (ddH2O) was 
used for all experiments. 
 Cisplatin, cis-diamminedichloridoplatinum(II), was purchased from Alfa 
Aesar. The complexes cis-[PtCl(NH3)2X]+/0 or cis-[Pt(NH3)2X2]2
+/0, in which X was 
H2O, DMF, or NO3-, were prepared as described in Chapter 2. Platinum-DMF 
complex stock solutions were stored at -20 °C for up to 1 week and diluted as 
required just prior to use. 
 Single-stranded DNA primers that were used to probe the free 16S rRNA 
were also used to probe the 30S subunits and the 70S ribosomes. Purification of 
primers was carried out as described in Chapter 2. Sequences of the DNA 
primers were named according to the beginning position of the transcribed 
nucleotides, and are same as those in Chapter 2. 
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3.3.2 Isolation of the 30S subunits and the 70S ribosomes  
The 70S ribosomes and 30S subunits were isolated from E. coli MRE600 
strain by the sucrose gradient method (145, 241) as described in Chapter 2. 
3.3.3 Platination reactions  
The platination reactions with the 30S subunits and the 70S ribosomes 
were performed with monoaquated cisplatin. Prior to platination, the 30S subunits 
and the 70S ribosomes, were activated by incubating in ribosome buffer (20 mM 
HEPES, pH 7.2, 50 mM KCl, and 10 mM MgCl2) at 40 ºC for 30 min (241). 
Platination was carried out in 20 mM HEPES, pH 6.5, 20 mM potassium acetate, 
and 10 mM MgSO4 (buffer H). The 30S subunits and the 70S ribosomes were 
incubated at 37 °C with aquated complex in 1:150 and 1:75 ratios of metal 
complex to nucleotides. After the reactions, samples were quenched with NaCl 
by raising the concentration to 200 mM, followed by immediate freezing. 
3.3.4 Primer extension  
  Samples for primer extension were prepared by three times extraction with 
an equal volume of phenol (phenol:chloroform:isoamyl alcohol; 25:24:1) followed 
by two times with chloroform in the presence of 6 mM EDTA. Finally, samples 
were ethanol precipitated with 0.1 volumes of 3.0 M sodium acetate, pH 5.3, and 
2.5 volumes of ethanol. Samples were dried in a speed vacuum and dissolved in 
ddH2O. The concentrations were measured spectrophotometrically at 260 nm 
using a Nano Drop spectrometer in triplicate. For primer extension, 1 µg 
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equivalent of 16S rRNA was used. Primer labeling and primer extension was 
carried out as described in Chapter 2. 
3.3.5  In vivo probing 
 E. coli cells MRE600 were streaked from a glycerol storage culture on 
Luria–Bertani (LB) agar and incubated at 37 °C overnight. A single colony was 
picked to inoculate a starter culture, which was grown at 37 °C overnight. The 
starter culture was used to seed 3 ml medium (1/100–1/250 dilution), which was 
grown with shaking to 0.2–0.3 OD600. Cisplatin dissolved in DMSO was added to 
0 to 200 µg/ ml and the cells were further incubated in a shaker at 37 °C for 2 hrs 
to an OD600 of 0.6 to 0.8. Cells were then chilled on an ice bath for 30 min and 
harvested in pre-chilled 15 ml tubes at 5,000 r.p.m. for 10 min at 4 °C. Cells 
pellet were washed 3 times with buffer A (50 mM Tris•HCl, pH 7.5 and 10 mM 
MgCl2 and 100 mM NH4Cl) and resuspended in 100 µl buffer A. Cell lysis was 
carried out with lysozyme (0.1 mg/ml) by freezing and thawing (242), and then 1 
unit of RNase-free DNase I (Promega) was added, and the mixture was 
incubated in ice for 15 min. The cell lysate was centrifuged at 5,000 r.p.m. for 10 
min at 4 °C. The supernatant was transferred to a new tube and extracted with 
an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1).The aqueous 
phase was separated by centrifugation at 12,000 r.p.m. for 15 min at 4 °C and 
was extracted one more time with phenol:chloroform:isoamyl alcohol followed by 
3 times extraction with chloroform to remove all proteins. RNA was precipitated 
from the final aqueous phase with 3 M sodium acetate (pH 5.3) and 2.5 volumes 
of ethanol. The RNA was collected by centrifugation for 15 min at 12,000 g (4 
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°C), washed with 70% ethanol and resuspended in 20 μl RNase-free water. The 
RNA (2 µl) was analyzed on a 1.0% agarose gel prepared in 50 mM Tris–acetate 
and 1 mM EDTA. Primer extension was carried out as described for the in vitro 
method after isolation of RNA.   
3.4 Results 
3.4.1 Probing the 30S subunits and the 70S ribosomes in vitro 
The 30S subunits and the 70S ribosomes were isolated from E. coli MRE 
600 by the sucrose gradient method (145). The platination reaction was carried 
out similar to that with free 16S rRNA, as described in Chapter 2. Concentrations 
of the 30S subunits (1 A260 unit is equivalent to 69 pmol) and the 70S ribosomes 
(1 A260 unit is equivalent to 23 pmol) (241, 243) were determined 
spectrophotometrically. The reaction was carried out in 1:75 and 1:150 ratios of 
monoaquated species to nucleotides. Before the reaction, both the 30S subunits 
and the 70S ribosomes were activated by incubating in ribosome buffer at 42 ºC 
for 30 min. The reaction with monoaquated metal complex was carried out at 37 
ºC for 5 hours and quenched with NaCl, followed by freezing. Samples for the 
primer extension were prepared by removing proteins with phenol-chloroform 
extraction followed by ethanol precipitation.  
Primer extension was carried out as described in Chapter 2 with free 16S 
rRNA. The same primers that were used for free 16S rRNA was used to map 
the cisplatin coordination sites on 16S rRNA of the 30S subunits and the 70S 
ribosomes. Cisplatin coordination sites were then determined by pauses or 
stops of reverse transcriptase compare to a corresponding control in the same 
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gel. Bands on the gel arising due to nicks in the RNA or strong secondary 
structures were distinguished from the cisplatin binding sites by comparing with 
a control treated in a similar manner, but lacking aquated complex. The 
magnitudes of the reactivity were classified based by the intensities of the bands 
on the autoradiograms. Representative autoradiograms of the cisplatin probing 
experiments with the 30S subunit and the 70S ribosomes are shown in Figures 
3.1 to 3.3. Additional gels are shown in the Appendix. The gels were quantified 
by using ‘Image Quant’ software as described in Chapter 2. Similar to the free 
16S, the intensities of bands could be measured up to approximately 100 
nucleotides from the transcription start site. The reactive nucleotides were 
mostly found to be consecutive Gs, predominantly near mismatches or loop 
regions. Since cisplatin was known to prefer Gs in the DNA targets, it was not 
surprising that the major hits on the 16S rRNA from the 30S subunits, as well as 
70S ribosomes, were also consecutive Gs. Out of 103 sites with consecutive Gs 
(two or more Gs present are counted as one site), strong reactivity was 
observed in 38 sites, and 36 were moderate hits. In addition, several 
nonconsecutive Gs also showed strong or moderate reactivity. The overall 
results of cisplatin binding to 16S rRNA in the 30S subunits and the 70S 
ribosomes are shown in Figure 3.4 on a secondary structure model of 16S 
rRNA with reactive sites in red (strong hits) and green (moderate hits).   
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Figure 3.1. Probing results of 16S rRNA of the 30S subunits and the 70S ribosomes at the 
5' domain with primers 245 and 561 are shown. (A) The autoradiogram shows the reverse 
transcriptase pauses or stops by using primer 245. (B) The autoradiogram shows the 
reverse transcriptase pauses or stops by using primer 561. In both gels, C, U, A, G 
represent the sequencing lanes, 0 represents the control, and other lanes are 30S subunits 
and 70S ribosomes treated with increasing concentrations of monoaquated cisplatin 
(cisplatin:nucleotide is 1:150 and 1:75). The strong and moderate hits are indicated with 
arrows and corresponding nucleotides numbers (▲ ﴾strong hits﴿, Δ ﴾moderate hits﴿, and ● 
(minor hits)). 
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Figure 3.2. Probing results of 16S rRNA of the 30S subunits and the 70S ribosomes at the 
central domain with primers 831 and 906 are shown. (A) The autoradiogram shows the 
reverse transcriptase pauses or stops by using primer 831. (B) The autoradiogram shows 
the reverse transcriptase pauses or stops by using primer 906. In both gels, C, U, A, G 
represent the sequencing lanes, 0 represents the control, and other lanes are 30S subunits 
and 70S ribosomes treated with increasing concentrations of monoaquated cisplatin 
(cisplatin:nucleotide is 1:150 and 1:75). The strong and moderate hits are indicated with 
arrows and corresponding nucleotides numbers (▲ ﴾strong hits﴿, Δ ﴾moderate hits﴿, and ● 
(minor hits)). 
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Figure 3.3. Probing results of 16S rRNA of the 30S subunits and the 70S ribosomes at the 
3' domain with primers 1110 and 1435 are shown. (A) The autoradiogram shows the 
reverse transcriptase pauses or stops by using primer 1110. (B) The autoradiogram shows 
the reverse transcriptase pauses or stops by using primer 1435. In both gels, C, U, A, G 
represent the sequencing lanes, 0 represents the control, and other lanes are 30S subunits 
and 70S ribosomes treated with increasing concentrations of monoaquated cisplatin 
(cisplatin:nucleotide is 1:150 and 1:75). The strong and moderate hits are indicated with 
arrows and corresponding nucleotides numbers (▲ ﴾strong hits﴿, Δ ﴾moderate hits﴿, and ● 
(minor hits)). 
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Figure 3.4. Secondary structure map of 16S rRNA (244) with probing results from the 30S 
subunits and the 70S ribosomes is shown. Strong hits (reactive nucleotides) are colored 
red (shown with▲), moderate hits are colored green (shown with Δ), and weak hits are 
colored blue (shown with ●). The helix numbers are also indicated (1 to 45). 
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Figure 3.5. Secondary structure map of 16S rRNA (244) with probing results from the 30S 
subunits and the 70S ribosomes is shown. Strong hits (reactive nucleotides) are colored 
red (shown with▲), moderate hits are colored green (shown with Δ), and very weak hits 
are colored blue (shown with ●). Nucleotides with lower reactivity in 30S/70S compared to 
free 16S rRNA are indicated with green circles and with higher reactivity with red circles. 
The helix numbers are also indicated (1 to 45). 
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The 5' domain of 16S rRNA (nucleotides 1-566), which includes helices 1 
to 18, is the main body of the 30S subunit. This domain is mainly stabilized by 
RNA-RNA interactions (115, 222). Culver and coworkers found that modification 
of five nucleotides (G301, G302, G529, G530, and G558) in this domain of the 
ribosome were critical for the ribosome assembly (1). Previously, Moazed and 
Noller have shown that, upon A-site tRNA binding, G529 and G530 were strongly 
protected (3). Furthermore, Mankin and coworkers showed that mutations of 
several nucleotides in helix 18 were deleterious, including G529 and G530 (2). In 
cisplatin probing, moderate stops were observed before these consecutive Gs in 
the 30S subunits and the 70S ribosomes (Figure 3.1 B). Furthermore, G529 and 
G530 reacted strongly in free 16S, but were more protected in 30S/70S. Many of 
the sites in 5' domain of 16S rRNA were less reactive within the context of 
ribosomes. The significance of the result is that critical residues that are 
protected are also functionally important; therefore targeting of these sites might 
be feasible. 
 Mutation of G299A (helix 12) was found to increase both missense and 
nonsense errors during translation (4). Structure studies showed that in helix 12, 
G299 forms a Hoogsteen pair with G566 in helix 19, and the pair was found to 
involve Mg+2 coordination (245). This functionally important nucleotide G299 also 
showed a moderate reactivity with cisplatin, in which a reactivity difference was 
observed between free 16S and 30S/70S. In addition to these sites, a number of 
prominent stops were observed at G147, A160, U166, G201, G260, and G319 
(Figures 3.1 A and 3.6). All of these stops are on the 3' side of consecutive Gs.  
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Figure 3.6. Secondary structure map at the 5' domain of 16S rRNA with probing results 
from the 30S subunits and the 70S ribosomes is shown. Strong hits (reactive nucleotides) 
are colored red (shown with ▲), moderate hits are colored green (shown with Δ), and very 
weak hits are colored blue (shown with ●). A) The lower part of the 5' domain and B) the 
upper part of the 5' domain with probing results are given. Green circles represent 
nucleotides that showed strong hits on the free 16S rRNA, but are absent or very weak in 
the 30S subunits and the 70S ribosomes. The (*) indicates the difference in reactivity 
between 30S subunits and 70S ribosomes. 
 
a: role in ribosome assembly (1) 
b: antibiotic binding  
c: mutations are deleterious  
to RNA function (2) 
d: contact with tRNA (3) 
e: role in fidelity (4) 
f: Mg+2 coordination (4) 
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 In the upper part of the 5' domain, strong stops were observed at C418, G454, 
U462, C507, and U543 (Figure 3.1 B). Among these strong stops, all were 
before consecutive guanosines, except for U463, which is on the 3' side of a 
single guanosine. In addition to these, several other consecutive and single 
guanosines showed moderate to weak stops in this region (Figure 3.6). 
A majority of the nucleotides that showed reactivity with cisplatin in free 
16S rRNA also showed reactivity in the 30S subunits and the 70S ribosomes. 
However, numerous differences in reactivity were also observed, such as the 
strong stop observed at U426 in free 16S rRNA, which is not present in the 30S 
subunits and the 70S ribosomes.  Helix 16 forms a contact with protein S4, which 
might protect these nucleotides from cisplatin reaction in the 30S subunits and 
the 70S ribosomes (246). In addition, the reactive nucleotides (G416-417) 
contain a G○U pair compared to unreactive G-C pairs (G423-425); this cisplatin 
binding preference was observed on the free 16S rRNA as well. Similarly, a 
moderate hit at G446 was observed in 16S rRNA, but is not present in 30S or 
70S ribosome. In contrast, the stop at C507 is comparatively stronger in the 30S 
subunits and the 70S ribosomes (Figures 3.1 and 3.6). Helix 18 was shown 
previously to be dynamic in nature and several of its nucleotides are in contact 
with ribosomal protein S12 (246). Hence, in the 30S subunit and the 70S 
ribosome, the conformation and accessibility of nucleotides might be different 
than the naked 16S rRNA, which results in different reactivity with cisplatin. 
The central domain of 16S rRNA (nucleotides 567-915), which includes 
helices 19 to 27, folds to form the platform of the small subunit (115). Culver and 
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coworkers found six nucleotides in this region that are functionally important, and 
assembly was impaired when they were modified (1). Out of these six 
nucleotides, three are guanosines; G575, G791, and G818. Mankin and 
coworkers found clustering of moderately deleterious mutations in helix 24, and 
Cunningham and coworkers observed that none of the functional mutants in the 
790 loop of helix 24 involved G791 or U793 (2, 247). In addition, G791 is located 
on the functionally important 790 loop, which makes contact with initiation factor 
(IF3) and the P-site tRNA (248-249). In cisplatin probing, G575 in the 30S 
subunits and the 70S ribosomes showed strong reactivity. In contrast, G791 in 
the 30S subunit was a weak hit, but in the 70S ribosomes was a strong hit 
(Figures 3.2 A and 3.7), indicating that cisplatin reactivity is different in the 30S 
subunits and the 70S ribosomes.  
Several other strong cisplatin hits were observed on the 3' side of G799-
800, G773-776, and G741-742 (Figure 3.2 A and B). All of these consecutive Gs 
showed strong reactivity with the naked 16S rRNA, the 30S subunits and the 70S 
ribosomes. However, compared to the free 16S rRNA, reactivity at G799-G800 is 
stronger in the 30S subunits and the 70S ribosomes. G803 showed reactivity 
only in the naked 16S rRNA. Previously, G791 was found to be protected from 
kethoxal modification; however, this residue becomes more accessible when 30S 
subunits were converted from the active to inactive conformation (144).  
Similarly, in helices 22 and 23, several nucleotides showed differences in 
reactivity, such as G721-722, G730-731, and G733-734, which were not reactive 
in the 30S subunits and the 70S ribosomes but were in free 16S rRNA. 
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Previously, protection of G733, G734, and the 720 to 730 regions from kethoxal 
reactions has been observed due to S15 binding (145, 250), which is consistent 
these cisplatin probing results in which reactivity was reduced from free 16S 
rRNA to ribosome. 
 
 
 
Figure 3.7. Secondary structure map at the central domain of 16S rRNA with probing 
results from the 30S subunits and the 70S ribosomes is shown. Strong hits (reactive 
nucleotides) are colored red (shown with ▲), moderate hits are colored green (shown with 
Δ), and weak hits are colored blue (shown with ●). Red circles represent strong reactivity 
in the 70S ribosome compared to 30S and free 16S and green circles represent 
nucleotides that showed strong hits on the free 16S rRNA but are absent or weak in the 
30S/70S ribosomes. The (*) indicates the difference in reactivity between 30S subunits and 
70S ribosomes. 
a: role in ribosome assembly 
b: antibiotic binding  
c: mutations are deleterious  
to RNA function  
d: contact with tRNA 
e: role in fidelity  
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The 3' region of 16S rRNA, contains the 3' major (nucleotides 916-1396) 
and 3' minor (nucleotides 1397-1542) domains. The 3' major domain includes 
helices 28 to 43, and mainly constitutes the head of the small subunit, whereas 
the 3' minor domain extends from the body to head of the 30S subunit, which 
includes helices 44 and 45 (115).  Modifications of 30 nucleotides in the 3' major 
domain were found to affect ribosome assembly (1). Mutational studies showed a 
cluster of deleterious mutations in helices 34 to 37, which are located far from the 
known functional centers (2). G1058A and G1068A lead to a strong deleterious 
phenotype. In cisplatin probing, the consecutive Gs, G1057-G1058, showed 
strong reactivity only in free 16S rRNA, whereas in 30S subunits and 70S 
ribosomes, a strong stop appeared just before a single guanosine G1064 (Figure 
3.3 A and 3.8). In crystal structures of the ribosome, these consecutive Gs 
(G1057-1058) are in contact with ribosomal protein S3, which might protect them 
from cisplatin reactivity in 30S/70S ribosomes (246). Some other strong cisplatin 
stops were observed at G1185, C1267, and A1339. All of these stops are on the 
3' side of either single or consecutive guanosines.  
Modifications of 13 nucleotides on the 3’ minor domain were found to 
disrupt the assembly of the small subunit,t and a number of deleterious mutations 
were also located in this domain (1-2). However, due to limitations of cisplatin 
reactivity with guanosines, the accessibility of most of these functionally 
important nucleotides could not be monitored. The strong and moderate stops 
observed with cisplatin were at U1424, U1440, C1460, and U1490, which are all 
on the 3' side of the consecutive Gs (Figure 3.3 B). Due to the lack of 
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appropriate primer hybridization sites, a number of guanosines in the helix 45 
also could not be probed. 
 
 
 
 
Figure 3.8. Secondary structure map at the 3' domain of 16S rRNA with probing results 
from the 30S subunits and the 70S ribosomes is shown. Strong hits (reactive nucleotides) 
are colored red (shown with▲), moderate hits are colored green (shown with Δ), and very 
weak hits are colored blue (shown with ●). A) The 3' major domain, and B) the 3' minor 
domain are shown. Red circles represent strong reactivity in the 70S ribosome compared 
to 30S and free 16S and green circles represent nucleotides that showed strong hits on 
the free 16S rRNA but are absent or weak in the 30S/70S ribosomes. The (*) indicates the 
difference in reactivity between 30S subunits and 70S ribosomes. 
 
a: role in ribosome 
assembly 
 
b: antibiotic binding  
c: mutations are 
deleterious to RNA 
function  
 
d: contact with tRNA 
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3.4.2 In vivo probing  
Cisplatin is believed to enter cells by passive diffusion and undergoes 
hydration to form the aquated species due to low chloride concentration inside 
the cell (163). Therefore, it is hypothesized that cisplatin can be used to probe 
the bacterial ribosome in vivo. Cisplatin coordination sites can be mapped in a 
manner similar to in vitro studies by using reverse transcription. This type of 
probing could reveal new target sites for antibacterials on the ribosome. To probe 
the ribosome in vivo using cisplatin, E.coli DH5α was grown to ~ 0.2 to 0.3 OD600, 
100 to 200 µg/ml of cisplatin was added, and the cells were further incubated for 
two hours. After cooling on ice for 15 min, the cells were pelleted by 
centrifugation. The cells were washed three times with buffer (50 mM Tris·HCl, 
100 mM NH4Cl and 10 mM MgCl2) and total RNA was isolated. To carry out the 
primer extension analysis, total RNA was isolated by phenol-chloroform 
extraction followed by ethanol precipitation. A primer complementary to positions 
831 through 814 of 16S rRNA, as used for in vitro probing, was annealed, and 
then reverse transcription was carried out.  
Primer extension of 16S rRNA showed a prominent stop at U801, one 
nucleotide prior to the consecutive guanines G799 and G800 (Figure 3.9). This 
result is consistent with the strong stop observed with in vitro probing. Along with 
this, a minor stop also appeared before G791, which was seen only in the 70S 
ribosomes. This result demonstrates that cisplatin can be used to probe 
accessible guanosine residues in vitro and in vivo. Furthermore, the differences 
in nucleotide accessibility in free 16S rRNA vs. that in the ribosomes can be 
determined. It should be noted, however, that the in vivo results shown here 
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represent an average of all the ribosomes at various stages of protein synthesis 
in the cell. 
 
 
Figure 3.9. Probing results in 16S rRNA from in vivo studies are shown. A) An overview of 
the in vivo probing method, B) a partial secondary structure map of 16S rRNA h24 
(residues 769–820) with the primer-binding site, and C) an autoradiogram showing reverse 
transcription mapping of in vivo reactive sites (indicated by arrows; **major, *minor) of 
cisplatin on 16S rRNA/70S ribosomes (the concentrations of cisplatin are given for each 
lane, 0–200 µg/ml of cells) are shown. Dideoxy sequencing lanes are labeled as C, U, A, 
and G. Sites that are identical in the in vitro and in vivo probing experiments are indicated 
with symbols (▲,•). 
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3.4.3 Active and inactive conformations  
 Opposite reactivity of purines at the N1 and N7 positions has been 
observed previously in activated and inactivated ribosomes by chemical probing 
(249). Cisplatin showed similar reactivity as DMS in the 30S subunits and the 
70S ribosomes when used to probe the active form of the 30S subunit. For 
example, in helix 44, G1415-G1417 showed enhanced reactivity with DMS in the 
inactive form, and G1422-G1423 showed enhanced reactivity in the active 
conformation. Probing results with cisplatin showed similar reactivity with the 
activated 30S subunit, more specifically enhanced reactivity at G1422-G1423 
and no reactivity at G1415-G1417 in the 30S subunits and the 70S ribosomes. 
However, all of these Gs showed reactivity with naked 16S rRNA (Figure 3.10). 
These results demonstrate that cisplatin can be used to identify functionally 
important nucleotide and distinguish accessible nucleotide under active biological 
states. These results can be compared to accessible residues in inactive RNAs 
in the absence of protein factors. 
Another similarity of our probing results with DMS studies is observed at 
G926 and G1401. These nucleotides showed opposite reactivity at the N1 and 
N7 positions of guanosine when probed with DMS. In the active form, the 
reactivity of G926 at N1 was higher and there was no reactivity at N7. This result 
was opposite in an inactive ribosomal conformation (144). Cisplatin probing 
results showed reactivity of these nucleotides in free 16S rRNA and 
comparatively weaker reactivity in the 30S subunits or the 70S ribosomes; 
suggesting similar reactivity at the N7 of Gs. Since, both the 30S subunits and 
the 70S ribosomes were activated before the incubation with cisplatin, these 
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results indicate that the ribosome was in an active conformation during probing 
experiments.  
 
 
Figure 3.10. Secondary structure map at the 3' minor domain of 16S rRNA with probing 
results from free 16S rRNA and the 30S subunits and the 70S ribosomes are shown. 
Strong hits (reactive nucleotides) are colored red (shown with▲), moderate hits are 
colored green (shown with Δ), and weak hits are colored blue (shown with ●). A) Probing 
results from free 16S rRNA and B) results from 30S/70S are compared. 
3.5 Discussion  
 Although a number of chemical and enzymatic probes have been utilized 
to explore the accessibility of nucleotides in the ribosome, very little information is 
available regarding the reactivity of the N7 position of guanosines. Although DMS 
can react with the N7 position of guanosine, efficient strand scission is required 
for detection, which may be difficult to achieve. Cisplatin is believed to react with 
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the N7 position of guanosines and form a stable coordination complex; hence, it 
will be useful to provide information about the nucleotide accessibility and 
reactivity of the N7 position. 
The ribosome is a potential target for a number of antibiotics, and half of 
the known antibiotics already target the ribosome (104). However, pathogens 
become resistant to the common drugs by more than one mechanism. To 
overcome the problem of resistance, significant efforts have been made, mostly 
by modifying the existing antibiotics (251-252). Despite being a validated target, 
only a few attempts have been made to explore novel target sites in the ribosome 
(2, 103, 236). Cunningham and coworkers have carried out instant evolution 
experiments to investigate the nucleotides that do not undergo mutation, and if 
mutated are lethal. These nucleotides are found to be involved in interactions 
with tRNA, mRNA, or initiation factors, and are therefore functionally important. In 
the 790 and 690 loops of the small subunit, nucleotides such as G791, U793, 
and G691 were not mutated (247, 253). Previous probing experiments and now 
high-resolution crystal structures revealed that the 790 loop is in contact with 
tRNA and initiation factor 3 (238, 249). By targeting these functionally important 
nucleotides that cannot be mutated, we can be one step ahead of bacterial 
resistance involving target modification.  
To explore the potential drug target sites, in a similar manner, Mankin and 
coworkers carried out random mutagenesis in the small and the large subunits of 
the ribosome (2, 65). They observed 53 mutations in the small subunits and 54 in 
the larger subunits that were deleterious. These mutations either affect the 
103 
 
 
function of the ribosome or disrupt its structure leading to a deleterious 
phenotype. Deleterious mutations were clustered in certain functional regions 
that show >98% conservation in 16S rRNA (65). Hence, it can be expected that 
these nucleotides may be functionally important in other bacteria as well. Despite 
this information, more knowledge about the accessibility of these nucleotides will 
be needed to target these sites. Probing the 30S subunits and the 70S 
ribosomes with cisplatin revealed a number of strong and moderate hits. The 
binding sites of cisplatin in the ribosome are found to be distributed throughout 
the ribosome and a number of functionally important sites showed reactivity. The 
functionally important sites that are reactive towards cisplatin should be 
accessible to small molecules and, hence, could be exploited as novel target 
sites. 
Helix 17 and 18 are promising drug target sites in the ribosome because 
of their structural and functional importance. Helix 17 is structurally different in 
bacteria and eukaryotes (103). The internal loop is conserved in bacteria and 
absent in eukaryotes. Helix 18 is located on the surface of the small subunit at 
the interface that contacts the large subunit, and the 530 loop (nucleotides 515-
536) is highly conserved (244). The 530 loop is an essential component of 
ribosomal decoding and controls the accuracy of aminoacyl-tRNA selection (79). 
The lack of functional mutants in the 530 loop further indicates its functional 
importance (103). Another study showed that mutations of nine nucleotides in 
this loop are deleterious including G506, G521, and G527 (2). Cisplatin showed 
reactivity with several nucleotides in this region, including consecutive Gs in the 
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internal loop of helix 17 (G453-455), the pseudoknot region of helix 18 (G506-
507), and conserved nucleotides G529-530. These nucleotides are accessible to 
cisplatin and, hence, could be accessible to small molecules. Due to structural 
differences and the functional importance, these sites could be utilized as a novel 
target for antibiotics. Recently, a model system of helix 18 has been used as a 
target to find ligands by phase display (254). 
Helix 24 of 16S rRNA is very important because of its location near the 
decoding region, interactions with initiation factor (230, 248, 255), and key 
contacts with 50S subunit (231, 247, 249). In addition, the 790 loop in the small-
subunit platform and the nucleotides ridge (G1338-U1341 (helix 42)) in the head 
form a 13 Ǻ gap, which separates the anticodon stem-loop of the P-site tRNA 
from the E site (Figure 3.11 A) (222). The universally conserved residues G1338 
and A1339 also play a role in discrimination of initiator tRNAf-met by initiation 
factor (IF3) (256). Furthermore, helix 24 is located at the interface between the 
large and small subunits and is known to be exposed to solvent (231, 257). The 
antibiotic pactamycin is already known to bind to this helix (258). Hence, 
nucleotides in this helix need to be accessible to assist these numerous 
functional interactions, and blocking them could be an effective antibiotic 
strategy.  
All of the consecutive Gs present in helix 24 are accessible for cisplatin 
reactivity in free 16S, 30S subunits, and 70S ribosomes. However, specific 
residues such as G803 and G791 show different reactivity. G803 showed 
reactivity only with the naked 16S and G791 showed higher reactivity in the 70S 
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ribosomes. Instant evolution experiments with the 790 loop by Cunningham and 
coworkers showed that positions G791 and U789 do not allow for any viable 
mutations (103), indicating their functional importance. Nucleotides G773-776 are 
involved in forming bridge 7b and the mutation G775A is found to be lethal (2).   
 
 
 
Figure 3.11. Various functionally important helices of 16S rRNA in 70S ribosome crystal 
structures are shown. A) Helix 24 (790 loop) and helix 42 are in contact with tRNA and 
mRNA, B) the 790 loop and helix 28 are in close contact with tRNA and mRNA, C) the 790 
loop is in contact with functionally important 690 loop (helix 23), and D) helix 34 is in 
association with the antibiotic spectinomycin. Nucleotides that showed strong hits in 
cisplatin probing are shown in red color and moderate are shown in green color. This 
figure was created with Pymol using PDB: 2I2P and 2QOU (27, 74).  
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In addition, in the crystal structures, the 790 loop makes contacts with the 690 
loop through N1 and N6 of A696 and the 2'-OH of C797 (Figure 3.11 C) (78, 
253). The 690 loop is also found to be functionally important and involved in 
tRNA binding at the P site (3, 232, 249), initiation factor binding (230), and 
subunit association (147, 259). Further, mutational studies carried out on this 
loop also indicate its functional importance (253). Thus, due to its functional 
importance and extensive contacts with other helices, tRNA, and initiation factor, 
helix 24 is one of the most promising new drug target sites. All consecutive 
guanosines in this helix showed reactivity with cisplatin;  it is therefore expected 
that they will be accessible to other small molecules. Binding of small molecules 
even in the stem regions can disrupt the conformation or contacts of this helix 
with other helices, tRNA, and the initiation factor. 
 Similarly, helix 34 can also be exploited as a target site in the ribosome. 
This helix lies in the head region of the small subunit, and in the folded structure 
it is very close to the decoding region (74). Hence, it has been expected that it 
has an important role in the selection of the correct aminoacyl tRNA. The 
reactivity of nucleotides in this helix are different in free 16S rRNA, the 30S 
subunit, and the 70S ribosome. The consecutive Gs at positions 1058-1059 
showed strong reactivity within the free 16S rRNA and no reactivity in the 30S 
subunits, suggesting that these nucleotides become protected after the ribosome 
is assembled with proteins. The crystal structure of E. coli 70S revealed that 
ribosomal protein S3 binds to this helix and it contacts several nucleotides in this 
region (Figure 3.12) (246). Interestingly, a neighboring nucleotide, G1064, shows 
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higher reactivity towards cisplatin in 30S subunits and 70S ribosomes, but very 
weak reactivity in free 16S rRNA. Helix 34 is also a known binding site for the 
antibiotic spectinomycin, which contacts G1064 along with other nucleotides 
(Figure 3.11 D) (74). The lack of cisplatin reaction at the consecutive Gs may be 
due to protection or conformational changes that occur upon binding of protein 
S3, which conversely makes the neighboring G1064 accessible for small-
molecule interactions.  
 
Figure 3.12. Ribosomal protein S3 and part of 16S rRNA secondary structure 
corresponding to helix 34 are shown. A) The ribosomal protein S3 and helix 34 with 
cisplatin probing results are compared; nucleotides with strong hits on free 16S and 
protected in 30S/70S are shown in black, strong hits observed in 30S/70S are shown in 
red. B) The secondary structure of 16S rRNA shows the contacts of ribosomal protein S3. 
The nucleotides in contact with S3 are circled with: blue (backbone only), red (base only), 
and green (both backbone and base). Figure A was created with Pymol (PDB: 2AVY) and B 
was reprinted with permission (Brodersen et al.) (246).  
 
Thus, these results demonstrate the ability to discover potential antibiotic 
sites of both structure accessibility and functional importance. The platinum 
complex is sensitive to variations in the ribosome structure, and thus could be 
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employed to examine ribosomes at various stages of protein synthesis, or 
complexed with various factors, mRNA, or tRNAs. Most importantly, it is revealed 
that a positively charged platinum complex is useful for targeting rRNA, and has 
the ability to provide key information about helix or loop accessibility in the 
ribosomes. Sites that differ in platinum reactivity between 30S subunits and the 
70S ribosomes could reveal compelling regions for mechanism-based drug 
design. Furthermore, the fact that the platinum complex generates stable adducts 
is significant because the kinetics of the reaction can be monitored, which will 
allow the determination of how positively charged compounds such as 
aminoglycosides identify target sites with favorable electrostatic contributions 
from a number of possible reactive sites on the ribosome (204). 
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CHAPTER  4  
Study of Cisplatin Binding to a Small RNA Construct 
Representing the 790 Loop of 16S Ribosomal RNA  
4.1 Abstract 
DNA has been considered to be the major target of cisplatin, while RNA 
has been essentially overlooked. Previous studies in our laboratory 
demonstrated that RNA is the kinetically preferred target over DNA when similar 
sizes and structures of nucleic acids are compared. In the present study, we are 
extending our understanding of cisplatin binding to the 790 loop of E. coli 16S 
ribosomal RNA (rRNA). On the model RNA constructs, the number of platinum 
adducts were determined by using enzymatic digestion in conjunction with HPLC 
and atomic absorption spectroscopy. In addition, the binding sites, number, and 
types of adducts formed with RNA constructs were identified by using MALDI-
TOF mass spectrometry and LC-MS spectroscopy. The aquated platinum 
complex formed a variety of adducts with the 790 RNA hairpins. This information 
may be helpful towards understanding the usefulness of cisplatin as a probe of 
RNA structure and function, or to consider rRNA as a potential target of the 
antitumor drug. 
4.2 Introduction  
The ribosome is composed of rRNA and proteins, which are organized 
into the large and small subunits (48, 222). For the 70S ribosome of E. coli, the 
large subunit (50S subunit) is composed of 5S and 23S rRNAs and 34 ribosomal 
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proteins and the small subunit (30S subunit) is composed of 16S rRNA and 21 
proteins (222, 260). The ribosome is important because it catalyzes protein 
synthesis in all forms of life. The majority of ribosomal functions rely on the rRNA 
structure (222). 
This dependence of ribosome function on RNA is only possible because of 
the large variety of secondary and tertiary structures formed by RNA (34). Single-
stranded RNAs fold upon themselves to form well-defined structures that are of 
great functional importance (35). An example of this, which is found in, but not 
exclusive to, the ribosome is the structural motif called the stem-loop or hairpin 
(41, 244). Although most hairpins rely heavily on hydrogen bonding in the so-
called stem region, mismatch base pairing can also occur.  
Aside from studying RNA structural regions to understand their functions, 
such work may also lead to the discovery of new antibiotic binding sites (119, 
261). It has been reported that human pathogens from infections in patients from 
various sources have been growing more resistant to commonly used antibiotics 
(262). Since nearly half of the currently used antibiotics target the ribosome, it is 
important to find new regions for novel antibiotics to bind (86). Combined with 
genetic approaches, biophysical methods and chemical probing may be used as 
a discovery tools for new antibiotic binding sites (2, 103, 236). 
The work reported here focuses on a model structure of the 790 loop of E. 
coli 16S rRNA. This loop contains residues 783 to 799 and has been shown to be 
important for ribosomal function, due to its presence in the inter-subunit region 
(231) and its binding to protein IF3 (230). The 790 loop is exposed to solvent in 
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the small subunit, and it is present in the small subunit rRNAs of all organisms. It 
has also been shown to have decreased ribosomal function following mutations 
(247). So, not only is it accessible, but information pertaining to molecular binding 
to the 790 loop is useful for other organisms.  
While cisplatin is commonly used as a chemotherapeutic drug for several 
forms of cancer (163, 166), it has also been reported to be a probe for accessible 
residues of ribosomal RNA (204). In DNA, the aquated cisplatin coordinates to 
the N7 positions of adjacent purine bases to form primarily 1,2-intrastrand 
crosslinks, but the formation of interstrand and monofunctional adducts is known 
as well (172, 197, 263). The types of adducts formed with RNA have not yet 
been verified, but are presumed to be the same as DNA. The advantages that 
cisplatin probing has over other chemical probes is its ability for active or passive 
cellular uptake, activation within the cell, and stability of the adduct formation with 
nucleic acids (163, 264). Following passive diffusion, this square-planar complex 
is activated by the replacement of one chlorido ligand by hydrolysis in an 
aqueous environment because of the decreased chloride ion concentration in the 
cell (156). This reaction produces the mono-aquated form of cisplatin 
[Pt(NH3)2ClH2O]+ and following coordination, the remaining chlorido ligand is 
displaced by hydrolysis to produce the bis-aquated form of cisplatin, thus 
allowing the platinum to more easily coordinate to a second purine base (229). In 
vitro, hydrolysis products of cisplatin can be generated by using silver nitrate in 
order to precipitate the chloride ions out of solution as silver chloride.  
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Probing the RNA structure with cisplatin provides information concerning 
the environment of individual nucleotides that can be compared to RNA structural 
models and hypotheses about RNA function. This is important because a limited 
number of studies have revealed further details concerning interactions of 
cisplatin with RNA (169). In order to determine the location of cisplatin binding on 
the 790 RNA hairpin constructs and quantify the number of adducts, matrix-
assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry, atomic absorption spectroscopy (AAS), high-performance liquid 
chromatography (HPLC), and liquid chromatography-mass spectrometry (LC-
MS) were employed (Figure 4.1).  
4.3 Materials and Methods  
4.3.1 General 
Cisplatin (cis-diamminedichloridoplatinum (II)) was obtained from Alfa 
Aesar (Ward Hill, MA). Silver nitrate and ammonium acetate were obtained from 
Fisher Scientific. DMF (dimethylformamide) from Acros Organics was used for 
the preparation of the monoaquated and bioaquated cisplatin species. TBAF 
(tetrabutylammonium fluoride) was obtained from Aldrich, CIP (calf intestinal 
alkaline phosphatase) was obtained from Promega Corp (Madison, WI). P1 
nuclease was purchased from Sigma Chemicals. The remaining chemicals for 
buffers and reagents were obtained from Sigma Chemicals or Fisher. RNase-
free, distilled, deionized (ddH2O) was used for all experiments.  
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Figure 4.1. The basic outline of cisplatin activation, secondary structure of 16S rRNA, 
close-up to show 790 RNA constructs, and summary of various techniques used for study 
of cisplatin binding in RNA model system are shown. Three different RNA constructs used 
in this study (790 A○C wt, 790 A○C and 790 G○U hairpins) are indicated in the box.  
4.3.2 Preparation of aquated complexes  
For monoaquated cisplatin, molar equivalents (116 µmol) of cisplatin (35 
mg) and silver nitrate (18 mg) were added to 1 ml dH2O or DMF and dissolved by 
agitation in the dark overnight. Silver nitrate was introduced in order to precipitate 
out chloride ions. The solution was centrifuged at 12,000 RPM for 15 minutes to 
remove the silver chloride precipitate, and the monoaquated cisplatin 
supernatant was removed. An additional 5 minutes of centrifugation at 12,000 
RPM ensured that all of the silver chloride had been removed. The supernatant 
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was transferred to a new tube. The aquated samples of cisplatin in DMF were 
stored at -20 °C and kept no longer than one week.  
4.3.3 RNA preparation and purification 
Three RNA constructs 5'-GGCGAUUAGAUACCGCC-3' (790 A○C) 5'-
GGCGGUUAGAUAUCGCC-3' (790 G○U), and 5'-GCAGGAUUAGAUACCC 
UGC-3' (790 A○C wt) were chemically synthesized at the Keck Foundation, 
School of Medicine, Yale University. These RNAs were received as the 2'-
protected species and deprotected by dissolving in TBAF, followed by incubation 
at 35 ºC overnight. The RNA was then desalted with a Sep-Pak Light C18 
cartridge (Waters), dried in a speed-vac evaporator, and reconstituted in ddH2O. 
The RNA then underwent HPLC purification. Solvents were as follows: buffer A 
was 25 mM triethyl ammonium acetate, pH 6.5; buffer B was 40% acetonitrile in 
water. The column was pre-equilibrated with 80% buffer A and 20% buffer B with 
a flow rate 1 ml/min. RNA purification was achieved using the following elution 
gradient: 80% A and 20% of B to 50% A and 50% of B over 30 min at room 
temperature. The RNA fractions were detected at 260 nm and collected 
manually. Following HPLC purification, RNA were ethanol precipitated with 
sodium acetate and renatured in 20 mM Tris·HCl and 50 mM NaCl by heating to 
90 °C for 2 min followed by slow cooling. 
4.3.4 Cisplatin reaction with 790 RNA 
All cisplatin reactions were carried out with monoaquated complexes in 
1:1 or 1:20 ratios of RNA:complex. Prior to platination, RNA was renatured as 
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stated above. Platination was carried out in 20 mM sodium phosphate buffer, pH 
6.5, 10 mM MgCl2 and 10 mM NaCl (buffer P) at 37 °C for 5 hours. The reactions 
were quenched with 2 M NaCl followed by immediate freezing. 
4.3.5 MALDI-TOF mass spectrometry  
MALDI-TOF (Matrix Assisted Laser Desorption Ionisation Time of Flight) 
mass spectrometry analyses were carried out with a Bruker Daltonics TOF-300 
MALDI Ultraflex. After platination reaction, RNA oligos were separated by 20% 
polyacrylamide gel electrophoresis in order to separate bound and unbound RNA 
samples. The bands were cut out of the gel and electro-eluted. Following 
desalting with the Sep-Pak Light C18 cartridge, the samples were prepared for 
MALDI-TOF by mixing 1 µl (25 pmol) of platinated or unplatinated RNA with 3 µl 
of freshly prepared matrix solution (3-hydroxypicolinic acid in 50% acetonitrile). 
One μl of this mixture was placed on the MALDI plate and allowed to dry at room 
temperature. For RNase T1 digestion, 1 μl (1 unit) of RNase T1 was added to the 
sample and it was incubated at room temperature for 15 min. Then, one μl was 
spotted on the MALDI plate and allowed to dry at room temperature. The spectra 
of intact RNA molecules were acquired in positive-ion reflector mode using 
method RP-3147.par.  
4.3.6 Atomic absorption spectroscopy  
Atomic absorption spectroscopy (AAS) was used to analyze the amount of 
platinum bound to the 790 RNA constructs. The instrument used for this study 
was equipped with a graphite furnace with hollow cathode platinum lamp (Perkin-
116 
 
 
Elmer AAnalyst 700). The AAS has adjustable slit width wavelength and direct 
concentration readout capabilities. All 790 samples underwent 30 hours of 
dialysis with Spectra/Por 7 dialysis tubing, 3.5 KDa molecular weight cut off 
membrane to remove any excess platinum present in the reaction. The AAS was 
optimized and calibrated using calibration standards prior to each analysis. The 
platinum calibration standards were prepared from commercial standards of 
platinum (High-Purity Standards, Charleston, SC) in 5% HCl. The data were 
obtained by using the instrument protocol and the previously described methods 
in the literature (265-266). 
4.3.7 High performance liquid chromatography 
HPLC was carried out with a Waters system equipped with a C18 
Discovery column (250 x 4.6 mm, 0.5 µm). Separation was carried out by using 
buffer A (40 mM ammonium acetate) and B (40% acetonitrile) with a linear 
gradient in which the ratio of A to B changed from 95:5 to 70:30 over 30 minutes 
at a constant flow of 1 ml/min. The retention times of the standard nucleosides 
were confirmed by injection of known standard nucleosides. Control and 
platinated RNAs were digested with nuclease P1 to convert to nucleotides, and 
the CIP was used to remove phosphates and give free nucleosides. Nuclease P1 
digestion was carried out in 50 µl of digestion buffer (1 mM ZnCl2, 20 mM sodium 
acetate, pH 5.3), for both the control and the platinated RNAs with 10 µl (10 U) of 
nuclease P1 at 37 ºC overnight. The enzyme was then deactivated by heating at 
75 ºC for 15 min. Five µl of 1.5 M Tris·HCl, pH 8.8, and 1 µl (10 U) of calf 
intestinal phosphatase (CIP) was added to each sample and incubated for 4 hrs 
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at 37 ºC. After 4 hrs of incubation, samples were again heated at 75 ºC for 15 
min, vortexed, and centrifuged at 12,000 rpm for 5 min. Finally, samples were 
filtered through YM-3 microcon filters before injection into the HPLC or LC-MS.  
Samples were analyzed by HPLC and peaks areas were normalized to 
account for the differences in extinction coefficients at 260 nm, (C = 9,100 M-1 
cm-1, U= 10,100 M-1 cm-1, G= 13,600 M-1 cm-1, A= 14,900 M-1 cm-1) (217) and 
then peak ratios were calculated relative to the cytidine peak. 
4.3.8 Liquid chromatography mass spectrometry 
LC-MS (Liquid Chromatography Mass Spectrometry) is a powerful 
technique to separate and analyze complex mixtures with high sensitivity. LC-MS 
was carried out on an AQUITY Ultra Performance LC chromatography (UPLC) 
system (Waters Corporation, MA USA) equipped with an HSST3 C18 column 
(2.1 x 100 mm 1.8 µm). The column was maintained at 50 ºC and elution was 
carried out with a linear gradient of acetonitrile and 100 mM ammonium acetate, 
pH 6.0. The gradient was run for 3 min with a flow rate 700 µl/min, starting at 
100% ammonium acetate and decreasing to 60% over the course of the gradient. 
The column eluent was analyzed by directing it to the mass spectrometer. Mass 
spectra were collected in the positive ion mode. The percentage of adducts were 
calculated by normalizing the area with extinction coefficients followed by relative 
ratios of adduct present in sum of adducts. 
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4.4 Results 
4.4.1 Cisplatin binding studies in 790 RNA constructs 
Initially, two model systems of the 790 hairpin, 790 A○C and 790 G○U 
(mutant) were selected to study cisplatin binding (Figure 4.1). This 790 loop is 
part of helix 24 of 16S rRNA and is functionally important (249). In addition, 
extensive mutational and structural studies have been carried out previously in 
this helix (247, 258). MALDI mass spectrometry was used to check adduct 
formation with small RNA constructs. RNAs were reacted with one equivalent of 
monoaquated cisplatin for 5 hrs at 37 °C. The products were separated on 15% 
denaturing gels and visualized by UV shadowing. For the 790 A○C model, two 
bands were observed with cisplatin, whereas three bands were observed in the 
case of the G○U variant.  
The product bands A○C1, with higher mobility, and A○C2, with slower 
mobility, were isolated by electro-elution and subjected to MALDI-TOF mass 
spectrometry (Figure 4.2). The higher mobility product, A○C1, has a mass of 
5426.53 Da, which corresponds to free RNA. The slower mobility product, A○C2, 
has a mass 5653.2 Da, which is increased by 227 mass units [Pt(NH3)2] relative 
to the free RNA, and corresponds to the formation of a bifunctional adduct. 
Similarly, three products from the 790 G○U variant; G○U1 (higher mobility), 
G○U2 (intermediate mobility), and G○U3 (slowest mobility) were also isolated 
and analyzed by MALDI-TOF (Figure 4.2). In 790 G○U, the slower mobility 
product, G○U1, corresponds to unmodified 790 G○U with a mass 5443.2 Da. The 
other two products, G○U2 and G○U3, correspond to masses 5670.7 Da and 
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5670.2 Da, respectively, increased by of 227 mass units relative to the free RNA, 
equivalent to [(Pt(NH3)2] (Table 4.1). This result also indicates formation of 
bifunctional adducts. 
 
 
Figure 4.2. MALDI-mass spectrometry data show the masses of various products formed 
with 790 hairpin loops after the reaction with monoaquated cisplatin. 790 model constructs 
A○C and G○U with their sequence and calculated mass are also shown. 
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Table 4.1. Observed molecular mass and predicted species of various cisplatin adducts 
with 790 RNA model system. 
Molecular Ion  Observed mass (Da) (M+H)+ Predicted species 
790 A○C1 5426.53 790 A○C (RNA only) 
790 A○C2 5653.20        (+227) 790 A○C + Pt(NH3)2 
790 A○C2 5880.27        (+2*227) 790 A○C + 2[Pt(NH3)2] 
790 G○U1  5443.25     790 G○U (RNA only) 
790 G○U2 5670.72        (+227) 790 G○U + Pt(NH3)2 
790 G○U3 5670.20        (+227) 790 G○U + Pt(NH3)2 
 
4.4.2 Mapping binding sites by RNase T1 cleavage 
For further confirmation and mapping of the exact cisplatin-binding sites in 
these model systems, the products were partially digested with RNase T1, and 
the fragments were analyzed by MALDI-TOF mass spectrometry (Figure 4.3). 
RNase T1 fragments show that A○C1 has no platination in any fragments of 
RNase T1; however, in A○C2, the fragments corresponding to 3185.1 Da, 
[GGCGAUUAG>p+Pt(NH3)2], and 1568.2 Da, [GGCG>p+Pt(NH3)2], suggested 
platination at the 5' consecutive guanines (Figure 4.3 and Table 4.2). In the case 
of 790 G○U, the highest mobility band has no platination in any fragments of 
RNase T1 digestion; whereas, the other two slower mobility products, G○U2 and 
G○U3, had fragments corresponding to formation of bifunctional adducts (Figure 
4.4 and Table 4.3). The fragment corresponding to 1568.9 Da, [GGCG>p+ 
Pt(NH3)2], in G○U2, suggested a bifunctional adduct at the 5' consecutive  
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Figure 4.3. MALDI-mass spectrometry data after digestion of 790 A•C construct with RNase 
T1 are shown. RNA hairpin, platinated (♦) and corresponding unplatinated (◊) fragments, 
and +2 charge states (▪) are also indicated. The platinated site is shown on A○C2 at 
positions G1 and G2, which is consistant with the mass data.  
 
Table 4.2. RNase  T1 fragments of 790 A○C1 and A○C2 with calculated and observed mass. 
RNA fragments (5' to 3') 
Calculated 
mass  (Da) 
[M+H]+ 
Observed mass 
A○C1 (Da) [M+H]+ 
Observed mass A○C2 
(Da) [M+H]+ 
GGCGp 1341.81 1341.55 1568.27 [+ Pt(NH3)2] 
AUACCGp 1921.16 - 1920.74 
AUACCGCC 2469.56 2469.93 2469.68 
GGCGAUUAGp 2957.77 2957.83 3185.19 [+ Pt(NH3)2] 
AUUAGAUACCGCC 4085.53 4086.55 4086.28 
CGAUUAGAUACCGCC 4734.92 4734.31 - 
(M+H)+ 5425.3 5425.25 5653.27 [+ Pt(NH3)2] 
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Figure 4.4. MALDI-mass spectrometry data after digestion of 790 G○U construct gel 
fractions (G○U1, G○U2, and G○U3) with RNase T1 are shown. 790 G○U hairpin, platinated 
(♦) and corresponding unplatinated (◊) fragments of RNA are also indicated. The platinated 
site is shown on G○U2 at positions G1 and G2, and on G○U3 at positions G4 and G5, 
which is consistent with the mass data. 
 
guanines, and fragment with 2511.4 Da, [CGGUUAG>p+Pt(NH3)2], in G○U3 
indicated formation of an adduct at the G○U mismatch region. The fragment 
1568.9 Da is not significant in G○U3; but compared to G○U2, the mass 
corresponding to 2511.4 Da had higher intensity. The result is opposite in G○U2, 
which confirms adduct formation at two different sites. 
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Since the cisplatin was shown to bind preferably to the 5' consecutive 
guanosines on the modified construct, which were not the part of wild-type 16S 
rRNA, we made another construct with an A○C mismatch (wild type), but lacking 
the 5' consecutive guanosines. The rest of the binding studies in this chapter 
focus on the 790 A○C wild-type (wt) construct. 
 
 
Table 4.3. RNase T1 fragments of 790 G○U1, G○U2, and G○U3 with calculated and 
observed mass. 
RNA fragments 
(5' to 3') 
Calculated 
mass (Da) 
[M+H]+ 
Observed with 
G○U1 (Da) 
[M+H]+ 
Observed with 
G○U2 (Da) 
[M+H]+ 
Observed with 
G○U3 (Da) 
[M+H]+ 
UUAGp 1287.75 1287.58 1287.45 1287.40 
GGCGp 1341.81 1341.84 1568.95        [+ Pt (NH3)2] 
1568.7          
[+ Pt (NH3)2] 
GGCGGp 1687.02 1686.10 - - 
AUAUCGp 1922.14 1922.22 1922.42 1922.19 
CGGUUAGp 2283.35 2283.42 - 2511.42        [+ Pt (NH3)2] 
AUAUCGCC 2470.55 2471.60 2471.36 2471.26 
GGCGGUUAGp 2973.77 2973.67 3202.13        [+ Pt (NH3)2] 
3202.32        
[+ Pt (NH3)2] 
 
4.4.3 Binding studies in model system 790 A○C wild type 
The new 790 model RNA (790 A○C wt) was reacted with monoaquated 
cisplatin in an equimolar ratio with monoaquated platinum complex similar to the 
other constructs and the products were separated by gel electrophoresis. 
Separated products after desalting were examined by Ultraflex MALDI-TOF mass 
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spectrometry in the positive-ion mode (Figure 4.5). The band with the faster 
mobility was unplatinated RNA and the band with slower mobility contained a 
mixture of various adducts. The expected and observed mass of the possible 
adducts are summarized in Table 4.4. The reaction of cis-[PtCl(H2O)(NH3)2]+ 
resulted in the formation of what we believe to be a bifunctional adduct, RNA-
Pt(NH3)2, which was identified through an observed molecular mass of 6288.53 
Da. Two other products were observed in the MALDI spectrum with less 
intensity, corresponding to two and three platinum complexes bound to the 790 
RNA construct. 
 
Figure 4.5. MALDI-TOF spectra of undigested control (bottom) and platinated 790 A○C wt 
model (top) with aquated platinum complexes (stoichiometry of 1:1, 1:2, and 1:3 RNA:Pt 
adduct) are shown.  
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Table 4.4. Calculated and observed molecular mass of various cisplatin adducts with 790 
RNA model system. 
Molecular ion  Calculated mass (Da) [M+H]+ 
Observed mass (Da) 
[M+H]+ 
790 A○C wt control  6061.72 6061.70 
790 A○C wt + Pt(NH3)2 6290.74 6288.53     (+227) 
790 A○C wt + 2[Pt(NH3)2] 6519.76 6515.71     (+(2*227)) 
790 A○C wt + 3[Pt(NH3)2] 6748.78 6742.85     (+(3*227)) 
 
4.4.4 Mapping the binding site with RNase T1 cleavage 
In order to determine the location of the cisplatin-binding sites, both RNA 
samples (control and platinated) were partially digested with RNase T1. This 
digestion was performed to produce fragments of various lengths and molecular 
mass. The location of cisplatin-binding could then be localized to a specific 
fragment for closer analysis. Following a five-hour incubation at 37 °C of 
equimolar amounts of 790 RNA (A○C wt) and cis-[PtCl(H2O)(NH3)2]+, the 
products and control were subjected to RNase T1 cleavage. Figure 4.6 and 
Table 4.5 compare the mass spectra for the digested control and platinated 790 
loop.   
Three major fragments were observed in both samples and a fourth 
fragment was only observed in the product. The three fragments that are 
common to both spectra were the result of the RNase T1 digestion. The first 
fragment, CAGp, was identified with an observed molecular mass of 979.4 Da. 
whereas the second fragment, corresponding to AUUAGp, was identified with an 
observed molecular mass of 1615.5 Da, and the third fragment, AUACCCUGp, 
126 
 
 
contained the observed molecular mass of 2530.7 Da. The fourth fragment was 
observed only on the platinated sample, which corresponds to CAGGAUUAGp+ 
Pt(NH3)2. This is because the RNase T1 cleavage at the 3' end of guanine 
residues was likely blocked by a bifunctional platinum adduct at consecutive 
guanosine residues (residues 785 and 786). This is further supported by the fact 
that there is a mass peak with lower intensity at 1541.92 Da on the platinated 
sample, which corresponds to formation of bifunctional adduct on CAGGp. 
 
 
Figure 4.6. MALDI-TOF mass spectra of digested control and platinated 790 loop model 
(790 A○C wt) are shown. The model RNA construct, platinated (♦) and corresponding 
unplatinated (◊) fragments with RNA sequence are also indicated. The platinated site is 
shown on A○C wt (platinated) at positions G4 and G5, which is consistant with the mass 
data. 
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Table 4.5. RNA fragments, calculated and observed m/z values of 790 A○C wt are listed for 
the digested control RNA and platinated RNA. 
RNA fragments       
(5' to 3')   
Calculated 
mass (Da) 
[M+H]+ 
Observed mass 
control RNA 
(Da) [M+H]+ 
Observed mass 
platinated RNA (Da) 
[M+H]+ 
CAGp 979.6 979.68 979.05 
CAGGp 1324.81 1324.98 1541.42 [+ Pt (NH3)2] 
AUUAGp 1615.96 1616.25 1615.31 
AUACCCUGp 2531.51 2531.79 2530.65 
CAGGAUUAGp 2940.77 - 3167.63 [+ Pt (NH3)2] 
AUUAGAUACCCUGp 4147.48 4147.28 4147.00 
 
4.4.5 Determination of number of adducts formed with 790 A○C wt hairpin  
The 790 RNA (A○C wt) was reacted with a 20x excess amount of 
monoaquated platinum complex, cis-[PtCl(H2O)(NH3)2]+, in 10 mm phosphate 
buffer at 37 ºC for 5 hours. A control reaction was also prepared with a volume of 
H2O equivalent to that of the cisplatin added to the other reactions. After 5 hours, 
the reactions were quenched with NaCl followed by freezing. Next, all reaction 
mixtures were dialyzed with a tubing of a MW cut off of 3.5 kDa for 30 hours in 
order to remove any excess unbound platinum. The concentration of dialyzed 
RNA samples were measured spectrophotometrically (ε = 188,800 mol-1cm-1) 
and 0.1 OD was used for atomic absorption spectroscopy (AAS) to determine the 
number of platinum atoms bound to RNA. A calibration curve prepared from 
known concentrations of platinum was created and platinum concentrations of 
the sample volumes were determined in triplicate. These values were used to 
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determine the number of moles of platinum present in the sample and a ratio to 
the number of moles of 790 RNA in the sample were calculated. When a 20x 
excess of aquated platinum (80 nmol) was reacted with 790 RNA (4 nmol) nearly 
three moles of platinum were bound to every mole of 790 model RNA construct 
(Figure 4.7A). 
 
Figure 4.7. The molar ratio of the bound platinum to 790 RNA with 20x excess platinum is 
shown. A) Number of platinum atoms bound to each molecule of 790 construct (average of 
triplicate data) and B) MALDI mass spectra showing various adducts formed with excess 
aquated platinum complex are shown. 
 
Further, MALDI mass spectrometry was employed to elaborate on the 
findings of the excess platinum reaction previously analyzed with AAS. The 
MALDI spectrum of the analyzed reaction with 20x excess cisplatin showed three 
different products as shown in Figure 4.7B. The major molecular ion peak at 
6741.9 Da corresponds to the three platinum adducts associated with 790 
construct, while the other two peaks with lower intensities, 6514.9 Da and 6969.5 
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Da, correspond to two and four cisplatin adducts bound to the RNA molecule. 
This data supports the average three platinum complexes present in 790 RNA 
construct determined from AAS.  
4.4.6 Types of adducts 
 Five reactions of 790 RNA (A○C wt) with different molar amounts (1:1 to 
1:5) of cis-[PtCl(H2O)(NH3)2]+ in 10 mm phosphate buffer were incubated at 37 
ºC. After five hours, reactions were quenched with 2 M NaCl raising the 
concentration to 200 mM of NaCl and stored in the freezer. For comparison, a 
control reaction was also treated in a similar manner. All six reactions were 
treated with P1 nuclease to separate nucleotides and then CIP to remove 
phosphates. The concentrations of the sample volumes were determined by a 
UV-vis spectrophotometer and a volume corresponding to 0.1 OD was injected 
into the HPLC. An overlay of the resulting chromatograms showed that 
concentration of guanosine is decreased as the reaction ratio increases. The 
second major change is observed with adenosine, while the other two nucleotide 
concentrations remain fairly constant (Figure 4.8A). Quantification was carried 
out by Empower HPLC software and the peak areas were divided by the 
corresponding extinction coefficients to account for the differences in absorbance 
at 260 nm. The peak ratios were then normalized to the cytidine peak (Figure 
4.8B). 
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Figure 4.8. HPLC chromatograms (A) and quantification (B) of the digested 790 RNA after 
reaction with cisplatin is shown. A) An overlay of the HPLC chromatograms of control 
(digested 790 RNA) and platinated 790 RNA of different reaction ratios is shown. New 
peaks following platination of 790 RNA are indicated by symbols (Δ o ♦ ●). B) Relative 
molar concentrations of unreacted nucleosides to reaction ratios vs. relative moles are 
plotted (this data was collected by Christopher Lajeunesse). 
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Along with four standard nucleosides, several other peaks were observed 
in the HPLC traces. These peaks were observed to increase in intensity as the 
ratio of cisplain was increased in the reaction mixture. To characterize these 
unknown peaks, LC-MS characterization was carried out.  
To identify other unknown peaks, LC-MS was carried out with an Acquity 
UPLC system equipped with an HSST3 (2.1 × 100 mm, 1.8 µm) C18 column. 
The chromatogram and mass of the corresponding peaks are shown in Figure 
4.9. The observed and calculated masses with retention times are shown in 
Table 4.6. The major peak at retention time 0.90 min is assigned as the 
bifunctional adduct, GpGPt(NH3)2, with a molecular mass of 856.16 Da. Similarly, 
the peak at 1.60 min with mass 840.16 Da corresponds to ApGPt(NH3)2, and the 
peak at 1.68 min with mass 794.20 Da is assigned as GGPt(NH3)2. The peak at 
2.12 min with mass 778.22 Da is assigned as AGPt(NH3)2. Along with these, two 
monofunctional adducts were also assigned. The peak at 1.49 min with mass 
547.09 Da is GPt(NH3)2Cl and at 1.81 min with mass 531.08 Da is 
GPt(NH3)2H2O. These results show that cisplatin preferentially reacts with 
guanosine, forming both bifunctional and monofunctional adducts. 
Further, the ratio of these adduct-formations was calculated and found to 
be in favor of the GpG platinum adduct. The UV chromatogram from the LC-MS 
analysis of the 5:1 (Pt:RNA) molar ratio reaction was quantified using Mass Lynx 
software and Table 4.6 shows the relative percentage of adducts present in 
solution. The GpGPt(NH3)2 adduct was the most prevalent adduct found in the 
reaction volume accounting for 35% of the total adducts found. The bifunctional 
132 
 
 
ApGPt(NH3)2 adduct contributed to the second most preferred product with 24%. 
This was followed by the GGPt(NH3)2 and AGPt(NH3)2 adducts with values 12% 
and 11%, respectively. The monofunctional adducts were not as prevailing as the 
bifunctional adducts, but still provided 17% of the products with GPt(NH3)2Cl 
accounting for 9% and GPt(NH3)2H2O, 8%. The formation of the bifunctional 
adducts was the more preferred product by a factor of almost 4:1 in comparison 
to the monofunctional adducts. 
 
Figure 4.9. LC-MS data of digested 16S rRNA after reaction with cisplatin are shown. The 
chromatograms with retention times (upper) and mass spectra of the corresponding peaks 
(lower) are shown. 
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Table 4.6. Masses, retention times, and % of various adducts of cisplatin with model RNA 
construct. 
Types of 
adducts 
+1 charged state (Da) 
[M+H]+ 
+2 charged state (Da) 
[M+H]+ Retention 
time 
Relative 
% 
Calculated  Observed Calculated Observed
GpG[Pt(NH3)2] 857.15 856.14 428.57 428.59 0.96 min  35 
G[Pt(NH3)2Cl] 548.08 547.09 - - 1.49 min 9 
ApG or 
GpA[Pt(NH3)2] 
841.15 840.14 420.57 420.57 1.60 min 24 
GG[Pt(NH3)2] 796.20 794.20 398.1 397.60 1.68 min  12 
G[Pt(NH3)2H2O] 531.12 531.08 - - 1.81 8 
AG or 
GA[Pt(NH3)2] 
780.21 778.19 390.1 389.60 2.11 min  11 
 
4.5 Discussion 
 The binding study with small RNA constructs has shown that cis-
[PtCl(H2O)(NH3)2]+ coordinates with the 790 RNA loop preferentially at 
consecutive guanosines. MALDI and LC-MS data revealed that the aquated 
complex is capable of forming bifunctional adducts with consecutive guanine 
residues, as well as mono-functional adducts with single guanine residues. 
Results from MALDI-TOF and AAS have uncovered that more than three 
cisplatin molecules can bind to 790 RNA constructs, though there is only one 
consecutive guanosine. HPLC can be utilized to identify various types of adducts 
formed with RNA constructs; however, due to lack of authentic platinated 
standards, LC-MS was used for further confirmation. 
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 Our work has shown that MALDI-TOF, AAS, HPLC, and LC-MS are useful 
for characterizing and mapping the interactions between cisplatin and the 19-
nucleotide 790 RNA loop. Though HPLC has demonstrated to be effective in 
determining whether a reaction has occurred between cisplatin and the RNA, the 
information gained from this technique is limited. A high-resolution mass 
spectrometry technique is needed for product identification. MADLI-TOF allows 
for the detection of bound complexes, before or after digestion. In addition, the 
relative number of bound species can be obtained from the mass spectra.  
In MALDI-TOF, the platinated RNA showed masses with 227 Da 
increments compared to the parent RNA, which is two mass units (Hs) less than 
would be expected from the coordination of Pt(NH3)2 (229 Da). This is due to the 
proton necessary to compensate for the charge of Pt2+ and still produce singly 
charged molecular ions (267). However, it is still uncertain whether the products 
are mono- or bifunctional adducts, because of less number of purines and high 
laser intensity used for ionization. Previously, it has been suggested that the 
lower mass observed with platinated-RNA complex in MALDI-TOF was the result 
of possible ligand loss (chlorido) during the ionization process rather than 
formation of a bifunctional adduct (170). Using the relatively soft ionization 
method (LC-MS), both mono- and bifunctional adducts were detected. The 
monofunctional adduct includes both the chlorido and aqua ligand. In LC-MS, the 
monofunctional adduct with one chlorido ligand was detected with a mass one 
Da less than calculated. In bifunctional adducts, loss of two protons was 
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observed with GG-Pt(NH3)2 and AG-Pt(NH3)2, whereas only one proton loss was 
observed with the GpG and ApG adducts. 
In 16S rRNA and 790 model constructs, the preferable binding sites of 
aquated platinum complex were similar; mostly targeting the consecutives Gs. 
The similarity in type of adducts obtained from HPLC and LC-MS indicates that 
the 790 construct is a good model to understand the mechanism of cisplatin 
binding and kinetic studies. Due to the larger structure of 16S rRNA and 
numerous binding sites, kinetics studies are challenging; hence, the information 
obtained from a model system would be very useful. 
The 790 loop is an ideal site for small-molecule binding studies because it 
is highly conserved, and extensive genetic and NMR information are also 
available (247-248). Mutational studies showed that a number of nucleotides in 
this loop are functionally important, and cisplatin probing study revealed this loop 
is accessible for small molecules. Thus, 790 loop is a promising target for 
antibiotic development. The kinetics and chemical probing studies in 790 model 
system can help us to understand the mechanism of small-molecule interactions 
with RNA.  
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CHAPTER  5  
Synthesis of Amino-acid-linked Analogues of Cisplatin for 
Probing the Ribosome Structure 
5.1 Abstract 
Cisplatin has several advantages as a chemical probe to determine 
nucleotide accessibility in RNA structure. One advantage is the ease with which 
its ligands can be modified. Ammine ligands of cisplatin can be modified with 
various reagents to alter the size and charge of the complex. Several amino-acid-
linked platinum complexes were synthesized and a binding study was carried out 
with a model RNA system as well as 16S rRNA. Amino-acid-linked complexes 
alter the reactivity with RNA by increasing the charge, size, and H-bonding 
potential of the ligand. Lysine- and ornithine-linked platinum complexes showed 
higher reactivity with AG-rich sequences and the arginine-linked complex showed 
reactivity mostly in the bulge and loop regions of 16S rRNA.  
5.2 Introduction 
Cis-diamminedichloridoplatinum (II), cisplatin, is a clinically used antitumor 
drug that has long been believed to react preferentially with DNA (156, 163). The 
cross-links at GG sequences are considered to be crucial for its biological activity 
(156, 175). The main coordination site of cisplatin with DNA is the N7 of guanine, 
and the complex forms adducts mainly at runs of consecutive Gs, with less 
damage at AG or GA sequences (191, 197). The acquired and intrinsic 
resistance of tumor cells to the drug has lead researchers to look for other 
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platinum complexes that have better chemotherapeutic applications (268-269). 
Various platinum coordination compounds are currently used as clinical 
anticancer drugs (166) and lot of effort has been made to improve the therapeutic 
effectiveness of platinum compounds (181, 270). One of the strategies to 
improve the effectiveness of the drug is to design complexes that interact with 
the target DNA in a different manner. For this purpose, numerous cisplatin 
analogues composed of ligands that have high affinity with DNA, such as 
intercalators, have been synthesized (183, 271). A cisplatin analogue with a 
tethered 9-aminoacridine-4-carboxamide showed an altered DNA sequence 
specificity (272). This compound has a higher reactivity with purines (GA 
sequences). The biological activity of this and related compounds was similar 
compare to cisplatin, and they also exhibited activity against cisplatin-resistant 
cell lines (273).  
Several amino-acid-linked platinum complexes were synthesized and their 
activity was compared with cisplatin in various cell lines (187-189, 274). Other 
modifications include platinum complexes with charged, neutral, or hydrophobic 
amino acids coordinated to the platinum. These modifications increase the 
charge or hydrophobicity of the complex and potentially alter the binding 
interactions with the target. Similarly, peptide-tethered platinum conjugates were 
also synthesized and their interactions with DNA were studied; however, the 
additional functionalities in those cases did not lead to increased reactivity (186, 
190). The uncharged compounds had lower reactivity than cisplatin and the 
positively charged compounds had higher reactivity than the negatively charged 
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compounds, which may be due to electrostatic interactions (186). The overall 
reactivity of the amino-acid platinum complexes was lower than the parental 
compound cisplatin; however, their interactions with RNA were not discussed in 
the literature, to the best of my knowledge (186, 189-190).  
One of the advantages of using cisplatin as a probing agent is the ease 
with which its size and charge can be altered. Cisplatin is relatively small in size 
and numerous binding sites in 16S rRNA have been observed (Chapters 2 and 
3). In order to reduce or alter the number of binding sites to gain more 
information about accessibility of the RNA structure towards various ligands, the 
platinum complex can be modified to contain different functionalities. Introducing 
charged ligands such as lysine, arginine, and aspartic acid alters the net charge 
of the complex; whereas, the addition of glycine or alanine would change the 
bulkiness and hydrophobicity of the complex compared to the cationic amino 
acids. Electrostatic interactions play an important role in ligand binding with RNA 
(223), and it is expected that the introduction of positive charges or 
hydrophobicity alters the binding site preference and reactivity. Similarly, the 
presence of bulky groups may reduce the number of binding sites due to 
inaccessibility of the target nucleotides in the folded RNA structure. Having 
different functionalities tethered to the platinum complex could be useful in order 
to probe the ribosome and discover charged pockets and/or accessibility of RNA 
structural motifs as potential drug target sites. In this chapter, the interaction of 
amino-acid-linked platinum complexes (Figure 5.1) with the model RNA system 
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and their potential as chemical probes to study the ribosome structure will be 
explored.  
 
 
 
Figure 5.1. Structures of monoaquated amino-acid-linked platinum complexes used in this 
study are shown. Note that only one possible isomer is shown. 
 
5.3 Materials and Methods  
5.3.1 General 
Potassium tetrachloroplatinate (K2PtCl4) was purchased from Strem 
Chemicals, Inc. (Newburyport, MA). L-Ornithine hydrochloride, L-lysine, L-
arginine and L-aspartic acid were purchased from Alfa-Asear (Ward Hill, MA). All 
other chemicals and reagents were purchased from Sigma-Aldrich or Fisher, 
unless otherwise stated. RNase-free, distilled, deionized ddH2O (Millipore water) 
was used throughout the experiments.  
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5.3.2 Synthesis of amino-acid-linked complexes  
Amino-acid-linked complexes were synthesized as previously described in 
the literature (187, 189). For the synthesis of [cis-PtCl2(N,O-Lys)], (Kplatin), 
K2PtCl4 (0.21 g, 0.50 mmol) was dissolved in 500 µl of ddH2O in a centrifuge 
tube, and the solution was vortexed until the crystals were completely dissolved. 
In a separate tube, L-lysine monohydrochloride (0.18 g, 1.0 mmol), was 
dissolved in 500 µl of ddH2O and vortexed. The pH of the amino-acid solution 
was measured to ensure that it was between 5.0 and 6.0. Then, both solutions 
were combined in a dry 10 ml round bottom flask and stirred, which produced a 
reddish-colored solution. The flask was attached to a reflux condenser and 
heated at 80 ºC for two hours, until the solution had turned a yellowish color. The 
solution was allowed to cool and filtered by using gravity filtration. The filtrate was 
transferred to a beaker and kept in dark. The crystals started to appear after 12 
hours at room temperature. Yellow crystals formed over a period of 1-3 days. 
The crystals were collected and washed with cold ddH2O, ethanol, and ether. 
The yellowish-orange crystals, [cis-PtCl2(N,O-Lys)] (0.11 g, 46% yield), were 
dried thoroughly using a pressurized vacuum pump and the final product was 
confirmed and characterized by mass spectrometry and NMR spectroscopy. 
Electrospray MS (H2O/methanol, positive ion): m/z found 433.99 (M+Na)+. 1H 
NMR (δ, DMSO): 7.6, 5.6, 4.9, 3.0, 2.5, 1.8, 1.7 ppm.  
To synthesize the L-ornithine and L-arginine-linked platinum complexes, 
the procedure was the same as above, except 0.091 g (0.5 mmol) of L-ornithine 
and 0.087 g (0.5 mmol) of L-arginine were used instead of L-lysine. Oplation was 
precipitated as yellow crystals with a yield of 56%. Electrospray MS 
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(H2O/methanol, positive ion): m/z found 419.98 (M+Na)+. 1H NMR (δ, DMSO): 
7.67, 5.68, 4.91, 3.0, 2.4, 1.72, 1.6 ppm. Rplatin was obtained as light yellowish 
crystals with a yield of 38%. Electrospray MS (H2O/methanol, positive ion): m/z 
found 462.00 (M+Na)+. 1H NMR (δ, DMSO): 7.5, 5.6, 4.8, 3.0, 2.4, 1.7, 1.5 ppm.  
5.3.3 RNA and DNA  
RNA corresponding to the 790 loop (5'-GCAGGAUUAGAUACCCUGC-3') 
of 16S rRNA was purchaged from the Keck Oligo facility (Yale University). This 
RNA was received with 2' protection and was deprotected by dissolving in TBAF 
(tetrabutylammonium fluoride), followed by incubation at 35 ºC overnight. The 
RNA was then desalted with a Poly-pack cartridge (Glen Research) according to 
the company protocol, and dried in a speed-vac evaporator. The dried RNA was 
reconstituted in TE buffer (10 mM Tris·HCl and 1 mM EDTA) and gel purified. 
DNA primers were purchased from Sigma Genosis, purified, and labelled as 
described in Chapter 2. The 16S rRNA was isolated from E. coli MRE600 and 
renatured as described in Chapter 2. 
5.3.4 Platination reaction and primer extension 
All amino-acid-linked complexes were converted to the mono-aquated 
form by reaction with 1:1 molar ratios of complex:AgNO3, in dimethylformamide 
(DMF). Platinum-DMF complex stock solutions were stored at -20 °C for up to 1 
week and diluted as required just prior to use. The platination reaction with model 
RNA and 16S rRNA were performed with monoaquated complexes. Prior to 
platination, model RNA and 16S rRNA was renatured as described before. The 
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reaction was carried out in 20 mM HEPES, pH 6.5, 20 mM K2SO4 and 10 mM 
MgSO4 (buffer H) and incubated at 37 °C for 5 hours. In the model system, the 
molar reaction ratio was 1:1 (RNA:metal complex) and in 16S rRNA, the ratio 
was 1:20 (16S rRNA: complex) or 1:75 (complex: nucleotides). After the reaction, 
unreacted complex was removed by ethanol precipitation. To map the binding 
sites in 16S rRNA, primer extension was carried out as described in Chapter 2.  
5.3.5 MALDI-mass spectrometry 
MALDI-TOF mass spectrometry was carried out on a Bruker Daltonics in 
the Central Instrument Facility of the Chemistry department. The samples were 
reacted with cisplatin or amino-acid platinum complexes as described in section 
5.3.4 and the unreacted complex was removed by ethanol precipitation. A 
second ethanol precipitation with ammonium acetate was carried out, and the 
resulting pellet was washed with 70% ethanol and dried in a speed vaccum. 
Finally, the samples were resuspened in ddH2O. The concentration was 
measured spectrophotometrically and about 2 μl of RNA (20 pmol) was mixed 
with 3 μl of saturated hydroxypicolinic acid (HPA) matrix in 50% acetonitrile, and 
0.5 μl of 100 mM ammonium citrate. On the MALDI plate, 1 μl of the HPA:RNA 
mixture was spotted. For RNase T1 digestion, 1 unit of RNase T1 was added to 
the remaining RNA sample and incubated at room temperature for 30 min. One 
μl of the digested sample was spotted on the MALDI plate. All samples were 
checked in the positive ion mode using method RP-3147.par. 
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5.4 Results 
5.4.1 Synthesis of amino-acid-linked complexes 
Amino-acid-linked platinum complexes were synthesized in order to react 
and determine the number of binding sites on RNA. Positively charged amino-
acids such as ornithine, lysine, and arginine were linked to the platinum to 
determine the effects of altered electrostatics and bulkiness. Similarly, the 
platinum complex with the negatively charged amino acid, aspartic acid, was 
synthesized (the net charge of this complex is neutral). Amino-acid-linked 
platinum complexes were synthesized from potassium tetrachloroplatinate, and 
formations of the products were confirmed by NMR spectroscopy and mass 
spectrometry as described previously in the literature (188-189). 
5.4.2 Binding studies in small RNA constructs 
Amino-acid-linked complexes were converted to the corresponding 
monoaquated species by reacting them with AgNO3 overnight. Small RNA 
constructs (790 A○C loop) (Figure 5.2) and aquated amino-acid analogues were 
reacted in a 1:1 molar ratio at 37 °C for 5 hrs. The reaction was quenched with 
NaCl and followed by freezing. The samples were ethanol precipitated to desalt 
and adduct formation was checked by MALDI-mass spectrometry. Mass data 
showed the formation of bifunctional adducts with their corresponding amino-
acid-linked complexes (Figure 5.2 and Table 5.1). Oplatin showed a major peak 
with molecular mass of 6385.1 Da, which corresponds to the +1 adduct 
(increased in mass of RNA by 325 Da corresponding to the control RNA) and a  
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Figure 5.2. Mass spectral data of products after the reaction of amino-acid complexes with 
790 A○C construct are shown. Model RNA construct (790 A○C loop) with its molecular 
mass is also shown.  
 
 
Table 5.1. M/z values of the various adducts for RNA-Pt complexes are listed. 
Complexes  
RNA + Pt(amino-acid)  
[M+H]+ 
RNA +2 [Pt(amino-
acid)]    [M+H]+ 
RNA + 3 [Pt(amino-
acid)]     [M+H]+ 
Calculated  Observed Calculated Observed Caluclated  Observed 
Oplatin  6388.7  6386.5 6715.8 6712.1 7042.8 - 
Kplatin  6402.7 6400.3 6743.8 6739.2 7084.9 7078.4 
Rplatin  6430.74 6428.3 6799.8 6795.6 7168.8 7162.4 
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minor peak at 6710.7 Da, which corresponds to the +2 adduct formation 
(increased in mass by 2 x 325 Da) (Figure 5.2). Kplatin and Rplatin showed the 
formation of +1 adducts with masses corresponding to 6401.6 Da (RNA + 339 
Da) and 6428.0 Da (RNA + 367 Da), respectively. These complexes also showed 
molecular masses corresponding to +2 and +3 adduct formation with RNA 
(Figure 5.2 and Table 5.1). Although there is only one set of consecutive 
guanosines in this small RNA construct, more than one bifunctional adduct was 
detected. Hence, other binding sites such as guanosine and/or adenosine in the 
loop region had to be considered. This result is consistent with an increase in 
mass of RNA that is equivalent to the formation of a bifunctional adduct (Table 
5.1). Monofunctional adducts were not detected by MALDI-mass spectrometry 
with any of these complexes. In the MALDI spectrum, peaks of RNA showed 
masses corresponding to the parent RNA plus platinum complexes, with two less 
H’s than would be expected from the attachment of a Pt(amino-acid) fragment for 
each adduct. This result is due to a proton transfer necessary to counterbalance 
the binding of a charged complex and still produce singly charged molecular ions 
(267). This result is consistent with other adduct formation such as, 4 Da less in 
[RNA+2(Pt-amino-acid)] and 6 Da lower in case of [RNA+3(Pt-amino-acid)].  
Hence, the observed mass is 2 Da less than the calculated for each adduct 
formed with 790 RNA construct. 
5.4.3 RNase T1 cleavage study in small RNA construct  
To locate the binding site of amino-acid-linked complexes in the model 
RNA system, all reaction samples and controls were partially digested with 
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RNase T1. The fragments were analyzed by MALDI-TOF mass spectrometry 
(Figure 5.3) and compared to the control. Platinated RNA with Oplatin showed a 
fragment with a mass of 3266.3 Da, which corresponds to 
[CAGGAUUAG>p+Pt(ornithine)]. The increase in mass (325 Da) on the 
platinated fragment corresponds to the formation of a bifunctional adduct with 
Oplatin. Similarly, Kplatin and Rplatin also showed a fragment of RNA with 
complexes. The mass peak at 3624.9 Da with Kplatin suggested complex 
formation with the GCAGGAUUAG>p fragment of RNA (increase in mass by 339 
Da). Rplatin also showed RNA-complex formation with a mass of 3653.7 Da 
(increase in mass by 367 Da) corresponding to the same fragment of RNA. No 
other fragments of RNA shown in Table 5.2 contained platinum complexes. This 
result suggests platination somewhere on the 5' half of the 790 RNA.  
The complex-bound RNA fragment contains a pair of Gs and two AG 
sites; hence, the exact location of the binding sites could not be identified. 
Several RNA fragments were observed with these complexes; however, they 
were slightly different than those with the parental compound cisplatin. For 
example, cleavage occurred at the site of consecutive Gs with RNase T1 after 
reaction with the Oplatin and Rplatin complexes. This result indicates a possible 
alternation of sequence preference by the amino-acid-linked complexes 
compared to cisplatin. For example, with Kplatin and Rplatin, the RNA fragment 
GCAGG>p does not contain a platinum complex; however, GCAGGAUUAG>p was 
detected with the complex, which is evidence for adduct formation in the loop 
region. With cisplatin and Oplatin treated samples, the RNA fragment AUUAG>p  
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Figure 5.3. MALDI-mass spectrometry data showing the mass after digestion of 790 
constructs with RNaseT1. Platinated fragments are indicated with (♦). 
 
Table 5.2.The masses of RNase T1 fragments of 790 RNA after reaction with cisplatin and 
its analogues. 
Fragments 
Calculated 
mass (Da) 
Observed mass of RNase T1 fragments of 790 RNA 
following platination (Da) 
Control Cisplatin Oplatin Kplatin Rplatin  
GCAG>p 1324.81 1324.98 - 1324.48 1324.32 1324.42 
AUUAG>p 1615.96 1616.25 1615.31 1615.73 - - 
GCAGG>p 1670.02 - - - 1669.51 1669.63 
AUACCCUG>p 2531.51 2531.79 2530.65 2531.15 - - 
CAGGAUUAG>p 2940.76 - 
3167.63 
(+227) 
3266.31 
(+325) 
- - 
GCAGGAUUAG>p 3285.98 - - - 
3624.97 
(+339) 
3653.72 
(+367) 
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did not contain a platinum complex, and the platinated CAGGAUUAG>p was 
obtained with both complexes, suggesting adduct formation at the consecutive 
guanosines (Figure 5.4). 
 
 
 
 
 
Figure 5.4. Some of the possible adducts with cisplatin and amino-acid-linked complexes 
with 790 RNA model system are shown. The expected and observed mass of the RNA-Pt 
complexes are indicated. The observed masses are 2 Da less than the expected for the 
bifunctional adducts, because proton transfer necessary to compensate for the positive 
charges.  
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5.4.4 Mapping binding sites in 16S rRNA by primer extension 
Cisplatin and amino-acid-linked platinum complexes, after mono-aquation, 
were used to probe 16S rRNA. The monoaquated species contain positive 
charges that are different than the parental compound cisplatin, and hence, a 
change in reactivity was expected. The binding sites of monoaquated complexes 
were mapped on free 16S rRNA by using primer extension. The 16S rRNA was 
isolated from E. coli and renatured as described in Chapter 2. The reaction was 
carried out in 1:20 molar ratios of 16S rRNA:complex (or 1:75 molar ratios of 
complex:nucleotides) in 20 mM HEPES buffer, pH 6.5, at 37 °C in the dark for 5 
hours. The reaction was quenched by increasing the concentration of NaCl to 
200 mM, followed by freezing. The unreacted complex was removed by ethanol 
precipitation or dialysis. To compare the binding sites with the parental 
compound, several functionally important helices such as h18, h24, h27, and h28 
were selected for the probing studies. Primers corresponding to these helices of 
16S rRNA were used to map the coordination sites of complexes. 
The magnitudes of the reactivity were classified by the intensities of the 
bands on the autoradiograms. The intensities of bands could be measured up to 
approximately 100 nucleotides from the transcription start site. Coordination sites 
of cisplatin and analogues were determined by comparing with a control treated 
in a similar manner, but lacking metal complex. The positions of the stops due to 
coordination of the complexes were identified by comparing with dideoxy 
sequencing lanes on the same gel.  
The results showed clear differences in the binding sites of amino-acid-
linked complexes and cisplatin (Figure 5.5). Cisplatin showed reactivity mostly 
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with consecutive Gs, or Gs in mismatched or loop regions; however, several of 
the consecutive Gs that showed strong reactivity with cisplatin were not reactive 
towards the amino-acid-linked complexes. These complexes showed quite 
different patterns of reactivity, mostly with the ApG sequences and in the loop 
regions. 
 
 
 
Figure 5.5. Autoradiogram of probing results with amino-acid-linked complexes 
corresponding to the helix 24 of 16S rRNA is shown. A) The secondary structure of 16S 
rRNA corresponding to helix 24 is shown. Nucleotides with strong and moderate cisplatin 
hits are shown with red and green, respectively. B) The autoradiogram showing the 
reverse transcriptase pauses or stops is presented. In the gel, C, U, A, G represent the 
sequencing lanes; the control is 16S rRNA lacking treatment with complexes; and other 
lanes contain 16S rRNA treated with corresponding complexes Orn-Pt, Lys-Pt, Arg-Pt, or 
Asp-Pt (complex:nucleotide is 1:75). The strong and moderate hits are indicated with 
arrows and corresponding nucleotide numbers. Strong hits with: cisplatin (▲), Oplatin and 
Kplatin (**), Rplatin (♦); moderate stops with: cisplatin (Δ), Oplatin and Kplatin (*), and 
Rplatin (◊).  
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In helix 24, the strong cisplatin-binding site observed at U801 was not 
present with any of the amino-acid-linked complexes; however, a number of 
binding sites were observed in the loop region with Oplatin and Kplatin 
monoaquated complexes (Figure 5.5). The strong stops occurred at C795, 
G791, and U788, which were all on the 3' side of the adenosines on the loop 
region. Some additional minor stops were also observed, such as at U804 and 
G778, which had shown strong reactivity with cisplatin. Rplatin showed strong 
binding site on the three-nucleotide asymmetric bulge region of helix 24. Only 
minor reactivity with Rplatin was observed on the sites that showed strong 
reactivity with Kplatin and Oplatin. The preference for adenosine residues by 
these complexes is highly unusual, and being explored currently in more depth 
by another student in the laboratory. There were no such strong stops observed 
with the Dplatin complex. This result indicates that electrostatics and structure 
are likely to be important factors for platinum complexes to interact with RNA. 
The strong stop that appeared at the consecutive Gs on the stem region at A787 
with Oplatin and Kplatin might be the structural distortation caused by the A◦C 
mismatch close to it. Various other bands are observed in all lanes, including the 
control lane, possibly due to strong secondary structures in the RNA template 
that block reverse transcriptase. 
Helix 18 contains several universally conserved residues and showed 
reactivity with the parental compound cisplatin, such as consecutive Gs at 
residues 540-542 and 529-530; however, the amino-acid metal complexes 
showed different sequence selectivity (Figure 5.6). Instead of a strong hit  
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Figure 5.6. Autoradiogram of probing results with amino-acid-linked complexes at helix 17 
and 18 of 16S rRNA are shown. A) The secondary structure of 16S rRNA corresponding to 
helix 17 and 18 is shown. Nucleotides with strong and moderate cisplatin hits are shown 
with red and green, respectively. B) The autoradiogram showing the reverse transcriptase 
pauses or stops is presented. In the gel, C, U, A, G represent the sequencing lanes; the 
control is 16S rRNA lacking treatment with complexes; and other lanes contain 16S rRNA 
treated with corresponding complexes Orn-Pt, Lys-Pt, Arg-Pt, or Asp-Pt 
(complex:nucleotide is 1:75). The strong and moderate hits are indicated with arrows and 
corresponding nucleotide numbers. Strong hits with: cisplatin (▲), Oplatin and Kplatin 
(**), Rplatin (♦); moderate stops with: cisplatin (Δ), Oplatin and Kplatin (*), and Rplatin (◊).  
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present at U543 before the consecutive Gs, it appeared on the 3' side of A539, 
which is present between the two sets of consecutive Gs, indicating possible 
cross-links at the ApG sequence. Interestingly, this stop was strong with Oplatin 
and Kplatin, although the intensity was shifted by one nucleotide, and did not 
show strong reactivity with Rplatin. Another strong stop appeared at A533, which 
was also found one nucleotide prior to the cisplatin stop site. A number of other 
strong stops appeared at A510, G500, and A452, which were all different than 
the stops observed with the parental compound cisplatin. These stops are on the 
3' side of an ApG sequence on the RNA. From 490 to 500, there are three pairs 
of consecutive ApG, which all showed strong reactivity with the cationic amino-
acid complexes. 
The binding sites of amino-acid platinum complexes were also mapped on 
helices 27 to 31 (Figure 5.7). As observed in other regions, the stop sites were 
mostly at ApG sequences. A number of sites with consecutive Gs did not show 
reactivity with the amino-acid complexes, such as G953, G942, G927, and U904 
(stops with cisplatin). Residue A946, before the consecutive Gs, showed 
moderate reactivity with these analogues. One similarity with the parental 
compound was observed at G885, which was a strong hit on free 16S rRNA, 30S 
subunits, and the 70S ribosomes. Several sites with consecutive adenosines 
were also not reactive towards these complexes indicating that a neighboring 
guanosine is required for the adduct formation at these sites. 
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Figure 5.7. Autoradiograms of probing results with amino-acid-linked complexes and 
helices 27 to 31 of 16S rRNA are shown. A) The secondary structure of 16S rRNA 
corresponding to helix 27 to 31 is shown. Nucleotides with strong and moderate cisplatin 
hits are shown with red and green, respectively. B) The autoradiogram showing the 
reverse transcriptase pauses or stops is presented. In the gel, C, U, A, G represent the 
sequencing lanes; the control is 16S rRNA lacking treatment with complexes; and other 
lanes contain 16S rRNA treated with corresponding complexes Orn-Pt, Lys-Pt, Arg-Pt, or 
Asp-Pt (complex:nucleotide is 1:75). The strong and moderate hits are indicated with 
arrows and corresponding nucleotide numbers. Strong hits with: cisplatin (▲), Oplatin and 
Kplatin (**), Rplatin (♦); moderate stops with: cisplatin (Δ), Oplatin and Kplatin (*), and 
Rplatin (◊).  
5.5 Discussion  
The amino-acid-linked platinum complexes were synthesized and a 
binding study was carried out with a short RNA model system, as well as full 
length 16S rRNA. In both RNAs, differences in reactivity and binding-site 
preference of these complexes compared to the parent compound cisplatin were 
observed. The amino-acid-linked complexes in the model RNA system (790 
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RNA) showed the formation of more than one adduct indicating possible 
coordination at sites other than Gs. The model RNA contained only one site with 
consecutive Gs; hence, the strong mass signal with bis-adducts indicates the 
altered binding preferences of the cationic amino-acid complexes. The RNase T1 
cleavage experiments could not be used to locate the exact binding sites, but 
showed evidence that an adduct might have formed on a sequence containing 
many Gs. Probing studies on 16S rRNA showed that the binding-site preferences 
for Oplatin and Kplatin complexes were quite similar, mostly at AG sequence in 
the loop or bulge regions. This result was not surprising, because these two 
amino-acid complexes differ only by a CH2 group and each contains a single 
positive charge. Rplatin showed differences in reactivity compared to the other 
two cationic analogues, such as a stronger binding preference for nucleotides in 
the bulge or loop regions. The presence of the amino-acid ligand on these 
complexes leads to increased bulkiness of the cis-ligand and introduced an 
additional positive charge to the complex relative to the cisplatin; which, in turn, 
altered the interactions with the negatively charged RNA. The negatively charged 
amino-acid complex, Dplatin, did not show any significant reactivity compared to 
the cationic complexes at the same reaction ratio, leading to the likelihood that 
electrostatic repulsions prevented a favorable reaction with RNA.  
Previously, the binding sites of Kplatin were mapped on an 82-bp DNA 
fragment by exonuclease (274). This mapping study revealed that Kplatin 
induced a significant stops at all d(ApG) and d(GpG) sites in DNA. It had no 
apparent preference for d(GpG) over d(ApG)sequences. The authors of that 
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study also observed stops at other polypurine sequences, which were presumed 
to be monofunctional adducts. In this study, a similar result was observed with 
RNA. Most of the ApG sequences showed strong reactivity with Oplatin and 
Kplatin, whereas a number of GpG sequences did not show any reactivity. In 
contrast, Rplatin reactivity was different from the other complexes. Rather than 
being sequence selective, it showed a structural preference for reactivity, such as 
three nucleotide bulges or in the loop regions. This might be the result of the 
charge and larger size when compared to Oplatin and Kplatin. The reactivity of 
Rplatin at the internal bulge on helix 24 is quite similar to the TAR-Tat interaction 
in which the three-nucleotide bulge of TAR RNA is recognized by the arginine-
rich Tat protein (275). Arginine is an ideal RNA-binding molecule because of its 
positive charges, planar hydrogen-bonding patterns, and stacking interactions 
with the bases (223). It has been observed that molecular contacts with RNA 
occur at the bulge sites because they are more accessible to the ligand (223, 
276). In crystal structures of the ribosome, it is not as obvious as in the case of 
TAR RNA, but this interaction might be favorable due to a structural distortion 
caused by the presence of the asymmetric bulge in 16S rRNA. 
Another factor for coordination is the charge present in these complexes. 
Electrostatic interactions and local accumulation of cationic concentration 
determines the product formation. The amino-acid-linked complexes might 
increase the local concentration differently than the parental compound due to 
charge and hence, the binding sites are also different. The number of binding 
sites of amino-acid-linked complexes is higher than parental compound cisplatin; 
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however, Rplatin showed less number of hits in helix 24. In addition, the binding 
sites are also altered, which indicates that more factors must be involved than 
just electrostatic interaction. Previous studies showed that cisplatin preference 
for guanine is due to a strong hydrogen bond between the amine-hydrogen of 
cisplatin and the O=C6 moiety (Figure 5.8) (196) . In adenine, comparatively 
weaker hydrogen bond forms between amine-hydrogen of cisplatin and the H2N-
C6 group. In addition, significantly stronger molecular orbital interaction was also 
observed for guanine compared to adenine (196). The alternation of binding 
preference for amino-acid-linked complex is not very clear; however, the 
presence of NH2 group in adenosine might influence hydrogen bonding in the 
transition state, which results in preference for coordination with amino-acid-
linked complexes over cisplatin.  
 
Figure 5.8. Possible transition state for the formation of cisplatin adducts with guanosine 
and adenosine is shown. 
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The altered binding preferences of these complexes are highly unusual 
and further studies will be needed to understand the sites of interaction and types 
of adducts formed. Previously, several platinum complexes have been made in 
an attempt to alter the sequence specificity of cisplatin on DNA (269, 277). The 
minor groove binder distamycin was linked with cisplatin with the expectation that 
it would change the binding mode, but this approach was unsuccessful (277). 
One successful alteration of cisplatin binding sites was made by Bierbach and 
coworkers with the monofunctional platinum-acridinylthiourea conjugate, or Pt-
ACRAMTU, intercalators (278). They were able to increase sufficiently the 
product formation with AT-rich regions in the DNA sequence. However, these 
complexes were not studied with RNA to the best of my knowledge.  
Small molecules that bind to DNA or RNA in a sequence-specific manner 
have potential applications in cancer chemotherapy. In DNA, purine nitrogens are 
susceptible to covalent modifications both in the major and minor grooves. In the 
major groove, the most reactive site is guanine N7, while the N3 positions of 
adenine and guanine are mainly attacked by nucleophiles in the minor groove 
(279). The sugar edge of RNA is comparatively wider and shallower than the 
Hoogsteen edge; hence, ligands can interact through the sugar edge in RNA. 
The amino-acid-linked platinum complexes, due to their larger size compared to 
the parental compound, may be able to access RNA through the sugar edge, 
hence the preference would be for adenosine.  
In conclusion, amino-acid-linked complexes cross-link to RNA with 
different sequence specificity than cisplatin, preferably to ApG; therefore, the 
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accessibility of adenosine in the 16S rRNA could be monitored. The higher 
reactivity of Rplatin to the bulge or loop can give more information about 
accessibility to RNA motifs for ligand binding. In addition, the charge present in 
these complexes would be useful for monitoring the kinetics and interpreting how 
small charged molecules find their target sites. To understand the mechanism of 
action, however, further studies will be needed. 
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CHAPTER  6  
Targeting non-Hodgkin’s Lymphoma with siRNA Mediated 
through Liposomes  
6.1 Abstract 
Non-Hodgkin’s lymphoma (NHL) is a cancer of the lymphocytes, which is 
a significant cause of mortality in the United States. As a treatment for NHL, we 
propose reducing expression of the associated protooncogene c-myc using 
siRNAs. We first incorporated siRNAs into liposomes to improve drug delivery. 
Then, we attempted to purify an antibody fragment (scFv) that specifically 
recognizes CD20-positive NHL cancer cells. Our preliminary data suggest that 
this is a promising strategy.  
6.2 Introduction 
Non-Hodgkin’s lymphoma (NHL) is a cancer that starts in lymphocytes 
and can occur at any age. There are various types of non-Hodgkin lymphomas, 
but they are mainly divided into two types: aggressive (fast growing) and indolent 
(slow growing) (280). Out of various types of lymphomas, B-cell lymphoma is the 
most common in the United States (281). The National Cancer Institute 
estimated 65,540 new cases and 20,210 deaths from non-Hodgkin’s lymphoma 
in the United States in 2010 (282).  
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6.2.1 Non-Hodgkin’s lymphoma and c-myc 
 MYC regulates over 15% of all cellular gene expression and is involved in 
almost every aspect of cell biology (283). MYC contributes to the regulation of 
various genes including those involved in cell-cycle progression, protein 
biosynthesis, cell growth, and metabolism (283-284). The c-myc proto-oncogene 
is activated in a number of human tumors (283). In a normal cell, expression of 
the c-myc gene is under exquisitely fine control, and translocations in the B cell 
activate the c-myc gene and promote lymphoid malignancies (285). In cells 
affected by aggressive B-cell lymphomas, known as Burkitt lymphoma (BL), there 
is an arrangement of the c-myc oncogene, usually associated with a t(8;14) 
translocation (286). In addition, point mutations in the coding sequences of c-myc 
have been observed (287). The consequence of mutations is a negative 
regulation of c-Myc activity. In composite lymphoma, both the low (not 
aggressive) and high-grade (aggressive) components have an identical 
rearrangement of bcl-2; however, only the high-grade component has a c-myc 
oncogene rearrangement (288).  
6.2.2 Targeting non-Hodgkin’s lymphoma with siRNA 
Small-interfering RNAs (siRNA) suppress gene expression by a process 
called RNA interference (RNAi) (22, 289). RNAi is a highly regulated enzyme-
mediated process by which sequence-specific siRNA selectively targets and 
cleaves complementary mRNA (290). Long pieces of double-stranded RNA are 
cleaved by Dicer into small fragments of RNA (21 nucleotides), called siRNAs 
(291). Small-interfering RNAs can be directly introduced into the cell, thus 
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bypassing the Dicer mechanism (Figure 6.1) (292). In the cytoplasm, siRNA is 
incorporated into a protein complex called the RNA-induced silencing complex 
(RISC) (293). Argonaute 2, present in the RISC complex, unwinds the siRNA and 
cleaves the sense  
 
Figure 6.1. The mechanism of RNA interference is shown (292). Long double-stranded 
RNA (dsRNA) is cleaved by the enzyme Dicer into small-interfering RNA (siRNA). siRNA 
can be directly introduced into the cell by various methods. The siRNA is incorporated 
into the RNA-induced silencing complex (RISC), which results in cleavage of the sense 
strand and activation of siRNA-RISC complex. This activated complex binds to the 
targeted mRNA and degrades it, which causes silencing of the gene and reactivation of the 
siRNA-RISC complex. 
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strand (294). The activated RISC containing the antisense strand selectively 
degrades the complementary mRNA (295). After cleaving one mRNA strand, the 
activated RISC complex can then move on to destroy additional mRNA targets 
until siRNAs are diluted below the threshold concentration or degraded within the 
cell (292, 296). In theory, appropriately designed siRNAs can be used to silence 
any gene in the body. It has been shown that siRNA can be used to knock down 
targets in a number of diseases in vivo, such as liver cirrhosis (297), hepatitis B 
virus (298), human papillomavirus (299), ovarian cancer (300), and bone cancer 
(301). Since higher expression of c-Myc has been observed in non-Hodgkin’s 
lymphoma, siRNA specifically designed to target c-myc mRNA in NHL cells 
would be useful. For clinical purposes, however, a safe and effective delivery 
system is essential.  
The major challenge of siRNA therapy is to find an efficient delivery 
method to the intended target to minimize side effects. This approach is 
challenging due to off-target effects, aggregation with serum proteins, poor 
cellular uptake, and enzymatic degradation by nucleases (292, 302). To 
overcome these difficulties, a number of drug-delivery vehicles have been used, 
including liposomes, nanoparticles, synthetic polymers, carbon nanotubes, 
dendrimers, and polypeptides (303-305). Out of these, liposomes are used quite 
often because of their low toxicity and efficient cellular uptake.  
6.2.3 Drug delivery vehicles   
Liposomes are small, spherical, artificially prepared vesicles consisting of 
a lipid bilayer with an internal aqueous compartment (304). When phospholipids 
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are hydrated, they spontaneously form an internal aqueous environment 
surrounded by a phospholipid bilayer membrane. Liposomes, which can be 
prepared from cholesterols, glycolipids, sphingolipids,  and long chain fatty acids, 
are good carriers for a variety of molecules such as drugs, nucleic acids, and 
proteins (306). The work of Bangham and coworkers about 40 years ago 
revealed that phospholipids can form liposomes in aqueous solution (307), and 
this versatile method has been applied to biology, biochemistry, and medicine. 
This discovery is very important because liposomes are excellent carriers for 
delivering specific compounds to targets of interest. Preferred site targeting with 
liposomes can be achieved by the attachment of an antibody or appropriate 
fragments that specifically recognize the receptors present on the cells (308-
309). Liposomal drug delivery has several advantages such as enhanced drug 
solubilization, protection of sensitive drugs, enhanced uptake, and altered bio-
distribution (309).  
Liposomes are of many different sizes and shapes (310). Small-sized 
liposomes called small unilamellar vesicales (SUVs) are usually 100 nm in 
diameter. Larger-sized liposomes (200-800 nm) are classified as large 
unilamellar vesicles (LUVs), and multilamellar (MLVs) range in sizes from 500-
5000 nm and consist of several concentric bilayers (309-310). There are several 
methods for synthesizing liposomes including sonication, detergent dialysis, 
mechanical mixing, freeze-thaw, and solvent evaporation (309-310). Unequal 
vesicle sizes, low yields, uneven size distribution, and inconsistent encapsulation 
efficiencies are the major problems associated with these methods. It is essential 
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to generate liposomes with uniform size and distribution for therapeutic 
applications and to overcome these problems, a high pressure technique was 
used to prepare them (311). Liposome extruders use high pressures, 
approximately 200-800 lb/in2, and small-pore-size (~100 nm) membranes to 
generate relatively uniform vesicles. Membranes with different pore sizes can be 
utilized to generate liposomes of various sizes (310-311). Hence, the extruder 
can be utilized to generate either SUVs or LUVs. The advantages of this method 
include relatively rapid liposome preparation and potentially high encapsulation 
efficiencies.  
The application of liposomes has considerably expanded over the years. It 
is now possible to engineer a wide range of liposomes with various sizes, 
phospholipid compositions, and surface morphologies for increased therapeutic 
potential (304). In addition, biocompatibility and targeted delivery are important 
advantages of liposomes (312). Liposome encapsulation can also be used to 
increase delivery of hydrophilic drugs or oligonucleotides that often have difficulty 
crossing the cellular membrane. After entrapment, the drug does not interact with 
the lipid bilayer of a cell. In contrast, the liposome interacts favorably with the 
natural lipid and is embedded into the cellular membrane. A liposome can 
release the entrapped drug after its integration into the cellular membrane or by 
the mechanism of endocytosis (304, 312). Liposomes constitute an effective 
carrier of siRNA for in vivo delivery; when incorporated into a liposome, they are 
protected from nuclease degradation, which increases the half life and potency of 
RNA (313).  
166 
 
 
To increase the target specificity, at least three criteria need to be 
considered (313). First, the drug-delivery vehicle, such as a liposome, should 
reach and deliver theraupetic agents to the target cells. Second, the targeted 
mRNA should be preferentially expressed in tumor cells. Third, the carrier and 
siRNA should both eventually degrade. Targeting and selectively delivering 
siRNA to tumor cells in liposomes is an attractive therapeutic strategy. Cancer 
cells can be specifically targeted because many express unique antigens that are 
not available in normal cells. 
To study non-Hodgkin’s lymphoma, a human B-cell line (WSU-FSCCL) 
was used, which was established from peripheral blood of a patient (314). B cells 
express a wide variety of cell-surface antigens, such as CD20, throughout their 
development. B-cell-specific, cell-surface antigen CD20 is an appropriate target 
for therapeutic monoclonal antibodies (315). It is expressed at most stages of B-
cell development. Our collaborators (Ayad Al-Katib and coworkers) have 
engineered an antibody fragment (scFv) and GPI (glycosylphosphatidylinositol)-
tagged scFv by cloning VH and Vn regions from a widely available mouse 
hybridoma (HB-9645) directed against human CD20 (308). Previous studies 
showed that when this GPI-tagged scFv has been loaded onto the surface of 
sheep erythrocytes (Esh), it specifically forms rosettes with CD20-bearing tumor 
cells (308). In this study, we are extending this study to target specifically the 
CD20-positive cancer cells with siRNA.  
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6.3 Objectives 
siRNA has been widely used for silencing the oncogenic genes; however, 
the major challenge with siRNA is selective delivery to specific target cells (292). 
To achieve this we will use the newly engineered antibody fragment (scFv) to 
deliver liposome-encapsulated cytocidal agents to specific cancer cells. This 
antibody fragment can also be utilized for cell imaging using quantum dots or 
fluorescent tags packed into liposomes. Hence, the main goal is to generate a 
complex with siRNA, liposome, and antibody that would specifically target c-myc 
mRNA in NHL cells (Figure 6.2).  
 
 
Figure 6.2. Overview of targeting CD20-positive cancer cells by siRNA-GPI-scFv-liposome 
complex is shown.  
6.4 Materials and Methods  
6.4.1 General  
Lipids were purchased from Avanti Polar Lipids, Alabaster, AL. The 
extruder was obtained from LipexTM Extruder, Vancouver, BC, Canada. 
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Polycarbonate filters (0.1 μm) were purchased from Osmonics, Inc., Minnetonka, 
Minnesota. Sepharose 4B was purchased from Sigma. siRNAs were purchased 
from the Keck Foundation, School of Medicine, Yale University, CT. γ-32P-CTP 
was obtained from Perkin Elmer Life Sciences, Inc. Boston, MA. RPMI and 
Express Five SFM culture media were obtained from Invitrogen Corp. Primary 
antibody (HA.11 MoAb) was purchased from Covance, Princeton, NJ and 
seconday antibody (goat anti-mouse HRP conjugate) was obtained from Santa 
Cruz Biotechnology, Santa Cruz, CA. Other chemicals and buffers were 
purchased from Sigma Chemical or Fisher. Sterilized ddH2O was used for all 
experiments.  
6.4.2 RNA purification and labeling   
The siRNA obtained from Keck Foundation was deprotected, desalted and 
purified by polyacrylamide gel electrophoresis. Deprotection was carried out in 
TBAF (tetrabutylammonium fluoride) at 35 °C overnight. After deprotection, the 
RNA was desalted using poly pack (II) cartridges using 100 mM TEAA (triethyl 
amine acetate), pH 7.4. For the labeling and cell growth inhibition study, RNA 
was purified by polyacrylamide gel electrophoresis followed by ethanol 
precipitation. The trace amounts of organic reagents that may have been present 
in RNA were removed by ether extraction. In order to monitor the stability of RNA 
in buffer and media, the 3' end of the RNA was labeled with γ-32P-CTP. The 
PAGE-purified siRNA, 2 μl (25 pmol/μl), 5 μl of T4 RNA ligase buffer, and 41 μl of 
ddH2O were added to a centrifuge tube. The solution was mixed gently and 
centrifuged, 1 μl of γ-32P-CTP and 1 μl of T4 RNA ligase (10 units) was added. 
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The solution was incubated for 4 hours in ice. After the incubation, the contents 
of the labeling tube was quenched with ammonium acetate, added to a 
Sephadex G-25 column, and centrifuged for 2 min at 3,000 rpm to remove 
excess CTP. The radioactivity of the sample was measured using a scintillation 
counter. 
6.4.3 Lipid mixture preparation  
Lipids were brought to room temperature in desiccators just prior to 
weighing. First, 11 mg of cholesterol (294.1 g/mol, 28.4 μmol), 26.2 mg of DPPC 
(734 g/mol, 35.6 μmol), 10.4 mg of DODAP (684.5 g/mol, 16.2 μmol), and 0.6 mg 
of DPPE (692 g/mol, 0.8 μmol) were weighed and transferred to a tube. After 
that, 500 μl of CHCl3 was added to the lipid mixture, and the solution was 
vortexed to suspend the lipids. Aliquots containing 42 μl (6.5 μmol total lipids) of 
lipid mixture was transferred to several tubes. These aliquots were dried under 
reduced pressure and kept in the freezer until further use.  
6.4.4 Liposome size determination 
Dynamic light scattering (DLS), was performed on a Malvern Zetasizer 
Nano-ZS instrument. DLS analyzes the particle size by measuring dynamic 
fluctuations of light scattering caused by the particle. Liposomes were prepared 
by resuspending the lipid mixture in 500 µl ddH2O and passed through the 
extruder ten times by using a 0.1 µm polycarbonate membrane. In a low volume 
plastic cuvette, the measurements were carried out at a temperature of 25 °C. In 
order to eliminate dust particles, the samples were filtered through syringe filters 
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with 0.2 µm pore size membrane. At least three repeat measurements on each 
sample were taken. The intensity size distributions were obtained from analysis 
of the correlation functions in the instrument software.  
6.4.5 RNA incorporation and stability test  
The lipid mixture was hydrated by resuspending a dried sample of 6.5 
μmol mixed lipids with 200 μl of 300 mM sodium citrate (pH 4.0) and then 
vortexed to yield a white suspension. After that, 300 μl of 300 mM sodium citrate 
was added to approximately ~ 50 μg of unlabeled siRNA and a small amount of 
32P-labeled siRNA (~10,000-20,000 cpm) in another tube. Both solutions were 
vortexed and the lipid-containing solution was heated at 65 °C for five minutes. 
The clear siRNA solution was added drop-wise to the lipid suspension and the 
500 μl mixture was then passed ten times through 0.1 μm polycarbonate filters at 
200-300 psi using an extruder. The liposome was collected in a glass container 
and the extruded solution was dialyzed against 1 L of 25 mM HEPES and 50 mM 
NaCl buffer (pH 7.4) for 24 hours at 4 °C to raise the pH from 4.0 to 7.4. The 
unbound RNA from the complexes was separated by gel-exclusion 
chromatography with Sepharose 4B. The radioactivity present in various fractions 
was measured with a Beckman scintillation counter. 
To test the stability of the RNA, the RNA was labeled at the 3' end and 
renatured with unlabelled RNA by heating to 90 °C for 2 min followed by a slow 
cooling. For double-stranded RNA, the sense strand was labeled. Equimolar 
amount of both strands with trace amounts of labeled strand were annealed by 
heating to 90 °C for 2 min followed by slow cooling. The renatured RNA was 
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incubated with RPMI culture media (containing 5% serum) at 37 °C for various 
time intervals.    
6.4.6 Transfection of plasmid to Hi Five cells 
Plasmid (GPI-scFv) obtained from the Al-Katib laboratory was transfected 
in High Five cabbage looper cells using cellfectin according to the manufacturer’s 
protocols (InsectSelect system, Invitrogen). The pIZT/V5-His plasmid was used 
to clone the engineered scFv containing GFP-Zeocin fused in-frame for selection. 
The transfected insect cells express the GFP-Zeo and scFv with similar 
efficiencies; hence, GFP can be used to estimate the transfection efficiencies 
and Zeocin as a selection marker. Selection of stable transfectants was carried 
out using 200 μg/ml of Zeocin until the control cells completely died after which 
the concentration of Zeocin was lowered to 50 μg/ml. Approximately 15 μl of 
transfected and control High Five cells were spotted on microscope slides for 
checking GFP expression with an Olympus 1X71 microscope, equipped with a 
TH4 100 Olympus lamp and an Olympus UCMAD 3 camera. The magnification 
used was 60X, and images were taken in bright field and fluorescence mode for 
200 ms exposure times. 
6.4.7 Isolation and purification of protein  
For isolation of protein (GPI-scFv), stable transfected cells were grown to 
confluent in T-75 flasks in serum-free media at 27 °C. The cells were scraped out 
and spun down to remove the media. Cells were lysed in lysis buffer (300 mM 
NaCl, 50 mM Tris HCl pH 7.6, 0.5% Triton X-100, 10 mM PMSF, and EDTA free 
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cocktail protease inhibitor) using a French Press. After lysis, centrifugation was 
carried out at 13,000 rpm for 15 min at 4 °C to remove cellular debris. The 
clarified supernatant was transferred into the new tube and protein was purified 
using a Ni+2 affinity column (HisTrap, Amersham Biosciences) according to the 
manufacturer’s protocol.  
The crude cell lysate (10 μl) and aliquots from various stages of protein 
purification (10 μl each) were electrophoresed on a 12% SDS polyacrylamide gel 
at 170 V until the bromophenol blue migrated off the gel. The gel was transferred 
to a nitrocellulose membrane (Hybond- C Extra, Amersham Biosciences) at 300 
mA for one hour. After the proteins were transferred to the membrane, it was 
washed two times with TBST buffer for 15 min. The membrane was blocked with 
5% skim milk for one hour in TBST buffer and incubated with primary antibody 
(HA.11 MoAb) overnight at 4 °C. The membrane was again washed twice with 
TBST buffer for 15 min and incubated with secondary antibody (goat anti-mouse) 
coupled to horseradish peroxidase for one hour. After washing with TBST, the 
protein bands were visualized with the ECL Advance Western Blot detection 
system. The chemiluminescense was scanned by a Typhoon and analyzed by 
Image QuantTM software. 
6.5 Results 
Human cancers frequently show altered expression of c-Myc emphasizing 
the importance of this gene in cancer (287). The c-Myc protein or the c-myc gene 
is overexpressed in a wide variety of human cancers. To check our system, we 
are specifically targeting expression of c-Myc in lymphoma cells (WSU-FSCCL) 
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using siRNA. These cells express CD20 antigens that can be specifically 
recognized by an antibody fragment (scFv) (308). CD20 is a highly 
phosphorylated, non-glycosylated 33-37 kDa membrane protein found on both 
normal and neoplastic B-cells. CD20 is an excellent target for therapeutic 
purposes, because it is neither shed from the cell nor internalized upon binding 
with antibodies (316).   
6.5.1 Designing siRNA for targeting c-myc mRNA 
Humans have evolved a number of mechanisms to fight against viral 
infections, which also work against siRNA. Hence, siRNA is degraded before 
reaching the target by several mechanisms (317). To increase the stability of 
siRNA, a number of methods are currently in use such as RNA modification and 
encapsulation using various carrier molecules (292). Several modifications have 
been used in siRNA to increase its stability and efficiency. 2'-O-methyl 
modifications are resistant to endonucleases and also abolish off-target effects 
when incorporated into nucleotides 2-8 on the antisense strand (318). Similarly, 
introduction of phosphorothioate backbone linkages at the 3' end of the RNA 
reduces susceptibility to exonucleases, and a substitution of fluorine at the 2'–
position increases resistance to endonucleases (302). 
Initially, single-stranded RNA 5’-AAG CUA ACG UUG AGG GGC AU-3’, 
which is complementary to the c-Myc mRNA at positions 1 to 20 from the start 
codon, and the scrambled version 5’-GAU CGA UCG AGC GAU GAU AG-3’, 
were used to check the incorporation efficiency, stability, and effect on cell 
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growth. These RNAs contained 2'–OCH3 groups on the first three nucleotides at 
the 5'-end, which is the optimal site of modification.  
The second RNA is a double-stranded construct in which all pyrimidines 
have a 2'-F group and the 3' ends contain phophorothiorates to increase stability. 
To design this RNA, the following four rules were considered, as described in the 
literature (319) : i) A/U at the 5' end of the antisense strand; ii) G/C at the 5' end 
of the sense strand; iii) AU-richness on the 5' terminal one-third of the antisense 
strand; and iv)  absence of any GC stretch over nine base-pairs in length. The 
double-stranded siRNA targeting the c-Myc mRNA and a schematic 
representation of four rules used to designed siRNA are shown in Figure 6.3. 
 
Figure 6.3. An overview of the four rules to design siRNA and siRNA targeting c-Myc 
mRNA is shown. A) A schematic representation of siRNA with four rules is indicated. B) 
The siRNA designed according to the rules for targeting c-Myc mRNA in NHL cells is 
shown.  
6.5.2 Encapsulation of siRNA into the liposomes 
For efficient encapsulation of oligonucleotides into the liposomes, many 
variables have to be considered, such as lipid types and buffer pH. Currently, all 
types of phospholipids are available for liposome preparation: neutral, cationic, 
and anionic. Among them, cationic lipids are most commonly used to prepare 
encapsulated oligonucleotides. The positively charged lipids can interact with 
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negatively charged oligos through electrostatic interactions, which are considered 
an initial driving force for encapsulation. Previously, it has been shown that 
cationic liposomes are useful to efficiently encapsulate and deliver nucleic acids 
to the target. In this study, the protocol for liposome formulation was based on a 
previous study conducted in our lab (320), which was a modified protocol of 
Zelphati et al. (321). This composition contains four lipids: 1,2-dioleoyl-3- 
dimethylammoniumpropane (DODAP), dipalmitoylphosphotidyl choline (DPPC), 
cholesterol, and dipalmitoylphosphotidyl ethanolamine (DPPE). They were used 
in the ratio of 20:44:35:1 of DODAP:DPPE:cholesterol:DPPC to prepare 
liposomes (Figure 6.4). DODAP has improved encapsulation efficiencies 
because of an ionizable aminolipid with a tertiary amine (pKa 6.6), which 
becomes positively charged at low pH. Hence, pH 4.0 was used to encapsulate 
the siRNA into the liposomes. Furthermore, backbone modification with 
phosphorothiorates and the presence of a methyl group at 2'-positions also 
increases encapsulation efficiency and stability of the RNA.  
To check encapsulation efficiency, single-stranded RNA was labeled at 
the 3'-end with 32P in order to track the amount of RNA incorporated into the 
liposomes. A small amount of RNA (50 μg) and a trace amount of labeled RNA 
(5,000 cpm) was mixed with a hydrated lipid mixture and passed through the 
extruder at ~ 200 psi. The mixture was prepared in sodium citrate buffer at pH 
4.0, and after extrusion, the liposomal mixture was dialyzed against HEPES 
buffer at pH 7.5 for 12 hrs. Separation of unincorporated RNA from liposome-
RNA was done by using a Sepharose 4B column.  
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The level of encapsulation was determined by measuring the radioactivity 
of all fractions. The level of RNA encapsulation was found to be more than 30% 
by using the following equation (Figure 6.5 A); 
 
                                                 Cpm (liposome fraction) 
Encapsulation effenciency = ---------------------------------------------- X 100  % 
        Cpm (liposome fraction + void fraction)  
 
 
Figure 6.4. A liposome-siRNA complex is shown. Four different lipids; cholesterol, 
DODAP, DPPC, and DPPE were mixed at low pH with siRNA to generate the complexes. 
 
Particle sizes of liposomes were measured by using a dynamic light 
scattering (DLS) instrument. From the time-correlation function, the size of the 
particles were determined by the instrument software. The output can be used to 
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plot as a number or intensity percentage vs. size of the particles. Larger particles 
scattered more light compared to small particles and the plot of intensity vs. size 
may not reflect the actual distribution of the particles size. Thus, a histogram with 
number percentage vs. size of the liposome particles was plotted. The majority of 
liposomal particle size was found to be ~100 nm (Figure 6.5 B).   
 
 
 
Figure 6.5. Incorporation efficiencies and liposomal particle size are shown A) the % 
incorporation of single-stranded RNA into the liposomes; fractions 2 and 3 from column 
contain liposomes with RNA, whereas fractions 4 and 5 show the presence of 
unincorporated RNA. The data represents an average of three independent experiments. 
B) Particle size distribution of liposomes measured by DLS is represented.  
 
6.5.3 siRNA stability 
The single-stranded RNAs (modified and scrambled) were labeled at the 
3' end to test stability. After labeling, trace amounts of labeled RNA and 20 μg of 
unlabelled RNA were renatured in 25 mM HEPES and 50 mM NaCl. Fifty μl 
culture media or an equivalent amount of buffer were added to the renatured 
RNA (50 μl) and incubated at 37 °C for various time intervals. In the presence of 
media, both the modified and scrambled versions of single-stranded RNA were 
178 
 
 
degraded in less than 30 min (Figure 6.6 A). Similarly, to check the stability of 
double-stranded RNA, both strands of RNA (20 μg each) were annealed with 
trace amounts of 3' labeled sense strand. Fifty μl of annealed siRNA and 50 μl of 
the culture media was combined and incubated at 37 °C for various time 
intervals. After each time interval, the samples were quenched on dry ice and run 
on a polyacrylamide gel. The double-stranded RNA with modifications was found 
to be stable for more than 18 hours in RPMI media with serum (Figure 6.6 B). 
The presence of 2'-F and phosphorothiorate modifications makes the double-
stranded RNA less susceptible to the nucleases present in the medium.  
 
Figure 6.6. Autoradiogram of modified single- and double-stranded siRNA stability test in 
RPMI culture media at different time intervals is shown. A) Single-stranded RNA and the 
scrambled version with different buffers and media and B) double-stranded RNA with 
media at various time intervals are shown (autoradiogram B was done by Gayani Dedduwa 
Mudalige). 
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6.5.4 Transfection of GPI-scFv and protein purification  
The GPI-scFv expression plasmid (obtained from Al-Katib’s lab) (Figure 
6.7) was stably transfected into High FiveTM cells. After 4 rounds of selection with 
Zeocin (200 μg/ml), control cells died and green fluorescence from GFP was 
readily visible in transfected cells using fluorescence microscope (Figure 6.8). 
The presence of fluorescence compared to untransfected High FiveTM insect cells 
confirms the generation of stably transfected cells. Plasmid concentration (2-5 
µg), number of High Five cells (~ 1*106), and viability (> 90%) are important 
factors to generate the stable transfection. To avoid the contamination often 
found with the use petri dishes (as described in protocol), T75 flasks were used.  
 
 
Figure 6.7. A schematic diagram of the pIZT-GPI-anti-CD20 scFv expression construct 
obtained from Al-Katib laboratory (upper) and GPI-tagged SKLH6FG (lower) cloned in 
multiple cloning site are shown: The abbreviations are S: secretory signal, K: light chain 
variable region, L: linker, H: heavy chain variable region, 6: six histidine residues, F: Flu 
tag HA, and G: GPI (glycosylphosphatidyl inositol) signal. Modified with permission from 
Hamdy et al. (308). 
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Figure 6.8. GPI anchored scFv after stable transfection to the Hi Five cells are shown. The 
left panel represents the bright field and right panel represents the corresponding GFP 
fluorescence at 200 ms exposure time. Control (no transfection) cells do not show any 
fluorescence and most of the transfected cells showed fluorescence. 
 
GFP fluorescence and Zeocin resistance indicated the formation of stably 
transfected High Five cells. Protein purification was carried out from stably 
transfected cells using a Ni2+ column, and the presence of protein at various 
stages was detected by Western blotting. Western blotting showed presence of 
the desired protein in the crude lysate and in purified fractions of ~32 KDa, 
corresponding to the protein GPI-scFv (Figure 6.9). 
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Figure 6.9. A 12% SDS-polyacrylamide gel and immunobloting analysis of GPI-anchored 
scFv proteins at different stages of purification are shown: A) before protein purification 
showing lysate (control) from untransfected High Five cells; pellet and lysate from 
transfected cells; and B) fractions from different stages of protein purification from 
transfected cells.  
6.6 Conclusions and Future Directions  
The double-stranded siRNA with specific modifications was found to be 
stable long periods of time (> 20 h), even in the culture media.  We have 
successfully stably transfected High Five cells with a GPI-scFv expression 
plasmid and purified small amounts of the expressed protein. The stably 
transfected cells can be used to purify larger quantities of the GPI-anchored scFv 
for further experiments. Liposomes, siRNA, and the GPI-scFv complex can be 
used to deliver siRNA to CD20-positive cells. This can be confirmed by 
measuring the level of c-Myc expression in CD20-positive WSU-FSCCL cells. 
Further, instead of siRNA, quantum dots can be used to check the targeted 
delivery by scFv. Quantum dots can be incorporated into the liposomes and 
complexes with GPI-scFv can be generated. When this complex is incubated 
with cells, it is expected that QDs will be delivered to the cells. As QDs are highly 
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luminescent, they can be detected by fluorescence microscopy. This method will 
have the advantage of simultaneous cell imaging and targeted delivery of 
cytocidal agents to cancer cells. 
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CHAPTER  7  
Conclusions and Future Directions 
7.1 General Conclusions 
The ribosome is the protein synthesis machinery and serves as an ideal 
target for various classes of antibiotics because of its accessibility and structural 
diversity (68, 71). In the last decade, the growth of multiple-drug-resistance 
bacterial pathogens is rapidly evolving, while the development of new 
antibacterials is lagging behind.  To overcome the ever-growing problem of 
resistance, we can either design new drugs for traditional target sites, or explore 
novel target sites. Despite the existence of validated antibiotic binding sites, very 
few attempts have been made to explore novel drug target sites in the ribosome 
(2, 103). The ideal target sites should not only be functionally important, but also 
accessible to various small molecules. In this thesis, a new role for cisplatin as a 
discovery tool for potential new drug target sites on the ribosome was explored. 
Cisplatin has several advantages over other chemical probes due easy detection 
of its target sites and the possibility to use it in vitro as well as in vivo. In addition, 
the positive charge in aquated complex and stable adduct formation are useful to 
monitor binding and kinetics of the reaction. 
The first objective of this thesis was to understand the binding interaction 
of cisplatin with model RNA constructs and 16S rRNA. A number of methods 
were employed to obtain information about the binding sites, number of adducts, 
and types of cross-links formed with RNA. The binding studies showed that 
cisplatin interacts preferably with guanosine-rich RNA sequences. Many of the 
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consecutives Gs on the 16S rRNA that showed reactivity with cisplatin were 
involved in G○U wobble base pairs. Since G○U pairs are known to be 
functionally important for RNA-protein interactions (219, 221), the cisplatin 
complex may reveal preferential sites for protein binding on RNA that have ideal 
accessibility and structural compatibility. The various adduct profiles obtained 
from the small RNA construct and 16S rRNA also showed that RNA is a viable 
target and may be part of an alternate pathway for cisplatin anticancer activity. 
Cisplatin mainly forms bifunctional adducts with purine bases; however, it 
showed a unique adduct profile with RNA compared to that of DNA. In DNA, the 
most common cross-links are the 1,2-intrastrand with purine bases, mainly the 
1,2-intrastrand d(GpG) adduct (~65%) and the 1,2-intrastrand d(ApG) (~25%), 
and less common 1,3-intrastrand d(GpXpG) adducts (172, 191). In 16S rRNA, 
the adduct distribution is 63% GpG, ~20% ApG, 6% GG, and 11% AG. Strong 
reactivity with nonconsecutive Gs such as G462 and G791 may be the result of 
structural differences between DNA and RNA. RNA contains several secondary 
structural motifs, such as hairpins, internal loops and bulges, which cause 
distortion of the RNA structure and therefore change accessibility of the 
nucleotides.  
The second objective of this thesis was to map on the ribosome accessible 
binding sites that could possibly be used as a novel target sites for new 
antibiotics. This study showed that several helices of the ribosome are clearly 
accessible to platinum complexes, such as helix 18, 24, 27, and 34, and thus 
could also be accessible to small molecules and serve as targets for novel drug 
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leads. Several nucleotides in these helices that are functionally important, such 
as G530-531, G791, and G1058, were found to be highly reactive towards 
cisplatin. Mutational studies showed that these cisplatin reactive sites when 
mutated lead to deleterious phenotypic effects (2). A number of these mutations 
has impaired assembly of the ribosome and growth of the bacteria (1).  
Several sites in the 16S rRNA showed different platinum reactivity 
between 30S subunits and 70S ribosomes, which could be exploited for 
structure-based or mechanism-based drug design. Recently, a model system of 
helix 18 was used as a target to find ligands by phage display (254). Hence, 
phage display or SELEX could be carried out to find the ligands targeting the 
sites that showed different reactivity in 16S rRNA, 30S subunits and 70S 
ribosomes. 
The fact that the platinum complex generates stable adducts that can be 
quantified is significant, because the kinetics of the reaction can be monitored. 
This will allow determination of how positively charged compounds such as 
aminoglycosides identify their target sites from a number of possible reactive 
sites on the ribosome. In RNA, we do not know whether the known sites are the 
only ones for effective inhibition, or whether there are more possible target sites 
on the ribosome. Hence, it will be important understand the kinetic preference for 
charged small molecules binding to the functionally important sites on the 
ribosome. 
The third objective of this thesis was to exploit another aspect of cisplatin, 
namely, the ease with which its charge and size can be altered. Unlike other 
186 
 
 
probing agents, aquated cisplatin has a positive charge; thus, accessibility and 
kinetic information can be obtained simultaneously. For this purpose, a number 
of platinum complexes with various charges and sizes were synthesized by 
tethering amino acids. The binding studies with amino-acid-linked complexes 
with 16S rRNA showed a clear alteration of the binding sites compared to 
cisplatin. The positively charged Kplatin and Oplatin showed a preference for AG 
over GG sites on 16S rRNA. Similarly, Rplatin showed a preference for loop and 
bulge regions. The negatively charged amino-acid-linked complex Dplatin did not 
show any reactivity under similar reaction conditions. These results indicate that 
an electrostatic interaction is likely a primary driving force for charged small 
molecules to react with the negatively charged nucleic acids, although H-bonding 
might also play a role. 
In a different aspect of my thesis work, the use of siRNA to target non-
Hodgkin’s lymphoma was explored. siRNA has great therapeutic applications, 
including those related to anticancer approaches; however, it has been often 
difficult to achieve selective targeting, efficient delivery, and appropriate stability 
of the siRNA, while at the same time minimizing toxic side effects. A newly 
engineered antibody fragment (scFv) in conjugation with liposomes was 
proposed for this purpose. An scFv plasmid obtained from Al-Katib’s lab was 
successfully transfected to High Five insect cells to generate stably transfected 
cell lines. This step of the project presented a number of challenges that were 
overcome, and now with stably transfected cell lines, sufficient quantities of 
protein can be generated for future studies. siRNA stability in cell-growth media 
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and its incorporation into liposomes were also optimized. The siRNA with 2'-F, 
phopshorothiate, and 2'-OMe modifications were found to be stable in culture 
media for extended periods of time (24 hours), and gave ~30% incorporation 
efficiency into the liposome.    
7.2 Future Directions 
Future experiments include the use of these probing techniques to monitor 
the accessibility of purines in 23S rRNA, functional ribosomes in the presence of 
mRNA and tRNA, as well as polysomes. Mapping of cisplatin binding sites in 23S 
rRNA in vitro and in vivo will greatly increase accessibility information for various 
functionally important regions, such as the peptidyl-transferase center, helix 69, 
and the peptide exit tunnel. In addition, in vitro probing of the ribosome in 
presence of mRNA and/or tRNA can generate information about nucleotide 
accessibility in fully functional ribosomes. This work could be further expanded to 
the polysomes. Previous studies showed that a number of nucleotides were 
protected when mRNA, tRNA or initiation factors were assembled on the 
ribosome. Thus, cisplatin probing result can be compared with previously 
obtained results from biophysical and biochemical methods to find novel target 
site for antibiotics on the ribosome.  
The binding studies with amino-acid-linked cisplatin analogues and the 
790 region of 16S rRNA revealed an alteration of binding sites relative to the 
parent cisplatin; thus, the adduct profiles on 16S rRNA are expected to be 
different. The binding sites of cisplatin analogues on the 30S subunits and 70S 
ribosomes can be obtained by primer extension and in small constructs by 
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MALDI (TOP-DOWN sequencing or RNase cleavage) and chemical probing. The 
types and number of adducts formed with cisplatin analogues with varying 
ligands will further increase our understanding of RNA-platinum complex 
interaction. HPLC and LC-MS can be used for this purpose, as described in 
Chapter 2. In addition, NMR analysis of various products obtained with individual 
nucleosides or nucleotides could be useful to find the exact coordination site of 
platinum on the nucleotide base, which has not yet been verified on RNA. As 
charge and size of cisplatin can be altered easily, various analogues with bulkier 
groups, higher charge, or varying hydrophobic or H-bonding moieties can be 
synthesized. These compounds could be exploited to gain information about 
nucleotide or helix accessibility on the ribosome, as well as map the interaction 
modes.  
Cisplatin and its analogues were demonstrated as probing tools to gain 
information about nucleotide accessibility in the RNA tertiary or higher-order 
structure. Probing the ribosome from other organisms will have the great 
advantage of predicting accessibility and assisting with the design of selective 
structure-based drug targeting agents for pathogenic bacteria. It has been of 
great interest to know how charged small molecules such as aminoglycosides 
find their target sites out of the numerous possible sites in the ribosome. Cisplatin 
and analogues, due to their stable coordination and charges present in the 
aquated species, can be used as a model to understand how charged molecules 
find their target sites. This kinetic interaction combined with thermodynamic 
preferences will also aid in future drug design. 
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Small interfering RNAs (siRNA) were designed to specifically target the c-
Myc mRNA in non-Hodgkin’s lymphoma cells. High Five cells with stable 
transfection of GPI-scFv have been generated, which showed expression of the 
desired protein. The stably transfected cells can be used to purify larger 
quantities of the GPI-anchored scFv for further experiments. Liposome, siRNA, 
and the GPI-scFv can be combined to generate a complex that can be used to 
deliver siRNA to CD20-positive cells. This targeting can be confirmed by 
examining the levels of c-Myc expression in CD20-positive WSU-FSCCL cells or 
related cancer-cell lines. Further, instead of siRNA, quantum dots can be used to 
monitor the targeted delivery by scFv. Quantum dots can be incorporated into the 
liposomes, and complexes with GPI-scFv can be generated. When this complex 
is incubated with cells, it is expected that QDs will also be delivered to the cells 
and can be utilized for imaging purposes. As QDs are highly luminescent, they 
can be detected by fluorescence microscopy. This method will have the 
advantage of simultaneous cell imaging and targeted delivery of cytocidal agents 
to cancer cells. These projects taken together provide the basis for new 
applications directed towards novel drug discovery or selective targeting as 
antibacterial or anticancer agents. 
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APPENDIX 
 
 Figures in this appendix are additional autoradiograms for Chapters 2 and 3. The 
primer and RNA used for probing are mentioned in figure captions. 
  
 
 
Figure.  Probing results of 16S rRNA at the 3' domain with primers 171 and 323 are 
shown. (A) Autoradiogram showing the reverse transcriptase pauses or stops by 
using primer 171. (B) Autoradiogram showing the reverse transcriptase pauses or 
stops by using primer 323. In both gels, C, U, A, G represent the sequencing 
lanes, 0 represents the control, and other 3 lanes are 16S rRNA treated with 
increasing concentrations of monoaquated cisplatin (cisplatin:nucleotide is 1:150, 
1:75, and 1:30). The strong and moderate hits are indicated with arrows and 
corresponding nucleotides numbers (▲ ﴾strong hits﴿ and Δ ﴾moderate hits﴿). 
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Figure. Probing results of 16S rRNA with primers 485 and 686 are shown. (A) 
Autoradiogram showing the reverse transcriptase pauses or stops by using 
primer 485. (B) Autoradiogram showing the reverse transcriptase pauses or stops 
by using primer 686. In both gels, C, U, A, G represent the sequencing lanes, 0 
represents the control, and other 3 lanes are 16S rRNA treated with increasing 
concentrations of monoaquated cisplatin (cisplatin:nucleotide is 1:150, 1:75, and 
1:30). The strong and moderate hits are indicated with arrows and corresponding 
nucleotides numbers (▲ ﴾strong hits﴿ and Δ ﴾moderate hits﴿). 
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Figure. Probing results of 16S rRNA with primers 746 and 982 are shown. (A) 
Autoradiogram showing the reverse transcriptase pauses or stops by using 
primer 746. (B) Autoradiogram showing the reverse transcriptase pauses or stops 
by using primer 982. In both gels, C, U, A, G represent the sequencing lanes, 0 
represents the control, and other 3 lanes are 16S rRNA treated with increasing 
concentrations of monoaquated cisplatin (cisplatin:nucleotide is 1:150, 1:75, and 
1:30). The strong and moderate hits are indicated with arrows and corresponding 
nucleotides numbers (▲ ﴾strong hits﴿ and Δ ﴾moderate hits﴿). 
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Figure. Probing results of 16S rRNA with primers 1199 and 1296 are shown. (A) 
Autoradiogram showing the reverse transcriptase pauses or stops by using 
primer 1199. (B) Autoradiogram showing the reverse transcriptase pauses or 
stops by using primer 1296. In both gels, C, U, A, G represent the sequencing 
lanes, 0 represents the control, and other 3 lanes are 16S rRNA treated with 
increasing concentrations of monoaquated cisplatin (cisplatin:nucleotide is 1:150, 
1:75, and 1:30). The strong and moderate hits are indicated with arrows and 
corresponding nucleotides numbers (▲ ﴾strong hits﴿ and Δ ﴾moderate hits﴿). 
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Figure. Crystal structures and secondary structure regions of 16S rRNA 
corresponding to helix 15 and 42 are shown with reactive nucleotide (colored).  
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Figure. Probing results of 16S rRNA of the 30S subunits and the 70S ribosomes at the 5' 
domain with primers 171 and 323 are shown. (A) Autoradiogram showing the reverse 
transcriptase pauses or stops by using primer 171. (B) Autoradiogram showing the 
reverse transcriptase pauses or stops by using primer 323. In both gels, C, U, A, G 
represent the sequencing lanes, 0 represents the control, and other lanes are 30S subunits 
and 70S ribosomes treated with increasing concentrations of monoaquated cisplatin 
(cisplatin:nucleotide is 1:150 and 1:75). The strong and moderate hits are indicated with 
arrows and corresponding nucleotides numbers (▲ ﴾strong hits﴿ and Δ ﴾moderate hits﴿ and 
● (minor hits)). 
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Figure. Probing results of 16S rRNA of the 30S subunits and the 70S ribosomes at the 5' 
and central domain with primers 485 and 687 are shown. (A) Autoradiogram showing the 
reverse transcriptase pauses or stops by using primer 485. (B) Autoradiogram showing 
the reverse transcriptase pauses or stops by using primer 687. In both gels, C, U, A, G 
represent the sequencing lanes, 0 represents the control, and other lanes are 30S subunits 
and 70S ribosomes treated with increasing concentrations of monoaquated cisplatin 
(cisplatin:nucleotide is 1:150 and 1:75). The strong and moderate hits are indicated with 
arrows and corresponding nucleotides numbers (▲ ﴾strong hits﴿ and Δ ﴾moderate hits﴿ and 
● (minor hits)). 
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Figure. Probing results of 16S rRNA of the 30S subunits and the 70S ribosomes at the 
central and 3' major domain with primers 748 and 978 are shown. (A) Autoradiogram 
showing the reverse transcriptase pauses or stops by using primer 748. (B) 
Autoradiogram showing the reverse transcriptase pauses or stops by using primer 978. In 
both gels, C, U, A, G represent the sequencing lanes, 0 represents the control, and other 
lanes are 30S subunits and 70S ribosomes treated with increasing concentrations of 
monoaquated cisplatin (cisplatin:nucleotide is 1:150 and 1:75). The strong and moderate 
hits are indicated with arrows and corresponding nucleotides numbers (▲  ﴾strong hits﴿ 
and Δ ﴾moderate hits﴿ and ● (minor hits)). 
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Figure. Probing results of 16S rRNA of the 30S subunits and the 70S ribosomes at the 3' 
domain with primers 1199 and 1296 are shown. (A) Autoradiogram showing the reverse 
transcriptase pauses or stops by using primer 1199. (B) Autoradiogram showing the 
reverse transcriptase pauses or stops by using primer 1296. In both gels, C, U, A, G 
represent the sequencing lanes, 0 represents the control, and other lanes are 30S subunits 
and 70S ribosomes treated with increasing concentrations of monoaquated cisplatin 
(cisplatin:nucleotide is 1:150 and 1:75). The strong and moderate hits are indicated with 
arrows and corresponding nucleotides numbers (▲ ﴾strong hits﴿ and Δ ﴾moderate hits﴿ and 
● (minor hits)). 
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Cis-diamminodichloridoplatinum (II), cisplatin, is an antitumor drug that 
has been used to treat several types of cancers. The reaction of cisplatin with 
DNA has been studied and discussed extensively in the literature; however, the 
effects of cisplatin on RNA function are poorly understood. In this thesis, two 
aspects of cisplatin, its preferred sites of interaction with RNA and its use as a 
chemical probe to gain accessibility information, were explored. 
To understand the site-selectivity of cisplatin with RNA, model RNA 
constructs and full-length 16S rRNA were employed. The binding studies 
revealed a cisplatin preference for guanosine-rich sequences. Primer extensions 
in 16S rRNA and MALDI-TOF in model constructs were used to locate the 
binding sites of cisplatin. HPLC and LC-MS were useful to determine the types 
and ratios of various adducts formed. Cisplatin and its analogues were employed 
to probe the accessibility of nucleotides on 16S rRNA, 30S subunits and 70S 
ribosomes in vitro as well as in vivo. This study revealed that many functionally 
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important sites, such as helix 18, 24, 27, and 34 are accessible to the aquated 
platinum complex. Thus, these accessible sites can potentially be utilized as a 
new target sites in the design of structure-based antibiotics. When charge and 
size of the complex were changed, the binding preference was altered. In 
addition to the expected consecutive Gs, cisplatin analogues preferentially 
targeted AG sites on loop or bulge regions. Thus, several new complexes could 
be synthesized and utilized to gain more information about drug accessibility on 
the ribosome. 
The last part of the research focused on the application of siRNA to target 
non-Hodgkin’s lymphoma (NHL). Small interfering RNAs were designed to 
downregulate the c-Myc expression in NHL cells. Stabilities of designed siRNAs 
in media and their incorporation into liposomes were studied. Complexes of 
siRNA, liposomes, and antibody fragments (scFv) could be utilized in future 
applications to target specifically the c-Myc expression in NHL cells.  
Overall, this thesis work explored cisplatin binding to RNA and a number 
of possible new antibiotic target sites on the ribosome were identified. In the long 
term, further studies with fully functional ribosomes and comparisons with other 
organisms will have a greater impact on identifying novel drug target sites in 
pathogenic bacteria. 
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